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All mammalian cells encode microRNAs (miRNAs), which are small non-coding RNAs 
(~ 22 nucleotides) that control numerous physiological processes via regulation of gene 
expression. A number of viruses, in particular herpesviruses, also encode miRNAs. 
Gammaherpesviruses such as Epstein-Barr virus (EBV) and Kaposi’s sarcoma 
associated herpesvirus (KSHV) are associated with lymphoproliferative disorders and 
some types of cancer in humans. Gammaherpesvirus-encoded miRNAs are predicted to 
contribute to pathogenesis and virus life cycle by suppressing host and viral target genes. 
However, the exact functions of these miRNAs during virus infection in the natural host 
are largely unknown. Strict species specificity has limited research on the human 
gammaherpesviruses mainly to in vitro studies.  
 
Murine gammaherpesvirus 68 (MHV-68) encodes at least 15 miRNAs and provides a 
unique tractable small animal model to investigate in vivo gammaherpesvirus 
pathogenic features that are difficult to assess in humans. Following intranasal infection 
of lab mice, the virus undergoes primary lytic infection in the lung epithelial cells and 
then spreads to the spleen establishing latent infection in splenic B lymphocytes, 
macrophages, and dendritic cells. The peak of the latent viral load occurs in the spleen at 
14 dpi and then it decreases over time, but the virus is not completely eliminated and the 
latent viral genomes remain in the host cells for lifetime and can reactivate to produce 
infectious virus under certain conditions. 
 
The aims of my project were to: (1) establish and develop quantitative reverse 
transcription polymerase chain reaction (qRT-PCR) assays for quantification of the 
MHV-68 miRNAs, (2) determine the miRNAs expression profiles during the two stages 
of virus infection (lytic and latent infection), (3) investigate the kinetics of the miRNAs 
expression during latency in vivo, (4) construct an MHV-68 miRNA mutant virus 
lacking 9 miRNAs (designated MHV-68.ΔmiRNAs), and (5) carry out thorough 
phenotypic characterisation of this mutant virus in order to determine the possible 




It was found that the MHV-68 miRNAs expression pattern varied during different stages 
of infection, suggesting a differential regulation of the expression of these miRNAs 
depending on the phase of infection. In order to investigate the kinetics of miRNAs 
expression during latency in vivo, BALB/c mice were infected intranasally with MHV-
68 virus and spleens were harvested at days 10, 14, 21, and 32 post infection. The levels 
of miRNAs expression were determined by qRT-PCR in the splenocytes from infected 
mice. Interestingly, in contrast to the lytic MHV-68 protein coding genes, the expression 
of the miRNAs increased over time after 21 dpi, suggesting that the MHV-68-encoded 
miRNAs may play more fundamental roles during later stages of latent infection. 
 
In order to determine the potential roles of the MHV-68 miRNAs in virus pathogenesis, 
a miRNA mutant virus lacking the expression of 9 miRNAs, named MHV-
68.ΔmiRNAs, was constructed. The miRNA mutant virus replicated with the same 
kinetics as wild type virus in vitro and in vivo demonstrating that the deleted MHV-68 
miRNAs are dispensable for virus lytic replication. To examine the roles of the miRNAs 
during virus latency, the MHV-68.ΔmiRNAs virus was characterised throughout a 49-
day course of infection. 
 
Although the level of ex vivo reactivation of the MHV-68.ΔmiRNAs virus was 
comparable to that of the WT virus during the establishment of latency and as late as 28 
dpi, the reactivation of the MHV-68.ΔmiRNAs virus was approximately 18-times higher 
than that of the WT virus at 49 dpi despite the similar levels of the genomic viral DNA 
loads at the same time-point. This suggests that the MHV-68 miRNAs suppress virus 
reactivation and promote maintenance of long-term latency. Moreover, the lytic viral 
gene expression levels were higher in splenocytes from the MHV-68.ΔmiRNAs-infected 
mice than the basal expression levels in the splenocytes from WT MHV-68-infected 
mice, suggesting that the MHV-68 miRNAs may suppress viral lytic gene expression 







Human and animal cells produce small molecules called microRNAs (miRNAs). These 
molecules function as rheostats that make fine-scale adjustments to protein levels inside 
the cells by switching off gene expression. Therefore, they can regulate almost all the 
biological processes inside our cells. Interestingly, not only cells express miRNAs, but 
viruses also produce miRNAs to evade the immune system and turn the conditions 
within the host to their advantage. However, little is known about the exact functions of 
the viral miRNAs. Here my research comes in. I try to understand the functions of the 
miRNAs expressed by a virus called mouse gamma-herpesvirus-68 (MHV-68).  
Herpesviruses establish latent infection, which means the virus remains dormant for the 
lifetime of the host and its gene expression is shut off. However, under certain 
conditions such as stress or immunosuppression the virus can reactivate and its gene 
expression is turned on to produce infectious virus. During the latent infection, some 
human herpesviruses can cause some types of cancer such as Burkett’s lymphoma and 
Kaposi’s sarcoma. Unfortunately, we cannot infect lab animals with human 
herpesviruses because they are not susceptible to the infection with these viruses.  The 
mouse herpesvirus provides a tractable animal model for studying pathologic features 
that are difficult to assess in humans and thus we can apply the lessons we learn from the 
mouse to humans.  
In my research it was found that the expression levels of MHV-68 miRNAs increase 
during virus latency, implying that these miRNAs may play a role during latent 
infection. In order to explore this role, a mutant virus lacking the expression of a number 
of miRNAs was constructed. The characteristics of this mutant virus were examined in 
comparison with the intact wild-type virus in order to gain insight into the potential 
miRNAs functions. During long-term latency, it was found that the levels of viral gene 
expression and the levels of virus reactivation are higher in the mice infected with the 
miRNAs mutant virus than in those infected with the wild-type virus. This suggests that 
the MHV-68 miRNAs inhibit precocious reactivation so that it can maintain the viral 
latency and help the virus lay low, thus the virus can remain under the radar of the host 
immune surveillance. These results pave the way for further research that can unravel 
more about viral miRNAs functions and open doors for establishing novel therapeutic 
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The word herpes is taken from the Greek herpein, meaning to creep or crawl and  
refers to spreading of lesions characteristic of herpesvirus infections of the skin 
(Roizman, Campadelli-Fiume et al. 2011). Herpesviruses are now recognized to 
infect a wide range of tissues and organs in many species and in 2009 the family 
Herpesviridae was elevated to the order Herpesvirales following the discovery of 
fish and molluscs herpes viruses, comprising at least 135 members within 3 families: 
Herpesviridae, Alloherpesviridae, and Malacoherpesviridae, infecting a wide range 
of hosts including mammals, birds, fish, frogs, and molluscs (Davison 2010). The 
various herpesviruses have diverse genomic sequences, but they have similar 
structure and genome organisation.  
 
All the herpesviruses are able to replicate in the nucleus of the host cell, encode 
enzymes required for the DNA synthesis and protein processing, and  establish latent 
infection following the primary productive infection with the ability to reactivate at 
later stage under certain conditions (Roizman and Pellet 2013). The virus particles 
vary in diameter (120-300 nm) and contain double-stranded linear DNA genomes 
with sizes ranging from ~120 to 250 kilo base pairs depending on the virus species. 
The DNA genome is contained in an enveloped icosahedral capsid. A proteinaceous 
material is present between the lipid bilayer envelope and the capsid, called the 
tegument. The envelope carries glycoproteins that mediate attachment to the host cell 
and virus entry. Herpesviruses are important pathogens in both humans and animals. 
They cause a variety of diseases in humans including cold sores, chicken pox, 
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shingles, encephalitis, and cancer. In animals they can cause rhinotracheitis, 
pneumonia, genital infection, mastitis, malignant catarrhal fever, abortion, and 
cancer. 
1.1.1 Classification of the family Herpesviridae 
 
Early classification was based on the physical and biological properties such as 
virion morphology, host range, cell tropism, growth cycle, and pathogenic features. 
The classification is now based on the genomic organisation and sequence-based 
phylogeny (Davison 2010). The family Herpesviridae is divided into 3 subfamilies: 
Alphaherpesvirinae, Betaherpesvirinae, and gammaherpesvirinae. Table 1.1 shows a 




Members of the Alphaherpesvirinae subfamily are characterized by short growth 
cycle, rapid spread, and latency establishment primarily, but not exclusively, in 
sensory neurons (Roizman and Pellet 2013). The Alphaherpesvirinae subfamily 
includes the genera Simplexvirus (e.g. Herpes simplex virus 1 and 2), Varicellovirus 
(e.g. Varicella-zoster virus, Bovine herpesvirus 1, and Feline herpesvirus 1), Iltovirus 
(e.g. Gallid herpesvirus 1 and Psittacid herpesvirus 1), and Mardivirus (e.g. Gallid 
herpesvirus 2 (Marek’s disease virus)). The latter virus is different from the other 
alphaherpesviruses in that it establishes latency in CD4+ T-cells and can cause T-cell 
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 Subfamily  Genus Virus name Host Disease 
Alphaherpesvirinae 
Simplexvirus 
Herpes simplex virus 1 
and 2 
Human 





Varicella-zoster virus Human 
Chicken pox and 
zoster (shingles) 





Equid herpesvirus 4 Horses Rhinopneumonitis 





Gallid herpesvirus 1 Chickens 
Infectious 
laryngotracheitis 
Psittacid herpesvirus 1 Psittacinae Pacheco's disease 










Muromegalovirus Murine cytomegalovirus Mice Asymptomatic 
Roseolovirus 











Epstein-Barr virus (EBV)/ 




















Murine herpesvirus 68 
(MHV-68)/ Murid 














natural host, T-cell 
lymphoma in other 
monkey species  
Macavirus 























Chapter One                                                                                                                     Introduction
  
5 
Table ‎1-1 Selected Herpesviridae family members and their medical and 
veterinary importance. 
  





Betaherpesviruses have a narrower host range and are characterised by long growth 
cycle, slow spread, latency establishment in myeloid progenitor cells, persistence in 
epithelial cells of salivary glands and kidneys, and induction of cell enlargement 
(cytomegalia) (Mocarski, Shenk et al. 2013). 
The Betaaherpesvirinae subfamily includes the genera Cytomegalovirus (e.g. Human 
cytomegalovirus (HCMV)), Muromegalovirus (e.g. Murine cytomegalovirus 
(MCMV)), Roseolovirus (e.g. Human herpesvirus 6 and 7), and Probiscivirus (e.g. 




The subfamily Gammaherpesvirinae includes the genera Lymphocryptovirus (e,g. 
Epstein-Barr virus (EBV)), Rhadinovirus (e.g. Kaposi’s sarcoma herpesvirus 
(KSHV), murine gammaherpesvirus 68 (MHV-68), and herpesvirus saimiri), and 
Macavirus (e.g. Ovine herpesvirus 2 (OvHV-2)). The gammaherpesviruses are 
characterized by primary productive infection in epithelial cells followed by latency 
establishment in lymphocytes (Roizman and Pellet 2013).  Strict species specificity 
of gammaherpesviruses precludes infection of animals with the human viruses. 
MHV-68 (also referred to as γHV68 and Murid herpesvirus 4 (MuHV-4)) is 




1.1.2 Herpesvirus structure 
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All herpesvirus virions consist of 4 major structural elements (Figure 1.1): 
1- Genomic DNA core. It consists of a linear double-stranded DNA genome 
(120-250 kb). 
2- Capsid. It surrounds the DNA core, 100 nm in diameter, and is composed of 
162 capsomeres (150 hexons and 12 pentons), arranged in icosahedral 
symmetry (triangulation number T=16) (Brown and Newcomb 2011). The 
capsid contains 4 conserved proteins: the major capsid protein, the monomer 
and dimer proteins of the triplex, and the small capsomere-interacting protein 
(Roizman and Pellet 2013). 
3- Tegument. It is located between the capsid and the envelope. It contains 
proteins that facilitate virus infection immediately after entry such as by 
shutting down host protein synthesis, evading cell defences, and stimulating 
viral gene expression; in addition, it plays a role in virus assembly and egress 
(Guo, Shen et al. 2010, Roizman and Pellet 2013). 
4- Envelope. It is the outer layer of the virion. It mainly consists of host-cell 
derived lipid 
membranes containing virally encoded glycoproteins that appear in electron 
micrographs as short spikes embedded in the envelope (Roizman, 













  Capsid 
Tegument 
Envelope glycoproteins 
Figure 1.1 Diagram showing herpesvirus structure with major 
elements denoted. 
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1.1.3 Herpesvirus life cycle 
 
The herpesvirus life cycle is divided into lytic phase (characterised by production of 
infectious progeny) and latent phase (characterised by suppression of viral 
replication resulting in a quiescent state). The establishment of lytic or latent 
infection in an infected cell in the natural host mainly depends on the type of infected 
cells and virus tropism. The virus can undergo lytic reactivation from latency; for 
example during immunosuppression, leading to production of progeny virus that can 
infect new host. The HSV life cycle is the best understood and has been extensively 
studied; therefore, its life cycle will be reviewed in detail below. 
1.1.3.1 Lytic infection 
 
The purpose of the productive or lytic infection is to produce infectious virions that 
can infect other cells and spread to other hosts. Lytic infection involves virus 
attachment and entry into host cells, viral gene expression, viral DNA genome 
replication, and virion assembly and egress. 
1.1.3.1.1   Attachment and entry 
 
The initial step of virus entry into the host cell is virus attachment that involves the 
binding of the viral envelope glycoproteins to the cell receptors. Herpesviruses infect 
wide varieties of cell types and therefore they employ multiple cell surface receptors 
for virus entry. For most herpesviruses the initial attachment involves interactions of 
viral glycoprotein gB with cell surface heparan sulfate proteoglycans (Roizman and 
Pellet 2013). Herpes simplex virus glycoproteins gB and gC initially bind to cell 
surface receptor heparan sulfate followed by binding of the glycoprotein gD to at 
least one of the three classes of receptors nectins-1,  
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herpesvirus entry mediator (HVEM), or 3-O sulfated heparan sulfate (Shukla, Liu et 
al. 1999, Spear 2004, Akhtar and Shukla 2009). The binding of gD to its receptor 
causes gD conformational changes allowing its interaction with viral glycoproteins 
gB, gH, and gL forming a complex that mediates fusion of virion envelope with the 
host cell membrane (Subramanian and Geraghty 2007). After attachment to host cell 
receptors, herpesviruses enter cells by: fusion of virus envelope with the cell 
membrane at the cell surface (Roizman and Pellet 2013).  This results in release of 
viral capsids and the associated tegument proteins into the cytoplasm.   
 
Viral capsids are transported to the nuclear pores along the microtubular network via 
the microtubule motor dynein (Sodeik, Ebersold et al. 1997, Dohner, Nagel et al. 
2005, Wolfstein, Nagel et al. 2006, Radtke, Kieneke et al. 2010). The binding of the 
viral glycoproteins to the host receptors causes immediate rearrangement of host cell 
cytoskeleton (Lyman and Enquist 2009). For example, binding of the gB 
glycoprotein of KSHV to the α3β1 integrin receptor resulted in microtubular 
stabilisation and the activation of the RhoA and Rac1 GTPases (Naranatt, Krishnan 
et al. 2005). The inactivation of Rho GTPases by Clostridium difficile toxin B led to 
reduction in microtubular acetylation and decreased delivery of viral DNA to the 
nucleus. In contrast, the activation of Rho GTPases by E.coli cytotoxic necrotising 
factor resulted in increased nuclear delivery of viral DNA (Naranatt, Krishnan et al. 
2005).  Hence, activation of the Rho GTPases following receptor binding is a 
possible trigger for rearrangement of the cytoskeleton following herpesvirus 
infections.  
It has been suggested that the inner tegument proteins enhance capsid transport via 
the microtubules (Luxton, Haverlock et al. 2005, Wolfstein, Nagel et al. 2006). The 
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HSV inner tegument proteins VP1/2 and UL37 are required for efficient movement 
of capsids along the microtubules in vitro, whereas capsids without tegument 
proteins showed no movement (Wolfstein, Nagel et al. 2006). Furthermore, live-cell 
imaging experiments investigating the retrograde (minus-end) transport of 
pseudorabies virus capsids fused to monomeric red fluorescent protein and tegument 
proteins fused to green fluorescent protein in sensory neurons showed that the inner 
tegument proteins VP1/2 and UL36 were associated with the capsids as they entered 
the cells and transported to the nucleus, whereas the outer tegument proteins 
VP13/14, VP16, and VP22 were not associated with the capsids following virus 
entry and during the transport to the nucleus; however, they underwent anterograde 
transport and associated with progeny capsids, suggesting that they may direct viral 
egress (Luxton, Haverlock et al. 2005). 
Studies on the temperature-sensitive HSV-1 mutant (tsB7) showed that viral DNA is 
released at the nuclear pores and that the tsB7 mutation affects the VP1/2 tegument 
protein, which must be cleaved to allow the release of the viral DNA into nucleus 
(Jovasevic, Liang et al. 2008, Abaitua, Daikoku et al. 2011, Roizman, Knipe et al. 
2013). Interestingly, cellular proteins can also help the docking of viral DNA to 
nuclear pores such as the nuclear pore complex proteins Nup358/RanBP2 and 
Nup214/CAN as well as the nuclear factor importin β (Copeland, Newcomb et al. 
2009, Pasdeloup, Blondel et al. 2009, Roizman, Knipe et al. 2013). 
 
1.1.3.1.2 Gene expression 
 
During lytic infection, the viral genes form 3 classes depending on the order of gene 
expression and the mechanisms that drive them. These are the alpha (α) or 
immediate-early (IE) genes that do not require new protein synthesis for their 
Chapter One                                                                                                                     Introduction
  
12 
expression and regulate the expression of other viral genes, the beta (β) or early (E) 
genes whose expression is not dependent on viral DNA synthesis and is dependent 
on IE gene expression, and the gamma (γ) or late (L) genes whose transcription is 
dependent on viral DNA synthesis (Roizman and Pellet 2013). The late genes can be 
divided into 2 groups: (i) γ1 (also referred to as the leaky-late or early-late (E-L) 
genes) whose transcription is enhanced by viral DNA synthesis and (ii) the γ2 (true 
late) genes whose transcription is totally dependent on viral DNA synthesis. The 
HSV IE gene expression is transactivated by the HSV virion protein 16 (VP16), a 
tegument protein that assembles into a transactivator complex with two host cellular 
proteins, host cell factor 1 (HCF-1) and the octamer binding transcription factor 1 
(Oct-1) (Knipe 2015, Roizman and Zhou 2015). This complex binds to IE gene 
promoters leading to their transcription during lytic infection. Upon the entry of HSV 
DNA into the nucleus of the neuron, it is circularised and transcription is repressed 
and there is no DNA replication. As VP16 is a tegument protein that enters the 
neurons with the infecting virus, little VP16 reaches the nucleus of the neuron, which 
is a long distance along the axon from the site of infection (Roizman and Zhou 
2015). Moreover, neurons contain 2 transcription factors, Zhangfei and Luman, 
which bind to HCF-1 and prevent formation of  active transactivator complexes 
(Roizman, Knipe et al. 2013). In the absence of IE gene expression, the viral genome 
remains silent, with the exception of a class of RNAs called latency-associated 
transcripts (LATs) and a group of microRNAs.  
 
1.1.3.1.3 Viral DNA circularisation 
 
Following the entry into the nucleus, the viral DNA circularises rapidly in the 
absence of viral protein synthesis (Roizman, Knipe et al. 2013). Using mutant cell 
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lines and small interfering RNA-mediated knockdown, it has been shown that viral 
DNA circularisation, formation of endless genomes, and viral DNA replication 
require the cellular DNA ligase IV/XRCC4 (Muylaert and Elias 2007). 
 
1.1.3.1.4 Association of viral DNA with histones 
 
Herpesviral DNA in the virion is not associated with histones. Chromatin regulation 
by histone modification plays an important role in lytic or latent infection decision by 
herpesvirus (Knipe 2015). During HSV infection in epithelial cells, viral proteins 
minimise association of histones with viral lytic gene promoters and enhance 
euchromatin histone modification on histones that are associated with viral DNA. In 
contrast, during latent HSV infection in neurons, viral DNA is loaded with 
heterochromatin resulting in gene silencing and establishment of latent infection 
(Knipe and Cliffe 2008, Knipe 2015).  
HSV VP16 loads onto IE gene promoters, leading to recruitment of general 
transcription factors, RNA polymerase II, and chromatin-remodeling enzymes to IE 
promoters resulting in activation of IE gene transcription (Kristie 2015, Roizman and 
Zhou 2015). The cellular HCF-1 protein recruits the Set1 histone methyl transferase 
to IE gene promoters for the euchromatic histone H3 lysine 4 (H3K4) methylation 
modification, the LSD1 demethylase to remove the heterochromatic H3K9me and 
H3K9me2 methylation modification, and the JMJD2 demethylases to demethylate 
H3K9me3 (Knipe 2015). Thus, the IE gene promoters-associated histones contain 
euchromatic histone modifications that correspond to active transcription of IE 
genes.  
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A previous published study on HSV revealed that there are higher levels of 
acetylated H3 histone associated with the LAT promoter as compared to the key 
transcriptional activator infected cell protein 0 (ICP0) viral gene, suggesting that the 
active chromatin is specifically associated with the LAT gene (Kubat, Amelio et al. 
2004). Moreover, during the establishment of HSV latency, the lytic-gene promoters 
become increasingly associated with chromatin that contains modified histones, 
which are associated with heterochromatin, particularly dimethyl H3K9me2 (Wang, 
Zhou et al. 2005). The methylation of the HSV DNA cannot be detected during 
latency and hence the lytic genes are likely silenced by heterochromatin rather than 
by methylation of DNA (Dressler, Rock et al. 1987, Kubat, Tran et al. 2004). Thus, 
the lytic genes are associated with heterochromatin, whereas the LAT gene is 
associated with euchromatin. 
Concurrent with the viral DNA association with histones, the cellular nuclear domain 
10 (ND10) or promyelocytic leukemia nuclear bodies (PML), which are associated 
with multiple functions such as epigenetic regulation of gene expression and 
transcriptional activation, are localised adjacent to the newly entered DNA 
(Roizman, Knipe et al. 2013). The role of ND10 during HSV infection is 
controversial. Chee et. al. suggested that wild-type HSV replicated at similar levels 
in murine PML-/- and PML+/+ cells and that IFN-α or –γ have a major effects in 
PML+/+ cells and minimal effects in PML-/- cells; however, it was reported that the 
replication of an ICP0 mutant virus is 3-fold higher in PML-/- cells as compared to 
PML+/+ cells (Chee, Lopez et al. 2003). On the other hand, Everett et. al.  reported 
that ICP0 co-localises with ND10 and causes PML degradation and that an ICP0 
mutant virus was 3- to 5-fold more efficient in plaque formation when PML was 
depleted by short interfering RNA (Everett, Rechter et al. 2006). Recently, it has 
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been reported that HSV-1 at multiplicity of infection of 5 plaque forming units (pfu) 
per cell replicates to equal levels in the parental human epithelial cells and in PML-/- 
cells, which were generated by transfection of clustered regularly interspaced short 
palindromic repeats (CRISPR)/cas9 cassette targeting exon 1 of PML, but 
surprisingly, at low multiplicity of infection (0.1 pfu/cell), the virus replicated in the 
parental cells 100-fold higher than PML-/- cells (Xu, Mallon et al. 2016), suggesting 
that PML can also be beneficial to virus replication. 
 
1.1.3.1.5 Viral genome replication 
 
Herpesvirus DNA replication occurs in the nucleus and it is dependent on the 
presence of the viral early proteins, the DNA replication proteins, and sufficient 
biosynthetic precursors. Like other viruses, herpesviruses rely on the host cell 
metabolic activity to provide building blocks and energy for viral replication. Some 
herpesviruses can alter the cellular metabolic pathways in order to facilitate viral 
replication. For example, HSV enhances pyrimidine biosynthesis (Vastag, Koyuncu 
et al. 2011), whereas HCMV manipulates the tricarboxylic acid cycle to enhance 
lipid biosynthesis (Munger, Bennett et al. 2008, Vastag, Koyuncu et al. 2011, Yu, 
Clippinger et al. 2011).  
 
1.1.3.1.6 Virus assembly and egress 
 
The different stages of virion assembly occur initially in the nucleus and then the 
cytoplasm. In the nucleus, the newly formed capsids are assembled on temporary 
scaffolds, then filled with newly replicated viral genome in an energy dependent 
manner (Mettenleiter, Klupp et al. 2009, Roizman and Pellet 2013). The first main 
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barrier during virus egress is the nuclear membrane. The viral nucleocapsids are too 
large to pass through the nuclear pores, which exhibit no gross perturbation during 
viral movement across the nuclear membrane (Hofemeister and O'Hare 2008). 
Instead, the nucleocapsids become enveloped by budding at the inner nuclear 
membrane into the perinuclear space (primary envelopment). This process is 
followed by de-envelopment of the virus particles, involving membrane fusion 
between the outer nuclear membrane and the virus envelope, thereby the capsids are 
delivered into the cytoplasm (Johnson and Baines 2011). It has been shown recently 
that in the absence of regulated nuclear egress, the alphaherpesvirus pseudorabies 
virus was able to exit the nucleus after virus-induced nuclear envelope breakdown 
(Schulz, Klupp et al. 2015), suggesting that both mechanisms (envelopment-de-
envelopment pathway and nuclear envelope breakdown) can occur simultaneously 
under certain conditions.  
 
The newly formed virions that enter the cytoplasm consist of nucleocapsids and inner 
tegument proteins. Further assembly steps involve addition of tegument proteins and 
some RNAs (cytoplasmic tegumentation) followed by acquisition of mature envelope 
(secondary envelopment) during budding into cytoplasmic membranes, producing 
infectious virus. Then the enveloped virions are transported to the cell surface via the 
cytoplasmic vesicles followed by fusion between virion envelope and the plasma 
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1.1.3.2 Latent infection 
 
A common feature of the herpesviruses is their ability to establish and maintain latent 
infection within the natural host. In latently infected cells, the viral genome takes the 
form of a circular molecule from which a very limited number of viral genes are 
expressed and therefore no infectious virus can be detected. The latent virus genome 
is able to reactivate and undergo lytic infection cycle and produce infectious virions 
under certain conditions such as immunosuppression. Latent infection is different 
from chronic or persistent infection in that the infectious virus is not produced during 
latency. Different herpesviruses establish latent infection in different cell types. For 
example, HSV establishes latency in the neurons of sensory ganglia, whereas EBV 
establishes latency mainly in B lymphocytes (Roizman and Pellet 2013). 
 
Latency is a complex process that involves interaction between viral and host cellular 
factors. The exact molecular mechanisms behind the establishment of and the 
reactivation from latency are not fully understood. Latent infection is usually 
established following the primary lytic infection and it involves: (i) suppression of 
lytic infection and restriction of lytic gene expression while maintaining latent gene 
expression, (ii) enhanced survival of the latently infected cells through evasion of the 
immune response and prevention of apoptosis, and (iii) prevention of undesired 
reactivation whilst keeping the virus ability to reactivate under the appropriate 
conditions.  
In addition to viral proteins, which play crucial roles in latency, virally encoded 
microRNAs (miRNAs) also play important roles during latent infection. The 
miRNAs are small non-coding RNAs that regulate gene expression post-
transcriptionally. They are present in all mammalian cells and play various roles in 
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different biological processes such as cellular differentiation, proliferation, 
development, apoptosis, and cell cycle regulation (Bartel 2004). The miRNAs 
encoded by herpesviruses can be elegant tools for promoting viral latency because 
they are non-immunogenic and therefore can evade the innate and adaptive 
immunity. Many studies have shown that the miRNAs encoded by herpesviruses 
play various roles in promoting latent infection such as inhibition of lytic gene 
expression, enhancing the proliferation and survival of latently infected cells, and 
evading the immune response (reviewed in section 1.6).   
Almost all herpesviruses that have been studied in-depth encode miRNAs with the 
exception of Varicella Zoster Virus (VZV), a human herpesvirus that causes chicken 
pox and shingles (Umbach, Nagel et al. 2009). However, the other animal 
Varicelloviruses such as Bovine Herpesvirus-1 and Suid Herpesvirus-1 do encode 
miRNAs (Glazov, Horwood et al. 2010, Anselmo, Flori et al. 2011). This suggests 
that VZV latency is different from the latency of other herpesviruses in terms of viral 
miRNA utilisation. 
1.2 Important human gammaherpesviruses  
 
1.2.1 Epstein-Barr virus (EBV) 
 
In 1964, EBV was discovered by Anthony Epstein and his colleague Yvonne Barr 
using electron microscopy in cells cultured from Burkitt’s lymphoma biopsies 
(Epstein, Henle et al. 1965). A few years later, Werner and Gertrude Henle 
discovered that EBV is responsible for infectious mononucleosis, a self-limiting 
lymphoproliferative disease characterised by proliferation of infected B lymphocytes 
followed by their destruction by T cytotoxic lymphocytes  (Henle, Henle et al. 1968). 
After its discovery, EBV was shown to be associated with several neoplastic diseases 
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such as Burkitt’s lymphoma, nasopharyngeal carcinoma, Hodgkin’s lymphoma, non-
Hodgkin’s lymphoma, oral hairy leukoplakia, and extranodal NK-T-cell lymphoma 
(Pope, Horne et al. 1968, zur Hausen, Schulte-Holthausen et al. 1970, Cohen, Wang 
et al. 1989, Bignon, Bernard et al. 1990, Herbst, Niedobitek et al. 1990, Brocksmith, 
Angel et al. 1991, Bellas, Mampaso et al. 1993, Nicolas, Marechal et al. 1997).  
 
EBV is a highly successful virus that persists in over 90% of the human adult 
population where most primary infections occur in childhood with no obvious 
symptoms (Longnecker, Kieff et al. 2013). EBV infection is asymptomatic in 
immunocompetent individuals, but during immunosuppression the virus causes 
lymphoproliferative disorders and can be associated with some types of cancer 
(Young and Rickinson 2004). EBV infects B lymphocytes through binding of the 
viral glycoprotein gp350 to the CD21 receptor of the B cells in addition to binding of 
gp42 to human leukocyte antigen class II molecules as a co-receptor (Nemerow, 
Mold et al. 1987, Borza and Hutt-Fletcher 2002). EBV can also infect epithelial 
cells; however, at less efficiency than B cells and through different pathways (Borza 
and Hutt-Fletcher 2002). Interestingly, EBV is able to transform resting B 
lymphocytes into latently infected lymphoblastoid cell lines in vitro (LCLs) and 
therefore they are considered the dominant in vitro model for studying EBV latency 
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1.2.1.1 EBV Latency 
 
Like other herpesviruses, EBV gene expression is highly restricted during latent 
infection. There are 2 sets of EBV proteins produced in the latently infected B 
lymphocytes: Epstein-Barr nuclear antigens (EBNAs) and latent membrane proteins 
(LMPs). There are 6 distinct EBNAs (EBNA-1, -2, -3A, -3B, -3C, and LP) resulting 
from differential splicing of mRNAs from long primary transcripts, whereas there are 
3 LMPs: LMP-1, -2A, and -2B (Rowe, Lear et al. 1992). Fascinatingly, EBV makes 
use of the normal B cell biology to establish life-long latent infection in memory B 
cells through activation of naïve B cells to become proliferating blasts and 
consequently differentiate into resting memory B cells through the process of the 
germinal-center reaction (Figure 1.2) (Thorley-Lawson and Gross 2004). Therefore, 
the difference between the antigen- activated B cell blast and the virus-infected B cell 
blast is that viral genes, not antigens, provide the signals required for differentiation of 
the B cell blasts into memory B cells. 
 
The EBV infects naïve B cells where viral gene expression exhibits latency III pattern 
(growth programme) with expression of all EBNA proteins and LMP proteins as well 
as Epstein-Barr virus–encoded RNAs (EBERs), BamHI A rightward transcript 
(BART) miRNAs, and BamHI H reading frame 1 (BHRF1) miRNAs (Table 1.2). The 
EBNA-1 protein plays a central role in latency by maintaining the viral genome as an 
extrachromosal episome in dividing cells (Yates, Warren et al. 1984, Yates, Warren et 
al. 1985, Kang and Kieff 2015).  The EBNA-2 activates EBV-infected naïve B cells 
and trans-activates the expression of LMP-1 and LMP-2A proteins (Wang, Tsang et al. 
1990, Zimber-Strobl, Kremmer et al. 1993). LMP-2A mimics antigen-independent B 
cell receptor (BCR) signaling through constitutive activation of the ERK/MAPK 
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pathway, therefore EBV-infected naïve B cells undergo germinal-centre reaction 
(Caldwell, Wilson et al. 1998, Anderson and Longnecker 2008, Kang and Kieff 2015). 
LMP-1 mimics the constitutive active form of CD40, resulting in B cell growth and 
differentiation (Kilger, Kieser et al. 1998).  
 
It has been suggested that the virus drives the infected naïve B cells into the memory 
state by switching the viral transcription programme from the growth programme 
(latency III) to the default programme (latency II) (Thorley-Lawson and Gross 2004, 
Longnecker, Kieff et al. 2013) (Figure 1.2 and table 1.2). At this stage of latency, the 
virus expresses EBNA-1 and LMP proteins as well as EBERs and BART miRNAs 
(Babcock and Thorley-Lawson 2000, Longnecker, Kieff et al. 2013). The latently 
infected memory B cells shut down viral protein expression and circulate in the 
peripheral blood, entering latency 0 programme where only the EBERs can be 
detected in the infected cells (Hohaus, Santangelo et al. 2011, Longnecker, Kieff et al. 
2013). However, EBNA-1 along with EBERs and BART miRNAs are expressed in 
dividing latently infected memory B cells (latency programme/latency I) (Hochberg, 
Middeldorp et al. 2004, Longnecker, Kieff et al. 2013). When memory B cells 
differentiate into plasma cells, the latent virus is reactivated and replicates so that it 
can spread to a new host and infect new naïve B cells within the same host (Laichalk 
and Thorley-Lawson 2005). 
 
The type III latency is established in EBV-positive cells during the post-transplant 
lymphoproliferative disorder and in human B cells immortalised in vitro by EBV 
infection (LCLs), whereas biopsies from Hodgkin’s lymphomas and nasopharyngeal 
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carcinomas exhibit type II latency and the cells derived from Burkitt’s lymphoma and 
gastric carcinoma exhibit type I latency (Table 1.2).  
Besides EBV proteins, the miRNAs encoded by EBV play roles in promoting latency. 
For example, although mutant EBV viruses that lack BHRF1 miRNAs expression  
were able to generate LCLs following infection of naïve B cells, the initial 
proliferation and transformation capacity of LCLs were reduced as compared to the 
WT virus due to reduction in cell cycle progression and increased apoptosis (Seto, 
Moosmann et al. 2010, Feederle, Linnstaedt et al. 2011). It has been shown that the 
miRNA, BART-miR-18-5p, targets the cellular MAP3K2, which is important for 
initiation of lytic viral cycle, resulting in suppression of reactivation in latently 
infected memory B cells (Qiu and Thorley-Lawson 2014). Moreover, it has been 
demonstrated that BART miRNAs target multiple pro-apoptotic cellular mRNAs in 
latently infected epithelial cells derived from nasopharyngeal carcinoma, resulting in 
enhanced cell survival and robust long-term latent infection (Kang, Skalsky et al. 
2015).  
The most abundant EBV encoded non-coding RNAs, EBERs, play various roles 
during latency. They augment colony formation and enhance cell growth (Komano, 
Maruo et al. 1999, Houmani, Davis et al. 2009, Repellin, Tsimbouri et al. 2010) and 
play roles in enhancing cell survival through inhibition of PKR-dependent apoptosis 
(Nanbo and Takada 2002). In addition, they play roles in modulating innate immunity 
(Samanta, Iwakiri et al. 2006, Iwakiri, Zhou et al. 2009). 
 
1.2.1.2 EBV types 
 
To date, there are approximately 83 strains of EBV that have been completely 
sequenced (Palser, Grayson et al. 2015). Based on the genomic variation, there are 
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two types of EBV, type 1 and type 2, which differ mainly in the sequences of EBNA-
2 and EBNA-3 genes (Palser, Grayson et al. 2015). However, there are variations in 
other viral genes, mainly latent genes, but this variation does not correspond to the 
type 1/type 2 classification. The major phenotypic difference between the two EBV 
types is that type 1 is more efficient in transforming primary B cells (Palser, Grayson 
et al. 2015, Young, Yap et al. 2016). It has been shown recently that in contrast to 
type 1, Type 2 can latently infect T cells, inducing cell proliferation and cytokine 
production (Coleman, Wohlford et al. 2015). However, the impact of genomic 
variation on the biology of EBV infection is not clear.  
 
1.2.1.3 EBV latent transcripts 
 




 EBNA-1 maintains the viral genome as extrachromosomal episome in proliferating 
cells through binding to multiple sites within the plasmid latent origin of replication 
(oriP); thus, it segregates the daughter genomes into each of the two progeny cells 
during mitotic division (Yates, Warren et al. 1984, Rawlins, Milman et al. 1985, 
Kanda, Otter et al. 2001). The EBNA-1 protein carries a glycine-alanine repeat 
sequence that stablises the protein through blocking the protein proteasomal 
degradation as well as preventing antigen processing by inhibition of the MHC class 
I-restricted presentation, thereby inhibiting CD8+ T-cellcytotoxic response against 
EBV-infected cells (Levitskaya, Coram et al. 1995, Young and Rickinson 2004). 
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Figure 1.2 EBV resembles normal B cell differentiation in order to drive naïve B 
cells into memory B cell pool.  
Following infection of naïve B cells, EBV activates these cells to become proliferating B 
cell blasts that undergo germinal centre reaction using the growth programme in a 
manner similar to that of antigen-mediated activation of naïve B cells. The antigen-
specific T help signals lead to survival of activated B cells and entry into memory B cell 
pool. The virus uses the default programme in order to induce these survival signals in 
the latently infected B cells driving them into becoming memory B cells. These memory 
cells then exit cell cycle and enter the peripheral circulation and exhibit no viral protein 
expression. Occasionally, memory B cells divide as part of normal B cell homeostasis. If 
the dividing memory B cell is infected with EBV, it expresses EBNA-1 protein, allowing 
the division of the latent viral genome along with the cell. The latently infected memory 
B cells may differentiate into plasma cells, resulting in virus reactivation and infectious 
virus production. Gene expression during each latency phase is indicated. Figure 
adapted from (Thorley-Lawson and Gross 2004). 
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On the other hand, EBNA-1 is consistently recognised by CD4+ T cells and gains 
access to MHC II processing by autophagy and undergo lysosomal degradation 
(Paludan, Schmid et al. 2005). 
 
EBNA-1 acts as transcriptional activator, regulating its own expression as well as the 
expression of other viral latency genes e.g. EBNA-2 and -3 and LMP-1 (Levitskaya, 
Coram et al. 1995, Young and Rickinson 2004). It has been shown that EBNA-1 is 
highly expressed in nasopharyngeal carcinoma tissues and it plays a role in inducing 
epithelial to mesenchymal transition in these tissues through regulation of the 
signalling pathways involving transforming growth factor-β1 (TGF- β1), microRNA 
200a (miR-200a) and miR-200b, and zinc finger E-box binding homeobox 1 ( ZEB1) 
and ZEB2 (Wang, Tian et al. 2014). EBNA-1 can play a role in facilitating latency 
through induction of let-7a miRNA which in turn reduces the cellular protein Dicer 




 EBNA-2 plays a crucial role in B lymphocyte transformation (Cohen, Wang et al. 
1989). Restoration of the EBNA-2 gene into an EBV strain, P3HR-1, lacking the 
EBNA-2 gene confirmed the role of EBNA-2 protein in B immortalisation (Rabson, 
Gradoville et al. 1982, Hammerschmidt and Sugden 1989). EBNA-2 acts as a 
transcriptional activator of cellular and viral genes; it upregulates the expression of B 
cell antigens such as CD21 and CD23 and the viral LMP-1 and -2; in addition, it 
transactivates the Cp promoter resulting in a switch from Wp to Cp during B-cell 
infection (Wang, Gregory et al. 1990, Gahn and Sugden 1995, Altmann, Pich et al. 
2006). EBNA-2 does not bind DNA directly, but rather it activates gene expression 
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by interacting with the cellular proteins such as RBP-Jκ (Grossman, Johannsen et al. 
1994). Both EBNA-2 and EBNA-LP associate the transcription factor bound to 
upstream DNA elements of cMyc, forming a long-range DNA looping, resulting in 
cell cycle entry and proliferation (Alfieri, Birkenbach et al. 1991, Zhao, Zou et al. 
2011, Portal, Zhou et al. 2013). 
 
1.2.1.3.1.3 EBNA-3 family 
 
The EBNA-3 family of proteins comprises EBNA-3A, B, and C. It was shown that 
EBNA-3A and EBNA-3C are essential for B-cell transformation in vitro. In contrast, 
EBNA-3B is not required for transformation, but it acts as oncogenic suppressor 
(Tomkinson and Kieff 1992, Tomkinson, Robertson et al. 1993, White, Ramer et al. 
2012). EBNA-3 proteins bind to the transcription factor RBP-Jκ and disrupt its 
binding to EBNA-2, inhibiting EBNA-2 mediated transactivation (Waltzer, 
Perricaudet et al. 1996, Cludts and Farrell 1998). It has been recently shown that 
EBNA-3 proteins interact with the USP46/USP12 deubiquitination complexes to 




EBNA-LP is transcribed along with EBNA-2 at the start of infection in primary B 
cells and co-operates with EBNA-2 in upregulating viral and cellular gene expression 
(Harada and Kieff 1997, Nitsche, Bell et al. 1997) and in inducing B cell 
proliferation (Alfieri, Birkenbach et al. 1991, Zhao, Zou et al. 2011, Portal, Zhou et 
al. 2013). 
1.2.1.3.2 The EBV latent membrane proteins 
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1.2.1.3.2.1 Latent membrane protein 1 (LMP-1) 
 
LMP-1 is a constitutively active tumour necrosis factor receptor (TNFR) mimic and 
it plays a key role in transforming primary B cells into LCLs (Kaye, Izumi et al. 
1993, Mosialos, Birkenbach et al. 1995). LMP-1 is a major EBV oncogene that 
mimics CD40 signalling and activates several signalling pathways such as the NF-κB 
transcription factor pathway, the JAK/STAT pathway, and the phosphatidylinositol 
3-kinase (PI3-K) pathway resulting in induction of anti-apoptotic cytokine genes, cell 
survival, actin polymerisation, and cell motility (Gires, Kohlhuber et al. 1999, 
Eliopoulos, Davies et al. 2002, Dawson, Tramountanis et al. 2003). 
 
1.2.1.3.2.2 Latent membrane protein 2 (LMP-2) 
 
There are 2 LMP-2 proteins, LMP-2A and LMP-2B. The 2 proteins only differ in 
that the first exon of LMP-2A encodes 119 extra N-terminal cytoplasmic amino 
acids, whereas the LMP-2B first exon is non-coding. LMP-2A mimics a B cell 
receptor (BCR) signal and thus inhibits normal B-cell signal transduction through 
interaction of the N-terminal cytoplasmic domain with tyrosine kinases, resulting in 
inhibition of virus reactivation from latency in B cells (Miller, Lee et al. 1994, 
Schaadt, Baier et al. 2005). Therefore, LMP-2A can counterbalance deficient B cell 
receptors in mouse model or human B cells, promoting B cell survival (Caldwell, 
Wilson et al. 1998, Mancao and Hammerschmidt 2007). In addition, LMP-2A has 
been reported to inhibit recognition of B cells by EBV specific CD8+ T cells 
(Rancan, Schirrmann et al. 2015). LMP-2B was found to negatively regulate LMP-
2A function (Rechsteiner, Berger et al. 2008). In general, LMP proteins stimulate the 
normal activation of B cells i.e. mimic the normal antigen-mediated B cell 
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differentiation in order to allow the latently infected B cells to enter the long lived 
memory B cell pool. 
 
1.2.1.3.2.3 EBV-encoded RNAs (EBERs) 
 
EBV expresses 2 non-polyadenylated non-coding RNAs named EBER-1 and EBER-
2, which are highly expressed in EBV latently-infected cells (Arrand and Rymo 
1982). EBERs form stem–loop structures giving rise to double-stranded RNA-like 
molecules (Young, Yap et al. 2016). Although they are present in all forms of EBV 
latency, they are not essential for the EBV-induced B cell transformation 
(Swaminathan, Tomkinson et al. 1991). EBERs are present in exosomes released 
from EBV-transformed cells and can interact with cellular proteins, exerting various 
functions during EBV infection such as promoting cell growth (Houmani, Davis et 
al. 2009, Repellin, Tsimbouri et al. 2010), inhibiting apoptosis (Nanbo and Takada 
2002), and modulating the innate immune response (Samanta, Iwakiri et al. 2006, 
Iwakiri, Zhou et al. 2009, Young, Yap et al. 2016).  
 
1.2.1.3.2.4 EBV miRNAs 
 
EBV miRNAs were the first virally encoded miRNAs discovered (Pfeffer, Zavolan 
et al. 2004). EBV encodes at least 25 primary miRNAs giving rise to at least 44 
mature miRNAs: 4 primary miRNAs are encoded from the BHRF1 cluster and the 
rest are encoded from the BART clusters (Cai, Schafer et al. 2006, Grundhoff, 
Sullivan et al. 2006, Zhu, Pfuhl et al. 2009, Chen, Chen et al. 2010). Barth et. al. 
demonstrated that EBV-miR-BART2 miRNA, which is expressed antisense to the 3’ 
UTR of the viral DNA polymerase BALF5, inhibits BALF5 expression and results in 
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20% reduction in virus production, suggesting that EBV-miR-BART2 promotes 
latency by suppression of active virus replication (Barth, Pfuhl et al. 2008).  
BART cluster 1 miRNAs were reported to target the 3’UTR of the EBV oncogene 
LMP-1, which is a crucial protein for transformation, leading to inhibition of LMP-1 
expression (Lo, To et al. 2007). This effect seems paradoxical, but very high levels 
of LMP-1 are toxic to the cells and modulating the LMP-1 levels may prevent this 
toxicity; in addition, modulating the LMP-1 level can be an immunoevasion 
mechanism by which the virus may avoid immunological attack when the LMP-1 is 
expressed on the cell surface. Expression of LMP-2 can also be inhibited by another 
miRNA, EBV-miR-BART22 that is expressed at high levels in NPC (Lung, Tong et 
al. 2009). Suppression of LMP-1 and LMP-2 expression by EBV miRNAs can serve 
as a mechanism to prevent their toxic effect or to evade the specific immune 
response targeting these proteins. 
 
It was reported that expression of the chemokine CXCL11/I-TAC, whose 3’UTR can 
be targeted by BHRF1-3 miRNA, was inhibited following expression of BHRF1-3 
miRNA and this effect was reversed by transfection of an antisense oligonucleotide 
to BHRF1-3 (Xia, O'Hara et al. 2008). EBV miRNAs can enhance cell survival 
through exerting anti-apoptotic functions. For example, EBV-miR-BART5 inhibits 
the expression of p53-up-regulated modulator of apoptosis (PUMA) (Choy, Siu et al. 
2008). Another study demonstrated that BART cluster 1 miRNAs can inhibit the 
expression of the pro-apoptotic BIM protein as well as PUMA (Marquitz, Mathur et 
al. 2011). A recent study has identified the mRNA targets of BART miRNAs in NPC 
cell line using photoactivatable ribonucleoside-enhanced crosslinking and 
immunoprecipitation (PAR-CLIP), where 10 pro-apoptotic mRNA targets were 
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validated by indicator assays and ectopic expression of the miRNAs (Kang, Skalsky 
et al. 2015), suggesting that EBV BART miRNAs promote cell survival of the 
latently infected epithelial cells and thus enhance long-term infection.  
 
EBV miRNAs can promote latent infection through suppression of reactivation. For 
instance, BART-miR-18-5p has been demonstrated to inhibit the expression of the 
cellular protein MAP3K2 leading to increased viral lytic gene expression and virus 
production (Qiu and Thorley-Lawson 2014). In addition to their roles in promoting 
cell survival and latency, EBV miRNAs can contribute to the virus-induced 
oncogenesis and to B cell proliferation (Seto, Moosmann et al. 2010, Babu, Ponia et 
al. 2011, Vereide, Seto et al. 2014). It has been recently shown that EBV-miR-
BART1 targets the tumour suppressor, phosphatase and tensin homologue (PTEN), 
leading to activation of PTEN-dependent pathways and induction of epithelial–
mesenchymal transition and metastasis in nasopharyngeal carcinoma (Cai, Ye et al. 
2015). 
 
1.2.1.4 EBV associated diseases 
 
EBV is usually asymptomatic in immunocompetent individuals, but it can be 
associated with lymphoproliferative disorders and some types of cancers, particularly 
in immunocompromised individuals. 
 
1.2.1.4.1 Infectious mononucleosis (IM) 
 
IM mainly occurs during primary infection in immunocompetent young adults with 
symptoms including mild fever, pharyngitis, lymphadenopathy, and fatigue 
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(Williams and Crawford 2006). IM is an immunopathological disease resulting from 
increased CD8+ T cell cytotoxic response targeting EBV-infected B cells for 
destruction following EBV-induced B cell proliferation (Williams and Crawford 
2006). 
 
1.2.1.4.2 Post-transplant lymphoproliferative disorder (PTLD) 
 
This disease mainly occurs due to therapeutic immunosuppression following organ 
transplantation where EBV infection causes uncontrolled B lymphocyte proliferation 
(Singavi, Harrington et al. 2015). It is thought that the impaired T cell response leads 
to failure in eliminating EBV-infected cells and hence the uncontrolled B cell 
proliferation (Thorley-Lawson and Gross 2004). 
 
1.2.1.4.3 Burkitt’s lymphoma (BL) 
 
BL is a cancer in the lymphatic system involving B lymphocytes and is associated 
with EBV infection. It was named after Denis Parsons Burkitt, an Irish physician 
who first described the disease in 1958 while working in Uganda and saw a young 
boy with jaw swelling that was proved to be lymphoma tumour (Burkitt 1958). This 
lymphoma is the most common childhood cancer in equatorial Africa. In 1964, 
Anthony Epstein and Yvonne Barr studied lymphoma biopsies sent from Uganda and 
discovered via electron microscopy herpesvirus particles, named Epstein-Barr virus, 
in cells cultured from the tumour biopsies (Epstein, Henle et al. 1965).  
There are 3 clinical variants of BL (Molyneux, Rochford et al. 2012): (i) The 
endemic variant (also referred to as African variant) occurs in children living in 
malaria endemic regions (such as equatorial Africa, Brazil, and Papua New Guinea) 
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and the EBV infection is found in almost all patients and the disease involves jaw 
bones, distal ileum, kidney, ovaries, cecum, or breast (Molyneux, Rochford et al. 
2012);  (ii) The non-African BL (sporadic BL) is more common in places where 
malaria is not holoendemic and it is rarely associated with EBV infection and the jaw 
is less commonly affected, whereas the ileocecum is the most commonly affected site 
(Brady, MacArthur et al. 2007, Molyneux, Rochford et al. 2012), (iii) 
Immunodeficiency-associated BL is most commonly associated with human 
immunodeficiency virus (HIV) infection (Bellan, Lazzi et al. 2003). 
 
All BL variants are characterised by translocation between the c-myc gene and one 
of the immunoglobulin heavy or light chain loci and thus facilitate tumourigenesis 
(Brady, MacArthur et al. 2007). EBV virus infection plays different roles in BL 
tumour cells such as promoting cell survival and the malignant phenotype (Takada 
2001, Brady, MacArthur et al. 2007). 
 
1.2.1.4.4 Hodgkin’s lymphoma (HL) 
 
HL was first described in 1832 by Thomas Hodgkin (Hodgkin 1832). The 
characteristic mononucleated Hodgkin’s cells and the multinucleated Reed-Sternberg 
(RS) cells were first described by Dorothy Reed and Carl Sternberg (Kuppers 2009). 
There are 4 histologic subtypes of the classical HL (Roizman and Pellet 2013): (i) 
Nodular sclerosing HL: it is the most common subtype and characterised by large 
tumour nodules with varying degree of fibrosis; (ii) Mixed cellularity HL: it is most 
commonly associated with EBV infection and it consists of classic RS cell mixed 
with various inflammatory cells without fibrosis; (iii) Lymphocyte-rich HL: it is rare 
type and has the most favourable prognosis; (iv) Lymphocyte depleted HL: it is very 
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rare subtype composed of large number of pleomorphic RS cells with few reactive 
lymphocytes. 
EBV contributes to the pathogenesis of HL through several mechanisms such as 
protecting growth-transformed germinal centre B cells from apoptosis (Bechtel, 
Kurth et al. 2005, Chaganti, Bell et al. 2005, Mancao, Altmann et al. 2005, Mancao 
and Hammerschmidt 2007) and development of HRS cells from germinal centre B 
cells with Ig V gene mutations (Brauninger, Schmitz et al. 2006). 
 
1.2.1.4.5 Nasopharyngeal carcinoma (NPC) 
 
NPC is a cancer of squamous epithelium that is among the most common cancers in 
southern China, but   rare in   Europe and North America. It is divided into different 
types depending on the degree of tumour cells differentiation. Undifferentiated NPC 
are associated with EBV infection (Vasef, Ferlito et al. 1997). The viral encoded IL-
10 was shown to be highly expressed in NPC and to be associated with increased IL-
1α and IL-1β expression by epithelial cells and CD4+ T cells and thereby contribute 
to tumour growth and immune evasion (Huang, Sheen et al. 1999). 
 
1.2.2 Kaposi’s sarcoma-associated herpesvirus (KSHV) 
 
Kaposi’s sarcoma (KS) was first described in the 19
th
 century by Moritz Kaposi in 
patients with rare skin pigmentation (Kaposi 1872). Initially considered a non-
aggressive disease of old men in the Mediterranean, after emergence of the HIV 
pandemic in the 1980s, KS was given more attention as KS became associated with 
acquired immune deficiency syndrome (AIDS) (Gottlieb, Ragaz et al. 1981). In 1994 
Chang et al. identified viral DNA sequences in KS lesions but not in normal skin 
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using representational difference analysis (a PCR-based technique) and it was found 
that these sequences were homologous to capsid and tegument genes of the 
gammaherpesviruses EBV and HVS, leading to KSHV (also referred to as human 
herpesvirus 8, HHV8) discovery (Chang, Cesarman et al. 1994). 
 
1.2.2.1 KSHV latency  
 
KSHV is strictly human virus and therefore in vivo studies in the natural host is not 
possible. The knowledge of KSHV latency depends on the latently infected cell lines 
such as primary effusion lymphoma (PEL) cell lines from AIDS patients with 
advanced disease and biopsy samples. During latency, KSHV genome is maintained 
as a circular extrachromosomal episome within the nucleus of infected cells with 
most viral genes being silenced except a few latency-associated genes. Lytic 
infection can be triggered from latently infected cells by treatment with chemicals or 
the viral trans-activator RTA that can initiate lytic cycle, allowing for virus stock 
production and gene expression analysis. KSHV can latently infect several cell lines 
such as human fibroblasts, endothelial, and epithelial cells. Fibroblasts and epithelial 
cells have not been found to be infected in vivo, while B-cells, which are the site of 
latency in vivo, have been difficult to infect in vitro (Damania and Cesarman 2013) .  
 
PEL cells predominantly harbour latent infection where most transcripts are 
expressed from a region at the far right end of the genome (Damania and Cesarman 
2013). Latency-associated nuclear antigen-1 (LANA-1), vCyclin and vFLIP are 
transcribed through a program of alternative splicing and internal translational 
initiation. The kaposin locus gives rise to a family of proteins; kaposin A, B, and C, 
as well as miRNAs (Damania and Cesarman 2013). In KS lesions, the main 
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proliferating cell is called the spindle cell because it has spindle-like shape and it is 
thought to be of endothelial lineage because it expresses markers of endothelial 
origins (Gessain and Duprez 2005, Damania and Cesarman 2013). It has been 
demonstrated that the viral FLIP induces the spindle cell phenotype in the KSHV 
infected endothelial cells and to up-regulate cytokine production (Matta, Surabhi et 
al. 2007). Interestingly, viral gene expression is different between latent PEL and 
latent KS cells. For example, LANA-2/ viral interferon regulatory factor 3 (vIRF3) is 
a B-cell specific latency gene that is expressed in latently infected PEL, but not 
detected in KS tumours (Rivas, Thlick et al. 2001).  In contrast, vIRF1 is expressed 
in latently infected KS cells but not in latently infected PEL (Dittmer 2003). EBV 
has at least four latent viral gene transcription patterns. Hence, it is not surprising 
that KSHV also has a complex latent gene expression pattern. 
 
Hughes et. al. have recently shown that the ubiquitin-proteasome system is important 
for KSHV latency and lytic activation (Hughes, Wood et al. 2015). The authors used 
a small molecule inhibitor in order to inhibit the NEDDylation cascade in PEL cells. 
NEDDylation is an ubiquitination pathway that is dependent on the ubiquitin-like 
protein, NEDD8 (Xirodimas 2008). Following NEDDylation inhibition, the cells 
underwent cytotoxicity and exhibited lytic gene expression without viral DNA 
replication. This phenotype was partly attributed to the inhibition of NF-κB 
signalling, which is required for KSHV latency, as a result of blocking the 
proteasomal degradation of IκBα, an inhibitor of NF-κB transcription factors. 
Furthermore, the authors demonstrated that suppression of NEDDylation prevented 
the viral pre-replication complex recruitment to the origin of lytic DNA replication 
(OriLyt). 
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In addition to the cellular factors and viral proteins, KSHV encoded miRNAs play 
important roles during KSHV latency such as inhibition of lytic gene expression 
(Lei, Bai et al. 2010, Lin, Liang et al. 2011, Plaisance-Bonstaff, Choi et al. 2014), 
promoting cell survival (Lei, Bai et al. 2010), and cancer development (Gottwein, 
Mukherjee et al. 2007, Forte, Raja et al. 2015). These roles are discussed in detail in 
section 1.2.2.2.5. 
  
1.2.2.2 Latency transcripts 
 
1.2.2.2.1 Latency-associated nuclear antigen (LANA) 
 
LANA, the product of ORF73, is a large immunogenic protein expressed in all 
latently infected cells where it localises in the nucleus (Kedes, Lagunoff et al. 1997, 
Kellam, Boshoff et al. 1997, Rainbow, Platt et al. 1997). It is a multifunctional 
protein with DNA replication, anti-apoptotic, cell cycle and gene regulatory 
functions, most of which are exerted by interactions with other proteins (Kaul, 
Verma et al. 2007). It is essential for the establishment and maintenance of the latent 
viral episome in the nucleus. It activates the semiconservative replication of the 
episome by binding to DNA sequences within the terminal repeats; thus, showing 
functional resemblance to EBV EBNA-1 that binds to the oriP sequence (Hu, Garber 
et al. 2002, Grundhoff and Ganem 2003).  
 
Furthermore, LANA tethers the viral episome to host chromosomes during cell 
division, allowing for efficient segregation of the viral DNA to both daughter cells 
(Ballestas, Chatis et al. 1999, Cotter and Robertson 1999). It is also involved in the 
regulation of multiple pathways affecting cell cycle and survival; nevertheless, 
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LANA itself is not sufficient for transformation (Watanabe, Sugaya et al. 2003). Lan 
et. al. demonstrated that LANA inhibits lytic replication through negative regulation 
of the expression of the lytic trans-activator RTA and antagonising its function (Lan, 
Kuppers et al. 2004). 
 
Two groups demonstrated that LANA interacts with the cellular KRAB-associated 
protein 1 (KAP1) leading to down-regulation of lytic gene expression in order to 
promote latency (Sun, Liang et al. 2014, Zhang, Zhu et al. 2014). LANA has been 
shown to promote oncogenesis by interacting with the MH2-M, the LANA-binding 
domain of bone morphogenetic protein (BMP)-activated pSmad1 (Liang, Hu et al. 
2014). 
1.2.2.2.2 Viral Cyclin 
 
vCyclin, a product of ORF72, is a homologue of the cellular protein cyclin D and 
acts in a similar manner in regulating the cell cycle. It forms functional complexes 
with the cellular cyclin-dependent kinase 6 (cdk6), leading to phosphorylation of 
pRB and thereby stimulating cell cycle progression (Van Dross, Yao et al. 2005). 
However, there are differences between vCyclin and the cellular cyclin D. For 
example, vCyclin has a wider range of substrates such as histone H1 (Godden-Kent, 
Talbot et al. 1997) and origin recognition complex 1 (Laman, Coverley et al. 2001), 
suggesting that vCyclin may regulate multiple cell-cycle phases. It has been 
suggested that vCyclin mediates phosphorylation of nucleophosmin (NPM) via its 
association with CDK6 and facilitates NPM-LANA interaction and recruitment of 
HDAC1, enhancing KSHV latency (Sarek, Jarviluoma et al. 2010).  
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1.2.2.2.3 Viral FLIP 
 
vFLIP (also referred to as K13), a product of ORF71, is the viral homologue of the 
cellular FLIP (FLICE (FADD like interleukin1 beta-converting enzyme, now called 
caspase8) inhibitory protein). vFLIP up-regulates the anti-apoptotic transcription 
factor NFκB by interacting with the inhibitory κB kinase complex (Liu, Eby et al. 
2002). Activation of the NFκB signalling pathway has several effects, including 
inhibition of apoptosis by up-regulation of several anti-apoptotic molecules and 
enhancing cell proliferation (Guasparri, Keller et al. 2004, Chugh, Matta et al. 2005).  
 
In addition, vFLIP-mediated activation of NFκB signalling pathway results in 
suppression of the AP-1 pathway, which is critical for KSHV lytic replication and 
thus vFLIP can inhibit productive replication and promote latency (Ye, Zhou et al. 
2008). Consistent with the previous findings, Zhao et. al. demonstrated that vFLIP is 
able to antagonise RTA and inhibit lytic protein expression leading to inhibition of 
infectious virus production (Zhao, Punj et al. 2007). On the other hand, during lytic 
reactivation, RTA suppresses the vFLIP-mediated NFκB activation through vFLIP 
proteasomal degradation (Ehrlich, Chmura et al. 2014). 
vFLIP has also been reported to induce the spindle cell phenotype seen in KSHV 
infected endothelial cells and to up-regulate cytokine production (Sun, Matta et al. 




The kaposin proteins are encoded by alternative splicing of ORF12 giving rise to at 
least three proteins, kaposin A, B, and C (Sadler, Wu et al. 1999). Kaposin A is a 
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transmembrane protein that can transform rodent fibroblasts (Muralidhar, Pumfery et 
al. 1998). Kaposin A-transformed cells exhibt enhanced activation serine/threonine 
kinase pathways, some of which are involved in cell proliferation (Muralidhar, 
Veytsmann et al. 2000). Kliche et. al. demonstrated that kaposin A interacts with 
cytohesin-1, a guanine nucleotide exchange factor for ADP Ribosylation Factor 
(ARF) GTPases and a cell adhesion regulator, resulting in activation of the ERK-1/2 
MAP kinase signalling pathway, which is thought to be involved in transformation 
(Kliche, Nagel et al. 2001).  
 
Kaposin B was reported to enhance the expression of cytokines by inhibiting the 
degradation of their mRNAs (McCormick and Ganem 2005). Cytokine mRNAs 
contain AU-rich elements (AREs) in the 3’UTR that makes them unstable and 
exposed to degradation. Kaposin B stabilises the cytokine mRNAs by activating the 
kinase MK2, a target of the p38 mitogen-activated protein kinase signalling pathway 
and an inhibitor of ARE-mRNA decay (McCormick and Ganem 2005). Kaposin B 
contributes to the chronic inflammatory environment through activation of the proto-
oncogene STAT3 and inactivation the STAT3 transcriptional repressor TRIM28 in 
MK2 –dependent manner (King 2013). 
 
1.2.2.2.5 KSHV miRNAs 
 
KSHV encodes at least 12 primary miRNAs located in the KSHV latency-associated 
region (KLAR) of the genome (Cai, Lu et al. 2005, Pfeffer, Sewer et al. 2005, 
Samols, Hu et al. 2005). KSHV miRNAs play important roles in maintaining latent 
infection. miR-K12-7 and 9 inhibit the expression of the latent-lytic molecular switch 
protein RTA that is crucial for initiation of lytic viral replication (Bellare and Ganem 
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2009, Lin, Liang et al. 2011). miR-K12-4-5p inhibits the expression of 
retinoblastoma (Rb)-like protein 2 (Rbl2), which is an inhibitor of DNA methyl 
transferases (DNMT)-1-3a and -3b whose activity maintains methylation of the RTA 
promoter and inhibit its transcription (Lu, Stedman et al. 2010). Furthermore, miR-
K12-1 inhibits expression of IκBα, a suppressor of NF-κB complexes, enhancing 
NF-κB-dependent viral latency and cell survival (Lei, Bai et al. 2010). miR-K12-3 
can also promote KSHV latent infection via targeting the nuclear factor I/B, an 
activator of RTA promoter (Lu, Li et al. 2010). In contrast, miR-K12-5 and 9 inhibit 
the Bcl-2-associated factor (BCLAF1), resulting in an increase in lytic replication 
(Ziegelbauer, Sullivan et al. 2009). 
 
miR-K12-11 is an orthologue of the cellular miR-155, which plays key roles in 
physiological lymphocyte development and activation but its overexpression is 
associated with lymphoid cancer development (Eis, Tam et al. 2005, Gottwein, 
Mukherjee et al. 2007, Rodriguez, Vigorito et al. 2007, Skalsky, Samols et al. 2007). 
It was demonstrated that miR-K12-11 and miR-155 target a common set of mRNAs 
and that miR-K12-11 plays a role in B cell transformation in humanised mice and 
can complement the deficiency of miR-155 in vivo (Gottwein, Mukherjee et al. 2007, 
Skalsky, Samols et al. 2007, Boss, Nadeau et al. 2011, Sin, Kim et al. 2013).. A 
KSHV mutant virus lacking a cluster of 10 primary miRNAs revealed that the KSHV 
miRNAs are crucial for cellular transformation and oncogenesis in primary rat 
mesenchymal cells as well as for cell survival and apoptosis inhibition (Moody, Zhu 
et al. 2013). 
 
1.2.2.3 KSHV associated diseases 
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1.2.2.3.1 Kaposi’s sarcoma 
 
KS lesions occur in several tissues, but are most commonly located in the skin where 
they form brownish-purple raised nodules. The disease has been reported in four 
epidemiological forms: classic, endemic, immunocompromised, and HIV- associated 
KS. The classic form usually appears mostly in the toes and soles of elderly men 
from Mediterranean or eastern European regions (Fenig, Brenner et al. 1998, 
Iscovich, Boffetta et al. 1998, Damania and Cesarman 2013). Endemic KS has 
originally been described in young African people from sub-Saharan Africa. This 
form is aggressive and not related to HIV (Cook-Mozaffari, Newton et al. 1998, 
Olsen, Chang et al. 1998). The immunosuppression-associated KS form usually 
appears during immunosuppression or post-transplantation (Qunibi, Al-Furayh et al. 
1998, Luppi, Barozzi et al. 2000). The HIV-associated KS occurs in AIDS patients 
and is presented with cutaneous lesions that can spread to other organs and it is more 
common among AIDS patients than renal transplant recipients (Beral, Peterman et al. 
1990). 
Histologically KS lesions are different from other classical tumours and are more 
complex. The main proliferating cell is called the spindle cell because it has spindle-
like shape and it is thought to be of endothelial lineage because it expresses markers 
of endothelial origins (Damania and Cesarman 2013). KSHV is required for the 
development of KS. Various observations support this, including the correlation of 
seroprevalence and KS risk and the presence of KSHV DNA in all KS tumours 
where almost all spindle cells are latently infected (Boshoff and Weiss 2001). 
 
1.2.2.3.2 Primary effusion lymphoma (PEL) 
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PEL is commonly present as a lymphomatous effusion in the body cavity and is more 
common in male HIV patients; however, HIV-negative males and females can also 
develop PEL (Damania and Cesarman 2013). B cells within the tumour undergo 
malignant clonal expansion and every tumour cell is KSHV-positive (Boshoff and 
Weiss 2001). Tumour cells can be co-infected with EBV; however, PEL is not 
present without KSHV infection (Damania and Cesarman 2013). KSHV-infected 
PEL cells express latent viral proteins and viral IL-6 (Parravicini, Chandran et al. 
2000) that can be involved in oncogenesis. vFLIP and vIRF-3 are required for 
proliferation and survival of the cultured PEL cells (Guasparri, Keller et al. 2004, 
Wies, Mori et al. 2008) 
 
1.2.2.3.3 Multicentric Castleman’s disease (MCD) 
 
MCD is a rare systematic lymphoproliferative disorder characterised by 
hyperactivation of the immune system, proliferation of lymphocytes, excessive 
cytokine production, and multiple organ impairment (Fajgenbaum, van Rhee et al. 
2014). MCD occurs frequently in AIDS patients associated with KSHV infection; 
whereas only 40-50% of HIV-negative cases are associated with KSHV (Boshoff and 
Weiss 2001). During MCD, the plasmablasts localised in the mantle zones 
surrounding the germinal centres harbour KSHV virus (Dupin, Diss et al. 2000, Du, 
Liu et al. 2001). 
It is suggested that KSHV infects naïve B-cells and induces their differentiation into 
plasmablasts, bypassing the germinal centre reaction (Du, Liu et al. 2001). It has 
been shown that vIL-6 is expressed constitutively in the plasmoblasts surrounding 
the lymphoid follicles, suggesting that the systematic symptoms observed in the 
MCD can be due to the excessive vIL-6 cytokine production (Du, Liu et al. 2001). 




1.3 Gammaherpesviruses of veterinary importance 
 
Several gammaherpesviruses are of veterinary and scientific importance. They can 
cause huge economic loss, particularly in the livestock industry. MHV-68 provides a 
unique amenable small animal model for studying gammaherpesvirus pathogenesis 
in the context of natural virus-host interaction. MHV-68 is introduced in section 1.5. 
 
One of the important gammaherpesviruses in the veterinary field is the ovine 
herpesvirus-2 (OvHV-2). OvHV-2 is the causative agent of malignant catarrhal fever 
(MCF), a fatal lymphoproliferative disorder of cattle and some wild ruminants that is 
characterised by fever, ocular and nasal discharge, bilateral keratitis, and corneal 
opacity with death occurring a few days to several weeks after the onset of clinical 
symptoms (Russell, Stewart et al. 2009, Li, Cunha et al. 2014). Sheep are the 
reservoir hosts in which OvHV-2 infection is asymptomatic, but they can spread the 
infection to susceptible cattle (Russell, Stewart et al. 2009, Li, Cunha et al. 2014).  
 
OvHV-2 predominantly infects CD2+ T cells in sheep and cattle, but only cattle 
develop IL-2 dependent T cell proliferation and MCF disease (Schock, Collins et al. 
1998, Meier-Trummer, Ryf et al. 2010). Immortalised latently infected T cell lines 
can be cultured from infected cattle large granular lymphocytes (Reid, Buxton et al. 
1989). The mechanism(s) behind the development of MCF pathogenesis is poorly 
understood. 
 
OvHV-2 has been predicated to encode at least 45 candidate miRNAs using next-
generation sequencing, from which 35 miRNAs have been validated by northern blot 
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or qRT-PCR in an OvHV-2-immortalised T cell line (Levy, Hopkins et al. 2012, 
Nightingale, Levy et al. 2014). Riaz et. al. demonstrated that a number of OvHV-2 
miRNAs target viral mRNAs involved in latency and reactivation (Riaz, Dry et al. 
2014), suggesting that these miRNAs may play roles in facilitating OvHV-2 latent 
infection. 
 
Other animal gammaherpesviruses such as bovine herpesvirus-4 and equid 
herpesvirus-2 are associated with a variety of clinical symptoms in cattle and horses, 
respectively. However, the exact molecular mechanisms behind their pathogenesis 
are still largely unknown. 
 
1.4 Murine gammaherpesvirus-68 (MHV-68) 
 
MHV-68 (also referred to as murid herpesvirus-4 (MuHV-4) and γHV-68) was 
originally isolated from bank voles (Myodes glareolus) and yellow-necked field mice 
(Apodemus flavicollis) captured in Slovakia (Blaskovic, Stancekova et al. 1980). 
Other closely related viruses were also isolated from field voles (Microtus agrestis), 
wood mice (Apodemus sylvaticus), and white-toothed shrews (Crocidura russula) 
(Chastel, Beaucournu et al. 1994, Hughes, Kipar et al. 2010). In the United 
Kingdom, a survey showed that MHV-68 is endemic in wood mice, whereas it is not 
endemic in bank voles, suggesting that wood mice are the major MHV-68 reservoir 
(Blasdell, McCracken et al. 2003). Laboratory mice (Mus musculus) can be infected 
with MHV-68 where the virus can establish lifelong latent infection mainly in B 
cells, macrophages, and splenic dendritic cells (Sunil-Chandra, Efstathiou et al. 1992, 
Weck, Kim et al. 1999, Flano, Husain et al. 2000). 
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 MHV-68 is genetically related to and has similar pathogenic features as EBV and 
KSHV (Virgin, Latreille et al. 1997, Barton, Mandal et al. 2011). Due to strict 
species specificity of human gammaherpesviruses, it is difficult to study the different 
aspects of their pathogenesis in vivo; therefore, MHV-68 is considered a valuable 
small animal model for studying the pathogenesis of gammaherpesviruses. In 
addition, cloning of the MHV-68 genome into a bacterial artificial chromosome 
(BAC) can allow for studying viral genes functions by generating virus mutants 
(Adler, Messerle et al. 2000).  
 
1.4.1 MHV-68 genome 
 
The complete MHV-68 genome has been sequenced and aligned to other 
gammaherpesviruses sequences (Virgin, Latreille et al. 1997). The genome 
comprises a unique sequence of approximately 118 bp flanked by several copies of 
1,213 bp terminal repeat and contains 2 internal repeats: 100 bp and 40 bp internal 
repeats (Virgin, Latreille et al. 1997). The MHV-68 genome is co-linear with primate 
gammaherpesviruses genomes (Figure 1.3) and it encodes at least 80 open reading 
frames (ORFs), most of which are homologous to other gammaherpesviruses or 
cellular genes; however, there are a number of unique MHV-68 ORFs whose 
sequences are not related to viral or cellular genes, termed M1, M2, M3, and M4 and 
located at the left end of the genome (Figure 1.3) (Virgin, Latreille et al. 1997). In 
addition, this site of the genome also encodes unique 8 tRNA-like molecules 
associated with at least 15 miRNAs (see sections 1.5.4.6.1 and 1.5.4.6.2)  
 




Figure 1.3 Schematic diagram of gammaherpesvirus genomes showing 
their conserved and unique genes. Conserved genes are shown at the top. 
Essential genes that play a critical role in MHV-68 lytic replication in fibroblasts 
are indicated (based on signature-tagged transposon mutagenesis (Moorman, 
Lin et al. 2004, Song, Hwang et al. 2005)). Figure adapted from (Barton, Mandal 
et al. 2011). 
Chapter One                                                                                                                     Introduction
  
48 
(Virgin, Latreille et al. 1997, Zhu, Strehle et al. 2010). The genes that play a key 
role in MHV-68 replication were identified by transposon mutagenesis analyses and 
it was found that the MHV-68 unique genes are not involved in replication and thus 
they are suggested to be latency associated genes (Moorman, Lin et al. 2004, Song, 
Hwang et al. 2005) (Figure 1.3). 
 
1.4.2 MHV-68 pathogenesis 
 
The natural route of MHV-68 infection is unknown. However, the respiratory route 
is thought to be the natural route of infection (Nash, Dutia et al. 2001). Attempts to 
transmit the virus horizontally between laboratory mice by cage contact were 
unsuccessful (Aligo, Brosnan et al. 2014), therefore the route of virus transmission in 
natural host is not clear.  
When laboratory mice are infected intranasally with MHV-68 virus, the virus 
undergoes lytic replication in the lung where it replicates in the alveolar epithelial 
cells and reach peak lytic replication at 5 days post infection and clearance of this 
lytic replication occurs at 10 days after infection (Sunil-Chandra, Efstathiou et al. 
1992); however, long-term virus persistence in lung epithelial cells was also reported 
(Stewart, Usherwood et al. 1998). From the lung, the virus spreads to the mediastinal 
lymph nodes (MLN) and then to the spleen where virus latency is established 
predominately in B lymphocytes; however, latent virus also exists in macrophages 
and dendritic cells (Weck, Kim et al. 1999, Flano, Husain et al. 2000, Nash, Dutia et 
al. 2001, Flano, Kim et al. 2002, Kim, Flano et al. 2003, Willer and Speck 2003).  
 
MHV-68 latency is a dynamic process that involves viral components working in 
concert with cellular factors. The latent virus amplification in the spleen reaches peak 
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levels at 14 days post-infection (dpi) (acute phase of latent infection) accompanied 
by enlargement of the spleen (splenomegaly) due to B cell proliferation that is driven 
by CD4+ T cell response (Sunil-Chandra, Efstathiou et al. 1992, Ehtisham, Sunil-
Chandra et al. 1993, Usherwood, Ross et al. 1996). By day 21 post infection, the 
splenomegaly starts to resolve as the activated CD8+ T cells increase in numbers in 
peripheral blood, killing MHV-68-infected cells by cytotoxicity (Tripp, Hamilton-
Easton et al. 1997). This pathology (splenomegaly and activated CD8+ T cells in the 
peripheral blood) is reminiscent of the EBV-induced IM. The MHV-68 pathogenesis 
is summarised in figure 1.4 
 
1.4.3 MHV-68 life cycle 
 
1.4.3.1 MHV-68 primary lytic infection 
 
MHV-68 undergoes primary lytic infection in alveolar epithelial cells in the lung 
following intranasal infection of lab mice (Sunil-Chandra, Efstathiou et al. 1992). 
The host immune defence controls acute MHV-68 replication via CD8+ T cells, 
CD4+ T cells, and interferon gamma (IFNγ) by reducing the numbers of infected 
cells (Stevenson and Doherty 1998, Sparks-Thissen, Braaten et al. 2005). Antiviral 
agents such as thiopyrimidine analogue 2’-deoxy-5-ethyl-beta-4’-thiouridine (4’-S-
EtdU) can target viral thymidine kinase resulting in inhibition of virus replication in 
vitro and in vivo without affecting latency establishment (Barnes, Dyson et al. 1999).  















Day 21+ Splenomegaly resolving and 
latent infection established 
Day 14 Spleen 
(Latent infection and 
splenomegaly) 
B cells Macrophages & 
dendritic cells 
Figure ‎1.4 MHV-68 pathogenesis. The virus causes primary lytic infection in the lung 
epithelial cells with peak of virus replication at 5 days post infection (dpi) before it 
spreads to the spleen via the mediastinal lymph node to establish latent infection in B 
cells, macrophages, and dendritic cells with the peak of latent viral titre occurring at 14 
dpi and associated with clonal B cell expansion and splenomegaly. After 3 weeks post 
infection, the splenomegaly resolves and the latent infection is established for life. 




The immediate-early protein encoded by ORF50, the replication and transcription 
activator (RTA), plays a key role in initiating virus lytic replication during de novo 
infection and reactivation from latency resulting in release of infectious virus (Wu, 
Usherwood et al. 2000, Wu, Tong et al. 2001, Pavlova, Virgin et al. 2003, Boname, 
Coleman et al. 2004). RTA is conserved among all known gammaherpesviruses and 
has a DNA binding domain at its N-terminus and a transactivation domain at its C-
terminus allowing for acting as a transcriptional activator of many viral genes (Wu, 
Tong et al. 2001). Like MHV-68 RTA, the RTA of KSHV acts as a molecular switch 
essential for initiation of complete virus lytic cycle and for reactivation (Sun, Lin et 
al. 1998, Lukac, Kirshner et al. 1999). In EBV, RTA in association with another 
immediate-early protein, ZTA (also referred to as ZEBRA or Z), initiates the viral 
lytic replication through activation of lytic gene expression (Gruffat and Sergeant 
1994, Liu, Sista et al. 1996). 
 
ORF49 was reported to interact with the RTA negative regulator, poly (ADP-ribose) 
polymerase-1 (PARP-1), resulting in derepression of the PARylated RTA and thus 
promote RTA transactivation, leading to enhanced viral replication (Noh, Cho et al. 
2012). In addition, ORF49 can be packaged into virions as an inner tegument protein, 
allowing ORF49 to exert its function during the early phase of de novo lytic infection 
(Noh, Cho et al. 2012) 
 
1.4.3.2 MHV-68 latent infection 
 
After clearance of lytic virus from the lung a low level of virus persists in epithelial 
cells and during long-term latency in B cells (Stewart, Usherwood et al. 1998, Flano, 
Kim et al. 2003). The lung has been reported to be a major site for virus persistence 




(Stewart, Usherwood et al. 1998). The virus spreads from lung to the mediastinal 
lymph nodes where it establishes latency in B cells, macrophages, and dendritic cells 
(Nash, Dutia et al. 2001) followed by latency establishment in splenic B cells, 
macrophages, and dendritic cells at 10-14 days post-infection (dpi) and the latent 
virus load reaches peak levels at 14 dpi (Sunil-Chandra, Efstathiou et al. 1992, Weck, 
Barkon et al. 1996, Flano, Husain et al. 2000). During latency establishment in the 
spleen, the B cells undergo CD4+ T cell-dependent proliferation resulting in an 
increase in numbers of infected B cells and splenomegaly (Usherwood, Ross et al. 
1996). The numbers of latently infected cells decrease to low levels during long-term 
latency as a result of cell-mediated host immune response and the long-term latency 
is maintained in germinal centre and memory B cells (Flano, Kim et al. 2002, Willer 
and Speck 2003, Evans, Moser et al. 2008, Nealy, Coleman et al. 2010, Jennings, 
Grayson et al. 2014).  
 
Three weeks after infection, the CD4+ T cells decrease in number and the CD8+ T 
cells increase in numbers leading to destruction of large numbers of infected cells 
(Tripp, Hamilton-Easton et al. 1997). These pathological features are  reminiscent of 
the IM of EBV (Williams and Crawford 2006). Therefore, there are at least 2 stages 
of latency in the spleen: the early latency (acute latency), during which the viral 
latent load is maximum and the expression of a number of latency-associated genes 
can be readily detected, and the long-term latency, during which the viral latent load 
is very low and viral gene expression is rarely detected and the virus remains latent 
for life within the host with occasional spontaneous reactivation, which possibly 
helps boost latent infection by infecting naïve B cells; thus, the long-term latent 
infection depends on a precise balance between latency and reactivation. The exact 




molecular mechanisms behind the establishment and maintenance of latency are not 
fully understood. 
 
Recently, it has been reported that MHV-68 miRNAs are dispensable for productive 
infection nor establishment of latency in vivo , but can modulate reactivation in a 
virus dose-dependent manner and increase the numbers of MHV-68-infected 
memory B cells in vivo, and promote virus-induced lethal pneumonia in 
immunodeficient mice (Feldman, Kara et al. 2014, Diebel, Oko et al. 2015). 
 
1.4.3.3 MHV-68 reactivation from latency 
 
Periodic reactivation from latency is a crucial process that can contribute to the 
homoeostatic maintenance of long-term MHV-68 infection through re-seeding 
latency reservoirs; however, the balance between latency and reactivation has to be 
tightly regulated in order to guarantee successful virus infection. Spontaneous 
reactivation of MHV-68 virus during long-term latent infection was reported in 
previous published studies (Liu, Flano et al. 1999, Hwang, Wu et al. 2008). 
 
The molecular mechanisms governing MHV-68 reactivation control and induction 
are not completely understood. Viral and cellular influences can modulate 
reactivation. For example, the cellular CD8+ T cell response can control virus 
reactivation through long-term IFNγ production (Evans, Moser et al. 2008). The viral 
protein RTA encoded by ORF50 is a major key player in virus lytic reactivation as it 
can induce lytic gene expression and initiate complete virus lytic cycle (Wu, 
Usherwood et al. 2000). It has been shown that there is differential expression of the 
RTA transcript in spleen cell subpopulations, for example, RTA mRNA was detected 




in macrophages and dendritic cells, but not in B cells during the establishment of 
latent infection (Marques, Efstathiou et al. 2003), indicating that the mechanism of 
latency establishment can vary depending on the infected cell type. Alternatively, 
this may suggest that macrophages and dendritic cells may not support latent 
infection. 
 
Reactivation from latency is different from primary productive infection for many 
reasons: (1) the primary lytic infection cycle starts by attachment cell surface and 
entry into host cells, whereas initiation of reactivation is from inside of the latently 
infected cells; (2) primary lytic infection occurs in lung epithelia cells, whereas 
reactivation occurs mainly in peripheral lymphoid organs; (3) the immune response 
is stimulated following the primary lytic infection and therefore virus reactivation 
occurs after the specific antibodies and T cell response have been generated. This 
suggests that primary lytic infection and virus reactivation may require different 
molecular mechanisms. 
 
1.4.4 MHV-68 latent genes 
 
1.4.4.1 ORF73 (mLANA) 
 
MHV-68 ORF73 encodes a homolog of KSHV LANA (referred to as mLANA) that 
comprises the conserved C-terminal domain and lacks the N-terminal domains and 
the long internal repeat present in the LANA encoded by KSHV (Russo, Bohenzky 
et al. 1996, Virgin, Latreille et al. 1997). The MHV-68 mutant viruses lacking 
mLANA expression are deficient in establishment of latency after intranasal 
infection, which is consistent with the role of the mLANA in maintaining the viral 




genome as an extrachromosal episome in the nuclei of the dividing cells (Fowler, 
Marques et al. 2003, Moorman, Willer et al. 2003). However, a mLANA-null mutant 
virus was able to establish latent infection when the virus was inoculated 
intraperitoneally or when immunocompromised mice were used in the study (Paden, 
Forrest et al. 2010). In addition to the critical role played by mLANA during the 
establishment and maintenance of latency, it plays a role in acute lytic replication 
and it is essential for virus reactivation from latency (Forrest, Paden et al. 2007, 
Paden, Forrest et al. 2010). mLANA-null mutant MHV-68 virus exhibited an 
increase in viral lytic gene expression and induction of rapid cell death, a phenotype 
that is suggested to be due to the role played by mLANA in stabilising p53 (Forrest, 
Paden et al. 2007). 
1.4.4.2 M1 
 
The left end of MHV-68 genome encodes 4 unique proteins, designated M1-4, that 
are suggested to play roles during latent infection. The M1 secreted protein has 
sequence homology (~25%) to another MHV-68 protein, M3, that functions as a 
chemokine binding protein, and to the poxvirus serine proteinase inhibitor (serpin), 
SPI-1, that is involved in regulating apoptosis and in regulating T cell cytotoxicity in 
conjunction with another poxvirus serpin, SPI-2 (Ali, Turner et al. 1994, Brooks, Ali 
et al. 1995, Macen, Garner et al. 1996, Virgin, Latreille et al. 1997, van Berkel, 
Preiter et al. 1999). Despite the sequence homology between M1 and SPI-1, M1 
lacks sequence homology to the conserved functionally important hinge domain and 
reactive site loop existing in SPI-1 and other serpins (Potempa, Korzus et al. 1994). 
A mutant MHV-68 virus lacking M1 expression exhibited hyper-reactivation 
phenotype, indicating a role of M1 in suppressing virus reactivation, possibly 




through induction of Vβ4+ CD8+ T cell response and long-term IFNγ production in 




M2 is a membrane-associated protein that can be expressed during latent infection in 
vitro in the latently infected B lymphoma cell line S11 and in vivo in spleen (Husain, 
Usherwood et al. 1999, Virgin, Presti et al. 1999). M2 was reported to contain an 
actively recognised CD8+ T cell epitope and to be important in the establishment of 
and reactivation from latency (Jacoby, Virgin et al. 2002, Macrae, Usherwood et al. 
2003, Simas, Marques et al. 2004, Herskowitz, Jacoby et al. 2005). It has been 
reported that M2 interacts with the cellular Vav proteins and thus modulates the B 
cell receptor signalling pathway in order to promote latency through enhancing B 
cell activation, proliferation, and survival (Madureira, Matos et al. 2005). 
 
M2 is not involved in MHV-68-induced B cell clonal expansion nor Vβ4+ CD8+ T 
cell expansion, but it is required for differentiation of B cells into memory B cells 
and plasma cells (Macrae, Usherwood et al. 2003, Simas, Marques et al. 2004, 
Herskowitz, Jacoby et al. 2005, Liang, Collins et al. 2009). M2 expression in primary 
murine B cells resulted in increased proliferation and survival of the cells that was 
IL-10 dependent (Siegel, Herskowitz et al. 2008). Moreover, the use of M2-
transgenic mice revealed that M2 is required for regulation of antibody responses in a 
T-cell dependent manner and for inhibition of apoptosis in the infected B cells (de 
Oliveira, Almeida et al. 2013). 
 






M3 is a secreted protein that is highly expressed during lytic infection and it is also 
expressed during establishment of a latent infection, but not during long-term latency 
in the spleen (Simas, Swann et al. 1999, van Berkel, Preiter et al. 1999, Virgin, Presti 
et al. 1999, Marques, Efstathiou et al. 2003, Martinez-Guzman, Rickabaugh et al. 
2003). It functions as a broad-spectrum chemokine binding protein that inhibits 
chemokine action (Parry, Simas et al. 2000, van Berkel, Barrett et al. 2000).  
Disruption of M3 expression by insertion of a β-galactosidase expression cassette 
into the M3 had little effect on lytic replication in the lung, but significantly 
compromised latency establishment in mice infected with this mutant virus 
(Bridgeman, Stevenson et al. 2001). Another study that used M3 null virus generated 
by insertion of a stop codon and frame shift near the 5’ end of M3 ORF, designated 
M3.stop, revealed that the M3.stop mutant virus had similar levels of latency 
establishment and reactivation to that of its wild-type counterpart (van Berkel, 
Levine et al. 2002). However, this mutant virus was 100-fold less virulent than the 
wild-type virus following intracerebral virus inoculation into 3 weeks old mice (van 
Berkel, Levine et al. 2002). The lack of M3 expression caused significant reduction 
in latency and impaired germinal centre reaction in M3.stop-infected wood mice 
(Hughes, Kipar et al. 2011). 
1.4.4.5 M4 
 
M4 is a secreted glycosylated protein expressed by the M4 gene (Evans, Moorman et 
al. 2006). M4 is expressed during productive infection in the lung and during the 
establishment of latency in the spleen, but not during long-term latency (Marques, 
Efstathiou et al. 2003, Townsley, Dutia et al. 2004, Evans, Moorman et al. 2006). 




The role(s) of M4 in MHV-68 pathogenesis is not completely understood. However, 
it is suggested that M4 can modulate lytic and latent infection in vivo (Townsley, 
Dutia et al. 2004, Evans, Moorman et al. 2006, Geere, Ligertwood et al. 2006). M4 is 
believed to be a chemokine-binding protein (Dutia et. al., unpublished). 
 
1.4.4.6 v-Cyclin (ORF72) 
 
MHV-68 v-Cyclin is encoded by ORF72 and it is a homologue of the cellular cyclin 
D and is conserved among rhadinoviruses. Transgenic mice expressing MHV-68 v-
Cyclin under the control of the lymphocyte-specific protein tyrosine kinase (LCK) 
proximal promoter showed development of T cell lymphoma (van Dyk, Hess et al. 
1999). The crystal structure of MHV-68 v-Cyclin revealed that it interacts with 
cyclin-dependent kinase 1 (CDK1) and CDK2, thereby regulating cell cycle 
progression (Card, Knowles et al. 2000).  Furthermore, the crystal structure showed 
that v-Cyclin is resistant to the inhibition by the CDK inhibitor CKI p27
Kip1 
(Swanton, Card et al. 1999).  
 
v-Cyclin is expressed during both lytic and latent infections (Allen, Dickerson et al. 
2006). An MHV-68 mutant virus lacking v-Cyclin expression and carrying a β-
galactosidase expression cassette that was inserted in place of the v-cyclin ORF, 
showed a defect in acute virus replication and reactivation from latency (Hoge, 
Hendrickson et al. 2000), Further studies using v-Cyclin null MHV-68 and v-Cyclin 
CDK binding mutants demonstrated that these viruses exhibited a defect in lytic 
replication in the lung following low-dose intranasal inoculation, which was more 
severe as compared to that observed following intraperitoneal inoculation (Upton and 
Speck 2006). The same study showed that none of the mutant viruses induced 




splenomegaly. The authors also found that although the v-Cyclin null mutant virus 
was attenuated for reactivation from peritoneal exudate cells, none of the CDK 
binding mutants were defective in reactivation from these cells, suggesting that v-
Cyclin has CDK-independent functions that are important for reactivation from the 
peritoneal macrophages.  
The role of v-Cyclin during lytic replication was further characterised in the rat lung 
epithelial cell line, RL-65, showing that v-Cyclin plays a role in virus lytic 
replication and virus egress from the infected cells  (Scott and Speck 2014). 
 
1.4.4.7 vBcl-2 (M11) 
 
vBcl-2 is encoded by the MHV-68 M11 gene and it is a homologue of the cellular 
Bcl-2. All known gammaherpesviruses encode at least one Bcl-2 homologue. M11 
transcripts can be detected during lytic and latent infections (Virgin, Presti et al. 
1999, Roy, Ebrahimi et al. 2000, Marques, Efstathiou et al. 2003). Similar to the 
cellular ant-apoptotic Bcl-2 family members, the MHV-68 vBcl-2 contains a 
hydrophobic BH3 domain–binding groove which is important for vBcl-2 anti-
apoptotic function during latent infection in vivo (Loh, Huang et al. 2005). This 
domain is also important for binding to the pro-autophagic protein Beclin-1 and was 
able to suppress autophagy more efficiently than cellular Bcl-2 (Ku, Woo et al. 
2008). This autophagy inhibition has been shown to be important for MHV-68 
latency in vivo and it is distinguished from the vBcl-2 anti-apoptotic function (E, 
Hwang et al. 2009). Coleman et. al. have used vBcl-2 mutant MHV-68 viruses to 
demonstrate that vBcl-2 is required for inhibiting B cell receptor-mediated apoptosis 
in immature and transitional B cells, but not in mature B cells, suggesting that vBcl-2 




is important for survival of and viral latency in developing B cell (Coleman, 
McGraw et al. 2014). 
 
1.4.4.8 MHV-68 non-coding RNAs 
 
1.4.4.8.1 MHV-68 tRNAs  
 
MHV-68 encodes 8 viral tRNA-like molecules (vtRNAs) that are associated with at 
least 15 miRNAs (Bowden, Simas et al. 1997, Pfeffer, Sewer et al. 2005, Zhu, 
Strehle et al. 2010). The miRNAs are located immediately downstream of the 
vtRNAs. The vtRNAs and their associated miRNAs, also referred to as tRNA-
miRNA-encoded RNAs (TMERs) (Feldman, Kara et al. 2014, Diebel, Oko et al. 
2015), are clustered in the leftmost end of the genome between nucleotide position 
127 to 5585, dispersed between the two unique open reading frames, M1 and M2. 
The vtRNAs can be detected during lytic and latent infection. They are predicted to 
have cloverleaf-like secondary structure and they contain RNA polymerase III (pol 
III) type 2 promoter elements that drive their expression (Bowden, Simas et al. 
1997). Although the vtRNAs are processed into mature tRNAs with post-
transcriptional addition of 3’ CCA termini, which indicates that these vtRNAs are 
recognised as tRNAs by cellular machinery, they are not aminocylated by the cellular 
aminoacyl-tRNA synthestases and therefore they are unlikely involved in translation 
(Bowden, Simas et al. 1997).  
 
It has been demonstrated that the vtRNAs are selectively packaged within the virions 
indicating that they may constitute an integral part of the infectious virus and that 
they may be required immediately upon entry into the cells (Cliffe, Nash et al. 2009). 




A recent study has shown that MHV-68 virus lacking all the vtRNAs and miRNAs 
exhibited attenuation in lethal pneumonia in IFNγ knock-out mice, whereas 
expression of one vtRNA (vtRNA1) in the absence of all other vtRNAs and miRNAs 
partially reversed this attenuation in virulence, suggesting that at least one vtRNA 
may promote viral pathogenesis in immunocompromised mice (Feldman, Kara et al. 






miRNAs are short non-coding RNAs (~19-25 nucleotides) that regulate gene 
expression at the post-transcriptional level in multicellular organisms and play key 
roles in diverse biological processes (Zamore and Haley 2005, Bartel 2009). The first 
miRNA was discovered in 1993 during studies of genes controlling developmental 
timing of the nematode C. elegans (Lee, Feinbaum et al. 1993, Wightman, Ha et al. 
1993). It was found that the lin-4 gene of C. elegans is not a protein coding gene, but 
rather it encodes small RNAs that had sequence complementarity to the 3’ UTR of 
lin-14 leading to interaction between the lin-4 small RNA and the 3’ UTR of lin-14, 
resulting in reduction of lin-14 protein levels without affecting mRNA levels (Lee, 
Feinbaum et al. 1993, Wightman, Ha et al. 1993). Since then these small RNAs 
(miRNAs) have been found in almost all multicellular organisms as well as viruses 
and they affect different biological processes such as cellular differentiation, 
proliferation, apoptosis, development, and oncogenesis (Bartel 2004, Bartel 2009).  
The first virally encoded miRNAs were discovered in EBV and subsequent work 
identified miRNAs expressed by almost all herpesviruses as well as by viruses from 









Most cellular and viral miRNAs are transcribed by RNA polymerase II in the form of 
long primary stem-loop miRNAs (pri-miRNAs), containing one or multiple 
precursor(s) of imperfectly complementary stem-loop hairpin structure (pre-
miRNAs) (Figure 1.6) (Winter, Jung et al. 2009, Bogerd, Karnowski et al. 2010, 
Kincaid and Sullivan 2012, Rosewick, Momont et al. 2013). The pre-miRNAs are 
freed from the pri-miRNAs in the nucleus by a microprocessor complex that consists 
of Drosha and DGCR8 (Slezak-Prochazka, Durmus et al. 2010). The pre-miRNAs 
are then exported out of the nucleus into the cytoplasm via Exportin 5 (XPO5) 
(Figure 1.6) (Lee, Jeon et al. 2002, Kincaid and Sullivan 2012).  
 
The pre-miRNAs are cleaved in the cytoplasm by the endonuclease Dicer, resulting 
in a transient small RNA duplex (~ 22 nucleotides), of which one strand (guide 
strand) is stably incorporated into the RNA-induced silencing complex (RISC) and 
interact with its target mRNA by base pairing, whereas the other strand, called the 
star (*) or passenger strand, is less likely to associate with RISC and is usually found 
at lower levels than the guide strand (Winter, Jung et al. 2009). Argonaute protein 
(Ago) is a key component of the RISC complex and the Ago-loaded miRNAs 
(miRISC) bind to target transcripts and repress gene expression via mRNA 
degradation or translational inhibition (Winter, Jung et al. 2009). GW182 proteins 
are another group of proteins important for miRNA-induced downregulation (Liu, 
Rivas et al. 2005). Both GW182 and Ago proteins inhibit protein synthesis when 




artificially tethered to the 3’ UTR of the mRNA, suggesting that the RISC proteins 
act as effectors in the repression, while the miRNAs function mainly as guides that 
identify the target mRNAs (Pillai, Artus et al. 2004, Rehwinkel, Behm-Ansmant et 
al. 2005, Behm-Ansmant, Rehwinkel et al. 2006). 
 
Some viral miRNAs use non-canonical biogenesis pathway. For example, the MHV-
68 pri-miRNAs are transcribed from larger tRNA-like molecules by RNA pol III and 
are cleaved by the by host tRNase Z, but not Drosha, to liberate the pre-miRNAs 
(Bogerd, Karnowski et al. 2010). The BLV pre-miRNAs are transcribed directly by 
RNA pol III and do not require the Drosha cleavage step (Figure 1.6) (Cullen 2012, 
Rosewick, Momont et al. 2013). The herpesvirus saimiri (HVS) expresses Sm class 
U RNAs (HSURs) in the latently infected marmoset T cells. HSV does not utilise the 
microprocessor complex, but instead uses the host integrator complex to generate the 
3' end of the HSURs and the pre-miRNA hairpins (Cazalla, Xie et al. 2011).  
  





Figure 1.5  miRNAs biogenesis. Most of the host and viral miRNAs are transcribed 
as pri-miRNAs by host RNA pol II in the nucleus and then processed by the 
endonuclease Drosha to produce the pre-miRNAs. miRNAs of MHV-68 and BLV are  
transcribed by the RNA pol III. The MHV-68 pri-miRNAs are then processed by the 
host tRNase Z, but not Drosha, to generate the pre-miRNAs. BLV miRNAs are 
transcribed directly as pre-miRNAs and do not require Drosha processing. HVS pre-
miRNAs are produced following the integrator complex processing of the HSURs. 
The pre-miRNAs are then transported to the cytoplasm by Exportin 5 (XPO5) and 
further processed by the cellular Dicer to form the short RNA duplex. One strand of 
this RNA duplex (the guide strand) is incorporated into an Argonaute (Ago) protein 
within the RISC complex and direct the RISC to the target mRNA for degradation or 
translational inhibition. Figure adapted from (Kincaid and Sullivan 2012). 
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1.5.3 miRNA-mRNA interaction 
 
miRNAs interact with their target mRNAs by base pairing. In Plants, miRNAs base 
pair to mRNAs with almost perfect complementarity inducing endonucleolytic 
cleavage of the mRNA by an RNAi-like mechanism (Jones-Rhoades, Bartel et al. 
2006). In contrast, the majority of the metazoan miRNAs base pair with their mRNA 
targets imperfectly, according to a set of rules determined by bioinformatic and 
experimental analyses (Bartel 2009, Pasquinelli 2012).  
The first rule and a key determinant of the specific miRNA-mRNA base pairing is 
the perfect and contiguous base pairing of the nucleotide 2 to 8 in the 5’ end of the 
miRNA, representing the ‘seed’ region, to the seed match site in the target mRNA, 
which is mostly located in the 3’ URT (Lewis, Burge et al. 2005). However, some 
miRNAs can specifically target the 5’ UTR and/or the coding region of their mRNA 
targets (Lee, Ajay et al. 2009, Brümmer and Hausser 2014). Mismatches or GU pairs 
in the seed region can significantly affect the miRNA-mediated repression; 
nevertheless, an A residue across position 1 of the miRNA and an A or U across 
position 9 increase efficiency, although they do not need to base pair with the 
miRNA (reviewed in (Filipowicz, Bhattacharyya et al. 2008)).  
Another rule is that mismatches or bulges must be existing in the middle region of 
the miRNA-mRNA duplex, precluding the Ago-mediated mRNA cleavage by 
endonucleolytic activity  (Filipowicz, Bhattacharyya et al. 2008). The third rule is 
that there must be some degree of complementarity at the 3’ half of the miRNA in 
order to stabilise the interaction, particularly at nucleotide positions 13-16 of the 
miRNA (Brennecke, Stark et al. 2005, Lewis, Burge et al. 2005, Grimson, Farh et al. 
2007). 




1.5.4 Mechanisms of translational repression 
 
The mRNA translation comprises 3 steps: Initiation, elongation, and termination. 
Translation initiation involves the recognition of the mRNA 5′-terminal 
7-methylguanosine (m7G) cap by the eukaryotic translation initiation factor 4E 
(eIF4E) subunit of the translation initiation factor eIF4F, which also contains eIF4A 
(an RNA helicase) and eIF4G (a large protein that acts as a scaffold for the assembly 
of the ribosome initiation complex (Hinnebusch and Lorsch 2012). eIF4G can 
concurrently interact with the eIF4E and the poly(A) binding protein 1 (PABP1), 
which is associated with the poly(A) tail, leading to circularisation of the mRNA that 
induces translation initiation and ribosome recycling (Filipowicz, Bhattacharyya et 
al. 2008).  
eIF4G interacts with another initiation factor, eIF3, enabling the recruitment of  the 
40S ribosomal subunit, which scans the 5’ UTR of the mRNA in search of the 
initiation codon, and after joining of the 60S ribosomal subunit the elongation stage 
proceeds (Van Der Kelen, Beyaert et al. 2009, Hinnebusch and Lorsch 2012). When 
the ribosome finds a termination codon, the ribosomal subunits dissociate from each 
other and from the mRNA resulting in translation termination. Some cellular and 
many viral mRNAs initiate translation in an m7G cap and eIF4E-independent 
manner and the 40S ribosome subunits are recruited to the mRNA via interaction 
with internal ribosome entry sites (IRES), which are located in the 5’ UTR (Jackson 
2005).   
 
 




1.5.4.1 Inhibition of translation initiation 
 
It was reported that the central domain of the human Ago2 protein shows sequence 
similarity to eIF4E, resulting in competition with eIF4E for m7G cap binding leading 
to inhibition of translation initiation at the cap recognition step (Kiriakidou, Tan et al. 
2007). In the same study, the authors have shown that the two tryptophan residues 
(W56 and W102) of eIF4E, which bind to the m7G cap, correspond to two conserved 
phenylalanine residues (F470 and F505) in the Ago proteins and that the substitution 
of one or both phenylalanine residues of human Ago2 protein with valine resulted in 
abolition of the translational repression. 
A previous published study has shown that the let-7 miRNA and its target mRNAs 
are associated with the free messenger ribonucleoprotein pool but not with the 
polysomal fraction in sucrose gradients in the mammalian cells, suggesting an 
miRNA-mediated inhibition of translation initiation (Pillai, Bhattacharyya et al. 
2005). Moreover, the authors have shown that the IRES-mediated translation is 
resistant to repression by let-7 miRNA. This finding is consistent with other studies 
that showed that mRNAs translated through cap-independent mechanisms are 
immune to miRNA-mediated translation repression (Humphreys, Westman et al. 
2005, Mathonnet, Fabian et al. 2007, Wakiyama, Takimoto et al. 2007). 
In agreement with the notion that miRNAs can inhibit translation initiation, 
Mathonnet et. al. showed that addition of purified translation initiation complex 
eIF4F counteracted miRNA-mediated translation repression (Mathonnet, Fabian et 
al. 2007). Using siRNA screening for eIF4F components, it was recently revealed 
that the DEAD-box RNA helicase eIF4A2 plays a key role in the miRNA-mediated 




silencing and that it favourably binds to the CCR4–NOT complex rather than to 
eIF4G (Meijer, Kong et al. 2013, Wilczynska and Bushell 2015). 
1.5.4.2 Post-initiation mechanisms 
 
1.5.4.2.1 Inhibition of ribosomal subunit association 
 
Chendrimada et. al. showed that the depletion of eIF6, which is a ribosome inhibitory 
protein that prevents productive assembly of 80s ribosomes (Ceci, Gaviraghi et al. 
2003), results in abrogation of miRNAs-mediated translational inhibition, suggesting 
that miRNAs can suppress translation at an early stage before elongation 
(Chendrimada, Finn et al. 2007). The authors reported that eIF6 associates with the 
60s ribosomal subunit and Ago2 protein in human cells. These findings suggest that 
Ago2 may recruit eIF6 in order to disrupt the association of large and small 
ribosomal subunits and thus inhibit an early translation step. eIF6 is required for the 
biogenesis of the 60s ribosomal subunit (Miluzio, Beugnet et al. 2009, Brina, 
Miluzio et al. 2015). Therefore, another interpretation of Chendrimada’s results is 
that eIF6 depletion may have secondary effects that may not yet be completely 
appreciated.  
1.5.4.2.2 Premature ribosome dissociation (ribosome drop-off) 
 
Peterson et. al. designed a synthetic luciferase reporter mRNA containing a 3’ UTR 
that carries 6 identical sites partially complementary to a transfected miRNA mimic 
(Petersen, Bordeleau et al. 2006). In this system, although the transient expression of 
the reporter mRNA was repressed by the miRNA mimic, the mRNA was associated 
with polysomes. However, when the translation initiation was inhibited by 
hippuristanol, which is an eIF4A inhibitor, there was more rapid loss of the repressed 




mRNA from the polysome than that detected for the active unrepressed mRNA. 
These findings suggest that ribosomes are freed from their association with repressed 
mRNAs more rapidly than with active mRNAs as a result of miRNA-mediated 
premature ribosome dissociation (Petersen, Bordeleau et al. 2006, Eulalio, 
Huntzinger et al. 2008, Valinezhad Orang and Safaralizadeh 2014). 
1.5.4.2.3 Co-translational protein degradation 
 
miRNAs were suggested to mediate the destruction of the newly formed polypeptide 
chain co-translationally (Nottrott, Simard et al. 2006, Eulalio, Huntzinger et al. 2008, 
Valinezhad Orang and Safaralizadeh 2014). This suggestion was based on the 
evidence that miRNA target is actively translated although the protein product cannot 
be detected, whereas proteasome inhibitors are not able to restore the protein 
expression from repressed mRNAs; nevertheless, the putative peptidase remains 
unknown (Nottrott, Simard et al. 2006). 
1.5.4.3 mRNA decay 
 
Studies in C. elegans, D. melanogaster, zebrafish embryos, and human cells showed 
that miRNAs induce deadenylation from 3’ end and/or decapping from the 5’ end 
resulting in mRNA degradation not by Argonaute endonucleatic cleavage but rather 
by exonucleases and by enzymes such as DCP1/2 (Valencia-Sanchez, Liu et al. 2006, 
Garneau, Wilusz et al. 2007, Eulalio, Huntzinger et al. 2008, Fabian, Sonenberg et al. 
2010, Valinezhad Orang and Safaralizadeh 2014, Wilczynska and Bushell 2015). 
Some evidence suggests that translational repression can occur independent of 
mRNA-mediated mRNA degradation. For example, miR-430 was reported to induce 
translational repression in zebrafish embryos before complete mRNA deadenylation 
and decay, where inhibiting mRNA deadenylation did not block translational 




repression (Bazzini, Lee et al. 2012). It is possible that miRNAs can combine two 
mechanisms of action (mRNA decay and translational repression) at the same time in 
order to maximise their inhibitory effect. 
1.5.4.4 Sequestration in P bodies 
 
miRNAs, miRNA targets, and Argonaute proteins colocalise to distinct foci within 
the cytoplasm known as processing bodies (P bodies). Other P bodies components 
include GW182, the decapping enzyme DCP2, decapping activators (such as DCP1, 
EDC3, Ge-1), the CAF1-CCR4-NOT deadenylase complex, and the RNA helicase 
RCK/p54, all of which were involved in miRNA function (Eulalio, Behm-Ansmant 
et al. 2007, Parker and Sheth 2007, Filipowicz, Bhattacharyya et al. 2008, Kulkarni, 
Ozgur et al. 2010, Nishi, Takahashi et al. 2015). The detection of miRNAs, miRNA 
targets and Argonaute proteins in P bodies led to the notion that miRNA targets get 
sequestered in P bodies and thus isolated from the translation machinery. It has been 
debated whether the localisation of miRNA targets in the P bodies is a consequence 
or cause of miRNA-mediated gene expression silencing. It has been shown that 
miRNA-mediated silencing is unaffected in cells lacking detectable microscopic P 
bodies, suggesting that aggregation of miRNA silencing machinery in microscopic P 
bodies is not essential for miRNA function (Chu and Rana 2006, Eulalio, Behm-
Ansmant et al. 2007, Eulalio, Huntzinger et al. 2008, Kulkarni, Ozgur et al. 2010). 
1.5.5 miRNA-based therapeutic approaches 
 
Due to their powerful regulatory functions in a wide variety of diseases, miRNAs are 
considered as an attractive target for therapeutic intervention. Depending on the 
cause of miRNA disbalance, the therapeutic approach has to be adjusted. miRNA 
dysregulation can be caused by deficiency in the maturation pathway or altered 




regulation of a specific miRNA. If the total miRNA level in the cell is dysregulated, 
it is highly likely that one or more components of the miRNA processing machinery 
are altered and an indirect miRNA-targeting therapeutic approach should be used (De 
Santa, Iosue et al. 2013). If the expression of a specific miRNA is dysregulated, the 
therapy is based on direct miRNA targeting. The ideal drug should be (1) easily 
delivered into the target cells; (2) stable in vivo and has long-term effect; (3) specific 
to its target within the cell; (4) safe with minimal or no off-target effects.  
Disease-causing miRNA dysregulation can be due to downregulation of miRNA 
expression or overexpression of a normally lowly expressed miRNA. In cancer, 
miRNAs can have oncogenic or tumour suppressive functions. Depending on the 
function alteration, therapeutic strategy can be developed. Downregulated miRNA 
can be substituted by miRNA mimic, a synthetic RNA duplex designed to mimic the 
endogenous function of the miRNA of interest with modifications for cellular uptake 
and stability. Another way for substitution of the deficient miRNA is by the use of 
adeno-associated viruses (AAV) as vectors for stable expression of the miRNA of 
interest (van Rooij and Kauppinen 2014). AAV various serotypes allow for tissue 
specificity due to the natural tropism of the virus. In addition, the use of tissue-
specific promoter for miRNA expression can add another layer of specificity to this 
system.  
Inhibition of highly expressed miRNA can be achieved by miRNA sponges, in which 
RNA molecules carrying complementary binding sites to the miRNA of interest are 
transgenically expressed, or by antisense oligonucleotides (ASO), known as anti-
miRs (van Rooij and Kauppinen 2014). Anti-miRs are the most widely used 
approach to regulate miRNA expression in vivo. Anti-miR is an antisense 
oligonucleotide carrying the full or partial complementary reverse sequence of a 




mature miRNA, which can be modified to promote their stability, binding affinity 
and pharmacokinetic properties. The locked nucleic acid (LNA), which is RNA 
analogue in which the bicyclic furanose unit is locked in an RNA mimicking sugar 
conformation, is considered a very promising antisense oligonucleotide with proven 
therapeutic efficacy (Stenvang, Petri et al. 2012). 
1.5.5.1 Examples of miRNAs with therapeutic potential 
 
1.5.5.1.1 Inhibition of miR-122 for treatment of Hepatitis C virus 
 
In 2005, miR-122 was identified as a liver-specific miRNA that can modulate HCV 
replication and it has been shown to be inhibited by a 2′-OMe-modified anti-miR-
122 ASO (Jopling, Yi et al. 2005). Miravirsen, which is a 15-mer LNA- and 
phosphorothioate-modified anti-miR with a high affinity for miR-122, is currently in 
clinical trials (Li and Rana 2014). Preclinical trials showed that miravirsen was well-
tolerated and effectively inhibited miR-122 expression in healthy monkeys 
(Krutzfeldt, Rajewsky et al. 2005, Hildebrandt-Eriksen, Aarup et al. 2012). The same 
drug at a dose of 5 mg per kg decreased HCV infection by two orders of magnitude 
in chimpanzees with chronic HCV (Lanford, Hildebrandt-Eriksen et al. 2010). In a 
phase I clinical study, miravirsen was well tolerated and showed no dose-limiting 
toxicity in single-dose and multiple ascending-dose studies in healthy individuals 
(Lindow and Kauppinen 2012). The phase II clinical study showed that there is 2–3 
log decrease in serum HCV RNA in patients with chronic HCV infection who 
received five weekly subcutaneous injections of miravirsen. Moreover, HCV RNA 
was undetectable in 44.4% of patients who received the highest dose tested (7 mg per 
kg) and no serious side effects were reported (Lindow and Kauppinen 2012). This 




interesting data suggests that miravirsen can be the first anti-miR drug to enter the 
market. 
1.5.5.1.2 miR-34 mimic for treatment of liver cancer  
 
The miR-34 family comprises miR-34a, miR-34b and miR-34c whose genes are 
located in genomic regions involved in cancer (Calin, Sevignani et al. 2004). Several 
studies showed that miR-34 expression is reduced in cancer cells and that  it inhibits 
cell growth by targeting oncogenes involved in proliferation (histone deacetylase 1 
(HDAC1) and MYC), cell cycle control (cyclin-dependent kinase 4 (CDK4), CDK6 
and the transcription factor E2F3), metastasis (metastasis-associated protein MTA2), 
and apoptosis (B cell lymphoma 2 (BCL-2) and sirtuin1 (SIRT1)) (Li and Rana 
2014). This data suggested that miR-34 mimic can be a potential therapeutic option 
for restoring the normal regulation of cell growth and cell death genes in cancer cells. 
In 2013, Mirna Therapeutics announced the start of a phase 1 clinical study of a 
liposome-formulated miR-34 mimic, designated MRX34, in patients with liver 
cancer (Bouchie 2013). However, in 2016, the clinical study halted as a result of 
multiple immune-related severe adverse events such as severe cytokine release 
syndrome in patients treated with MRX34. 
 
1.5.5.1.3 Anti-miR-21 for treatment of Alport syndrome 
 
Alport syndrome is genetic kidney disease caused by mutations in the type IV 
collagen genes (Col4A3, Col4A4 and Col4A5) characterised by chronic 
glomerulonephritis (Hudson, Tryggvason et al. 2003). It has been shown that miR-21 
plays an important role in promoting kidney pathogenic progression in short-term 




rodent models of kidney disease (Chau, Xin et al. 2012, Zhong, Chung et al. 2013) 
and in progression of Alport syndrome (Gomez, MacKenna et al. 2015). Inhibition of 
miR-21 in Alport kidney mouse model by an anti-miR-21 oligonucleotide, which is 
chemically modified single-stranded RNA molecule with full sequence 
complementarity to miR-21, led to a considerably milder kidney disease, where the 
anti-miR-21 resulted in (i) Enhancement of PPARα/retinoid X receptor 
(PPARα/RXR) activity and downstream signaling pathways in glomerular, tubular, 
and interstitial cells; (ii) stimulation of mitochondrial function and reduction of 
mitochondrial ROS production, leading to improved tubular functions; (iii) 
protection against TGF-β–induced fibrogenesis and inflammation in interstitial and 
glomerular cells (Gomez, MacKenna et al. 2015). This data suggests that anti-miR21 
can be a candidate drug for treatment of Alport syndrome. A chemically modified 
anti-miR-21, designated RG-012, is currently being developed by Regulus 
Therapeutics. 
1.5.5.1.4 Anti-miR15/195 for post-myocardial infarction remodelling and 
cardiac regeneration 
 
Overexpression of miR-195 (miR-15 family) in the embryonic heart resulted in 
ventricular hypoplasia and septal defects (Porrello, Johnson et al. 2011). A 
mechanistic study has shown that miR-195 controlled cardiomyocyte proliferation by 
targeting a number of cell cycle genes, including checkpoint kinase 1 (CHEK1) 
(Porrello, Johnson et al. 2011). Interestingly, inhibiting miR-195 by LNA-modified 
anti-miRs in pigs and mice resulted in protection of treated animals from myocardial 
infarction and caused strong effects on cardiac regeneration (Hullinger, Montgomery 




et al. 2012, Porrello, Mahmoud et al. 2013). Currently, miRagen Therapeutics and 
Servier are developing an anti-miR15/195 and it is at the preclinical stage. 
1.5.5.2 Future perspectives 
 
The miRNA-based therapeutic field is growing; however, there are some challenges 
such as the potential drug resistance to anti-miRs and the off-target effects of the 
miRNA-based therapeutics. The potential resistance to an anti-miR could stem from 
(1) change in absorption, distribution, metabolism and excretion of the anti-miR of 
interest; (2) upregulation of targeted miRNAs expression and/or enhancing their 
processing or biogenesis to counteract the anti-miR effect; (3) upregulation of the 
expression of other miRNAs that can target the same gene and thus counteract the 
inhibitory effect of the anti-miR. Further understanding of the miRNA therapeutic 
resistance can lead to better miRNA-targeting strategies. 
Due to the ubiquitous nature of the miRNAs, it is possible that miRNA therapeutics 
can have off-target adverse effects especially in indications that require chronic 
treatment. Therefore, the delivery of the miRNA therapeutic to the cell type or tissue 
of interest is a key factor for a successful drug. One potential approach is to 
conjugate the miRNA with a bioactive molecule that can enhance the delivery of the 
miRNA therapeutic to the specific cell types. Another approach can involve 
encapsulation of the miRNA therapeutic into a lipid-based formulation that enhances 
specific cell uptake. Despite the challenges, the miRNA-based therapeutics has now 
become a viable option for addressing the unmet medical needs for serious and life-
threatening diseases.  
 




1.6 MHV-68 microRNAs 
 
MHV-68 encodes at least 15 miRNAs that were identified by cloning or deep 
sequencing (Pfeffer, Sewer et al. 2005, Reese, Xia et al. 2010, Zhu, Strehle et al. 
2010). The miRNAs are located immediately downstream of the vtRNAs in the left 
end of the genome (Figure 1.5). The primary miRNAs are transcribed by RNA pol 
III as hybrid transcripts with the vtRNAs (Pfeffer, Sewer et al. 2005). It has been 
shown that several MHV-68 miRNAs are functional and biologically active using 
luciferase reporter analyses and that this activity varies between different miRNAs 
(Diebel, Smith et al. 2010).  
 
While this project was underway, two groups published studies that investigated the 
functions of the MHV-68 miRNAs and vtRNAs using mutant viruses with reduced 
or abolished expression of 14 MHV-68 miRNAs (Feldman, Kara et al. 2014) or all 
vtRNAs and their associated miRNAs (Diebel, Oko et al. 2015). Feldman et. al. have 
demonstrated that the MHV-68 miRNAs are not essential for viral lytic replication in 
vitro and in vivo (Feldman, Kara et al. 2014). In the same study, although the 
splenocytes from mice infected with the miRNA mutant virus or the WT virus had 
identical levels of ex vivo reactivation, the miRNAs deletion caused a small reduction 
(2.3-fold) in the latent genome levels at 16 dpi. However, the ex vivo reactivation of 
virus from the splenocytes from the miRNA mutant virus-infected mice was reduced 
as compared to that of the WT virus when the mice were infected at a lower dose. 
The authors utilised a beta lactamase reporter gene fused in frame to the ORF73 
within the virus genome in order to isolate the latently infected B cells by flow 
cytometry. 





Figure 1.6 Genomic organisation of the MHV-68 encoded vtRNAs and 
miRNAs in the left end of MHV-68 genome.  The vtRNAs are represented as 
black arrows. The dashed lines indicate the locations of the MHV-68 miRNAs, 
which are numbered mghv-mir-M1-1 through-15. The miRNAs are named 
according to the miRBase nomenclature (Kozomara and Griffiths-Jones 2014). 
The open reading frames for M1 and M1 are shown as blue arrows. 




The splenic naïve, germinal centre, and memory B cells were isolated from mice 
infected with the miRNA mutant virus or the WT virus. It was revealed that the 
deletion of the 14 miRNAs resulted in approximately 2-fold decrease in the MHV-68 
infected memory B cells at 16 dpi. Interestingly, the deletion of the miRNAs resulted 
in attenuation of viral virulence in acute-lethal pneumonia model (Feldman, Kara et 
al. 2014). 
 
Diebel et. al. have demonstrated that the MHV-68 vtRNAs and their associated 
miRNAs are not essential for acute replication or establishment of latency in vivo 
(Diebel, Oko et al. 2015). Similar to Feldman et. al. observations, the authors 
demonstrated that the deletion of the vtRNAs and their associated miRNAs led to a 
reduction in the lethal pneumonia in IFNγ knock-out mice. However, in the same 
study, a recombinant virus expressing vtRNA1 only in the absence of other vtRNAs 
and miRNAs was able to partially restore the lethal pneumonia phenotype. 
Collectively, it is suggested that the vtRNAs may play an active role in MHV-68 
virulence and that they may co-operate with the viral miRNAs to achieve this role.  
 
A very recent study has shown that infection of mice with a mutant MHV-68 virus 
lacking all miRNAs and vtRNAs, resulted in slight reduction of ex vivo reactivation 
during early latency in spleen (17 days post infection) as compared to wild-type and 
revertant viruses despite similar viral genomic loads (Steer, Strehle et al. 2016). In 
the same study, the author have shown that during late latency in spleen (42 days 
post infection), there was significant increase of viral genomic load of the mutant 
virus as compared to the wild-type and revertant viruses; although, no ex vivo 
reactivation could be detected at this time-point. In contrast to Feldman’s and 




Diebel’s studies, Steer et al. found no difference in the lethal pneumonia in the 
infected IFNγ knock-out mice between wild-type and mutant virus. Possible cause of 
this discrepancy is that  Steer et al. sacrificed mice when they lost more than 15% of 
the initial body weight and animals were not given chance to recover.  
 
1.7 Role of herpesvirus miRNAs during latency 
 
To date, more than 300 virally encoded miRNAs have been identified and found to 
be encoded by several virus families including adenoviruses, polyomaviruses, and 
retroviruses; however, the majority of viral miRNAs are encoded by herpesviruses 
(Kincaid, Burke et al. 2012, Kozomara and Griffiths-Jones 2014). There has been an 
increasing evidence that the miRNAs encoded by herpesviruses play important roles 
during viral latency (Grey 2015). The best model for studying viral miRNAs is 
within the natural host; however, obviously this is not possible for human viruses. 
Animal models can provide a powerful tool for investigating viral miRNAs 
functions. For example, MHV-68 provides a unique small animal model for studying 
gammaherpesvirus-encoded miRNAs in the context of natural virus-host interplay.  
 
A common feature among all herpesviruses is their ability to establish latency within 
the natural host. A single miRNA can suppress the expression of hundreds or even 
thousands of target mRNAs, and thus an miRNA can inhibit the expression of 
multiple genes within the same physiological pathway (Feig, Giles et al. 2015). 
Furthermore, miRNAs have a relatively modest effect on their target transcripts and 
act as fine-tuners of gene expression, which may require time before causing a 
significant biological effect (Kincaid and Sullivan 2012). This makes viral miRNAs 
ideal proviral tools during the state of latent infection. 




Indeed, several studies demonstrated that the miRNAs encoded by herpesviruses play 
important roles in promoting latent infection through multiple strategies such as 
inhibiting lytic replication, evading the immune response, enhancing infected cell 
survival, and promoting infected cell proliferation. These roles are reviewed in the 
following sections. 
 
1.7.1 Inhibition of lytic infection  
 
Successful latent infection requires restricting viral lytic gene expression so that the 
infected cells cannot be detected by the host immune surveillance and be eliminated. 
However, at the same time the latent virus genome requires a suitable environment 
for reactivation under the appropriate conditions. This requires intricate homeostatic 
balance and fine tuning of gene expression, a function that is ideal for miRNAs.  
 
One strategy for restricting viral lytic infection is by inhibiting the viral 
transcriptional activators which play a key role in stimulating lytic gene expression 
and in the latent/lytic switch. It has been demonstrated that the KSHV miRNA, miR-
K12-9*, targets a sequence in the 3’ UTR of the immediate-early transcriptional 
activator RTA (Bellare and Ganem 2009). The authors demonstrated that the ectopic 
expression of miR-K12-9* inhibits RTA expression, while its specific knock down in 
latently infected cells increased lytic reactivation frequency by two to three fold, 
suggesting that the virally encoded miRNAs can act as fine tuners of the major lytic 
switch protein, RTA, in order to facilitate latency by preventing any fortuitous 
reactivation. These findings were reminiscent of the reported inhibition of the 
expression of the trans-activating protein, IE72, of HCMV by the HCMV miRNA 
miR-UL112-1 (Grey, Meyers et al. 2007, Murphy, Vanicek et al. 2008).  




Similarly, The HSV-1 miRNA, miR-H2-3p, which is transcribed antisense to the 
transcriptional activator infected cell protein 0 (ICP0), was able to reduce the ICP0 
protein levels without affecting ICP0 mRNA levels (Umbach, Kramer et al. 2008). 
Additionally, co-transfection experiments revealed that HSV-2 miR-H3 and miR-H4 
(also referred to as miR-I and miR-III respectively) were able to reduce the levels of 
ICP34.5 protein (Tang, Patel et al. 2009), which is involved in virus replication, 
reactivation, and neurovirluence (Whitley, Kern et al. 1993, Bolovan, Sawtell et al. 
1994).  
 
Strassheim et. al.  reported that MDV-1 miRNA, miR-M7-5p, inhibits the expression 
of the immediate-early genes ICP4 and ICP27 using luciferase reporter assays; in 
addition, there was an increase in miR-M7-5p expression and decrease of ICP27 
expression during virus reactivation, suggesting that this miRNA facilitates latent 
infection (Strassheim, Stik et al. 2012).  
 
Several other studies revealed the herpesviruses from different families can inhibit 
their own trans-activating gene expression via their miRNAs (Lu, Li et al. 2010, Lin, 
Liang et al. 2011, Jung, Choi et al. 2014, Riaz, Dry et al. 2014). Viral miRNA-
mediated inhibition of the lytic switch protein expression in different herpesviruses 
indicates that this is an evolutionary conserved mechanism that allows herpesvirus to 
restrict lytic infection and thereby establish and maintain latency. 
 
Another strategy for restricting viral lytic gene expression is by regulating cellular 
targets that are involved in the viral lytic replication. One clear example for this is 
the inhibition of IκBα, a suppressor of NF-κB complexes, by KSHV miR-K12-1 




leading to enhanced NF-κB-dependent viral latency (Lei, Bai et al. 2010).  miR-K12-
3 can also promote KSHV latent infection via targeting the nuclear factor I/B, an 
activator of RTA promoter (Lu, Li et al. 2010). Furthermore, the EBV miRNA, 
BART-miR-18-5p, has been reported to inhibit the expression of the cellular protein 
MAP3K2 resulting in decreased viral lytic gene expression and virus production (Qiu 
and Thorley-Lawson 2014).  
Pavelin et. al.  used combined approach of RNA-induced silencing complex 
immunoprecipitation (RISC-IP) and siRNA screening techniques for identification of 
HCMV miRNAs targets that have a role in the virus life cycle (Pavelin, Reynolds et 
al. 2013). The top identified target was the cellular ATP6V0C that is a component of 
Vacuolar ATPase involved in acidification of endosomal compartments (Forgac 
2007). The authors demonstrated that knock down of ATP6V0C resulted in almost 
complete inhibition of infectious virus production and that ATP6V0C is targeted by 
US25-1 miRNA, suggesting that US25-1 can inhibit virus lytic replication through 
down-regulation of ATP6V0C. 
 
1.7.2 Evading the immune response 
 
The virus use of miRNAs during latency is itself a way of immune evasion because 
the miRNAs are non-immunogenic and cannot be detected by the conventional 
immune defence. There has been growing evidence that herpesvirus miRNAs can 
play a role in evading the host immune response. Dolken et. al. provided the first in 
vivo evidence that links viral miRNAs to immune evasion through investigating the 
phenotype of an MCMV virus lacking  2 miRNAs, miR-M21-1 and miR-M23-2. The 
authors demonstrated that deletion of the miRNAs resulted in reduction in virus 
production in the salivary gland, which is a site for virus persistence, a phenotype 




seen in C57BL/6 mice but not BALB/c mice and could be rescued by combined 
depletion of NK and CD4+ T cells, suggesting that these miRNAs may help the virus 
evade the immune response and allow for long-term persistence (Dolken, Krmpotic 
et al. 2010). 
 
Furthermore, an miRNA encoded by another betaherpesvirus, HCMV UL112-1, 
inhibits the MHC class I-related chain B (MICB) protein, which is a stress-induced 
ligand that is targeted by NK cells via the NKG2D ligand, resulting in reduction of 
the cytotoxic effects of NK cells (Stern-Ginossar, Elefant et al. 2007). Similarly, 
miRNAs encoded by KSHV and EBV have been shown to target the MICB mRNA 
and down-regulate its expression (Nachmani, Stern-Ginossar et al. 2009), suggesting 
that viral miRNAs can have similar function; although, that they share no sequence 
homology.  
 
Several studies have shown that herpesvirus miRNAs can target genes that inhibit the 
production of pro-inflammatory cytokines in order to suppress the recruitment of 
immune cells to the site of infection (Abend, Uldrick et al. 2010, Abend, 
Ramalingam et al. 2012, Hook, Hancock et al. 2014). For example, the KSHV 
miRNA, miR-K12-10a, targets TWEAKR (TNF-like weak inducer of apoptosis 









1.7.3 Survival of latently infected cells through anti-apoptotic 
mechanisms 
 
Survival of the latently infected cells is an absolute requirement for viral long-term 
latency because cell death means the virus loses its host. EBV miRNAs promote cell 
survival through anti-apoptotic mechanisms. For instance, EBV-miR-BART5 
inhibits the expression of p53-up-regulated modulator of apoptosis (PUMA) (Choy, 
Siu et al. 2008). Another study demonstrated that BART cluster 1 miRNAs can 
inhibit the expression of the pro-apoptotic BIM protein as well as PUMA (Marquitz, 
Mathur et al. 2011). Moreover, EBV miRNAs, BART16 and BART1-3p, target the 
cellular caspase 3, leading to apoptosis suppression (Vereide, Seto et al. 2014). 
 
A recent study has identified the mRNA targets of BART miRNAs in 
nasopharyngeal carcinoma cell line using photoactivatable ribonucleoside-enhanced 
crosslinking and immunoprecipitation (PAR-CLIP), where 10 pro-apoptotic mRNA 
targets were validated by indicator assays and ectopic expression of the miRNAs 
(Kang, Skalsky et al. 2015), suggesting that EBV BART miRNAs enhance survival 
of the latently infected epithelial cells and thereby promote long-term infection.  
 
It has been demonstrated that a KSHV miRNA, miR-K12-1, hijacks the NF-κB 
pathway by inhibiting the expression of IκBα, an inhibitor of NF-κB transcription 
factors, resulting in enhanced NF-κB-dependent viral latency and cell survival (Lei, 
Bai et al. 2010). Viral miRNA-mediated anti-apoptotic activity is not only restricted 
to gammaherpesviruses, an alphaherpesvirus miRNA, MDV-1 miR-M3, has been 
reported to promote cell survival through suppression of cisplatin-induced apoptosis 
by targeting SMAD2 (Xu, Xue et al. 2011). 




1.7.4 Cellular proliferation and oncogenesis 
 
Remarkably, both KSHV miR-K12-11 and MDV-1 miR-M4 share sequence 
homology with the cellular oncomiR miR-155, which plays crucial roles in 
physiological lymphocyte development and activation but  whose  overexpression is 
associated with lymphoid cancer development (Eis, Tam et al. 2005, Gottwein, 
Mukherjee et al. 2007, Rodriguez, Vigorito et al. 2007, Skalsky, Samols et al. 2007). 
Indeed, it has been demonstrated that miR-K12-11 and miR-155 target common sets 
of mRNAs and that miR-K12-11 plays a role in B cell transformation in humanised 
mice and can complement the deficiency of miR-155 in vivo (Gottwein, Mukherjee 
et al. 2007, Skalsky, Samols et al. 2007, Boss, Nadeau et al. 2011, Sin, Kim et al. 
2013). An MDV-1 virus lacking miR-M4 expression was unable to transform 
infected T-cells, suggesting a major role played by miR-M4 in MDV tumourigenesis 
(Zhao, Xu et al. 2011). 
 
A KSHV mutant virus lacking a cluster of 10 primary miRNAs revealed that the 
KSHV miRNAs are crucial for cellular transformation and oncogenesis as well as for 
cell survival and apoptosis inhibition in primary rat mesenchymal cells (Moody, Zhu 
et al. 2013). EBV miRNAs have also been reported to contribute to the virus-induced 
oncogenesis and to B cell proliferation (Seto, Moosmann et al. 2010, Babu, Ponia et 
al. 2011, Vereide, Seto et al. 2014).  
 
Recently, it has been shown that EBV-miR-BART1 targets the tumour suppressor, 
phosphatase and tensin homologue (PTEN), resulting in activation of the PTEN-
dependent pathways and induction of epithelial–mesenchymal transition and 
metastasis in nasopharyngeal carcinoma (Cai, Ye et al. 2015).  




1.8 miRNAs encoded by viruses other than herpesviruses 
 
1.8.1 Polyomavirus miRNAs 
 
Polyomaviruses is a family of non-enveloped double stranded DNA tumour viruses 
with circular genome of approximately 5,100 bp that can infect humans and animals 
(DeCaprio, Imperiale et al. 2013). The closely related polyomaviruses, Simian virus 
40 (SV40), JC polyomavirus (JCPyV), BK polyomavirus (BKPyV), and Baboon 
polyomavirus 1 (SA12), encode at least one primary miRNA from a late strand of the 
viral genome downstream of the late polyadenylation site (Cantalupo, Doering et al. 
2005, Seo, Fink et al. 2008, Bauman, Nachmani et al. 2011). Murine polyomavirus 
(MuPyV) and Merkel Cell Virus (MCPyV) encode a single primary miRNA located 
at the 5’ end of the second LTAg exon and it is complementary to the early mRNA 
transcript (Seo, Chen et al. 2009, Sullivan, Sung et al. 2009).  
 
The miRNAs of SV40, the first polyomavirus found to encode miRNAs, down-
regulate the expression of viral early proteins and thus reduce the viral T antigens 
presentation (Sullivan, Grundhoff et al. 2005). Furthermore, Zhang et. al. have 
demonstrated that a SV40 mutant virus lacking the miRNAs expression showed 
higher levels of viral DNA in liver and kidney tissues of infected syrian golden 
hamsters as compared to those infected with the WT virus (Zhang, Sroller et al. 
2014). The higher levels of viral T-antigens in the mutant SV40-infected animals are 
likely to support the increased viral DNA replication. However, a mutant SV40 virus 
lacking the primary miRNA exhibited levels of virus production in cell culture 
similar to that of the WT virus (Sullivan, Grundhoff et al. 2005). This highlights the 
importance of in vivo models for analysis of viral miRNAs functions. 




The miRNA mutant SV40-infected cells were more sensitive to lysis by cytotoxic T 
cells and triggered more cytokine production that the WT SV40-infected cells 
(Sullivan, Grundhoff et al. 2005), suggesting that SV40 miRNAs auto-regulate early 
viral protein expression and play a role in evading the cytotoxic immune response. 
The miRNAs of the other polyomaviruses, JCPyV, BKPyV, MuPyV, MCPyV, and 
SA12, have been shown to down-regulate early gene expression (Cantalupo, Doering 
et al. 2005, Seo, Fink et al. 2008, Seo, Chen et al. 2009, Sullivan, Sung et al. 2009, 
Bauman, Nachmani et al. 2011). 
 
1.8.2 Adenovirus miRNAs 
 
Adenoviruses encode several non-coding virus associated (VA) RNAs that can use 
the RNA interference processing pathway such as Exportin 5 and Dicer (Carnero, 
Sutherland et al. 2011). A number of these VA RNAs are cleaved by Dicer into viral 
miRNAs (mivaRNAs). Suppression of mivaRNAs with 2-o-methyl (2ome)-modified 
oligonucleotides, which prevents miRNA interaction with the target, resulted in 
deficient virus production (Aparicio, Razquin et al. 2006). There are no predicted 
mivaRNAs targets in the adenoviral genome by bioinformatic analysis (Aparicio, 
Razquin et al. 2006), excluding potential auto-regulatory roles of these miRNAs. 
Potential cellular targets have been identified using genomic and bioinformatics 
analyses (Aparicio, Carnero et al. 2010). These targets include proteins involved in 








1.8.3 Retrovirus miRNAs 
 
1.8.3.1 Human immunodeficiency virus 1 (HIV-1) miRNAs 
 
Multiple HIV-1 miRNAs are derived from the TAR motif, which is a stable hairpin 
structure found at the 5’ end of all HIV-1 transcripts that facilitates the binding of the 
trans-activator protein Tat  in order to enhance transcription (Berkhout, Silverman et 
al. 1989, Berkhout 1992, Bennasser, Le et al. 2004, Ouellet, Plante et al. 2008, 
Harwig, Das et al. 2014). The TAR miRNAs can be detected in both latently and 
lytically infected human cells and they play a role in transcriptional silencing at the 
long-terminal repeat (LTR) promoter by chromatic remodelling (Bennasser, Le et al. 
2004, Klase, Kale et al. 2007, Ouellet, Plante et al. 2008).  
 
Microarray analysis has shown that TAR miRNAs target apoptotic genes for down-
regulation and therefore it can promote cell survival and chronic infection (Klase, 
Winograd et al. 2009, Ouellet, Vigneault-Edwards et al. 2013). This is consistent 
with the detection of TAR miRNAs in chronically infected CD4+ T cells where virus 
production is very low (Klase, Kale et al. 2007). On the other hand, a HIV-1-encoded 
miRNA (miR-H3) located in the reverse transcriptase gene can target the 5’ LTR 
promoter and induce viral transcription, thereby facilitate exit from latency (Zhang, 
Fan et al. 2014). This indicates that HIV-1 miRNAs can have contrasting effects. 
 
Narayanan et. al. have shown that TAR miRNAs are also found in exosomes from 
HIV-infected cells in cell culture and in the serum of HIV-infected patients, 
suggesting that these miRNAs may have trans-cellular effects on naïve cells 
(Narayanan, Iordanskiy et al. 2013).  




1.8.3.2 Bovine leukemia virus (BLV) miRNAs 
 
BLV is the causative agent of enzootic bovine leukosis, an economically important 
disease in cattle. BLV encodes at least 5 primary miRNAs that are transcribed by 
RNA pol III (Rosewick, Momont et al. 2013). These miRNAs are abundantly 
expressed in pre-leukomic and malignant cells where viral gene expression is 
restricted, raising the possibility that these miRNAs may play roles in latency and 
tumourigenesis (Rosewick, Momont et al. 2013). Indeed, the seed sequence of BLV-
miR-B4 is homologous to that of the cellular pro-oncogenic miR-29 and both 
miRNAs share common target mRNAs, suggesting a role of BLV-miR-B4 in BLV 
oncogenesis (Kincaid, Burke et al. 2012). This mimicry is reminiscent of the KSHV 
miR-K12-11 and MDV-1 miR-4 homology with the cellular oncogenic miRNA, 
miR-155 (Gottwein, Mukherjee et al. 2007, Skalsky, Samols et al. 2007, Zhao, Yao 
et al. 2009). 
 
1.9 Project outline and aims 
 
The human gammaherpesviruses such as KSHV and EBV are associated with 
lymphoproliferative disorders and some types of cancer during their latent infection 
within the host. The exact molecular mechanisms behind this latent infection are 
poorly understood. The discovery of gammaherpesvirus encoded miRNAs opened 
doors for better understanding of latent infection through investigating their 
functions during latency, providing potential novel therapeutic approaches.  
 
Due to species specificity of gammaherpesviruses, dissecting the functions of the 
human gammaherpesvirus-encoded miRNAs in vivo is impossible. MHV-68 is 




genetically related to and shares pathological features with KSHV and EBV. Hence, 
it provides a small animal model for studying gammaherpesvirus life cycle and 
pathogenesis. In this project, the MHV-68 was used as a model for characterising the 
expression of MHV-68 miRNAs and investigating their potential functions in vivo. 
 
The first aim of this study was to establish qRT-PCR assays for quantification of 
MHV-68 miRNAs in vivo. In order to provide a platform for characterising the 
miRNAs expression in vivo, the miRNAs expression was first examined in lytically 
and latently infected cells in vitro. The expression kinetics of the MHV-68 miRNAs 
were then evaluated at different time-points during the different stages of latent 
infection in vivo (latency establishment and latency maintenance). The second aim 
was to construct an miRNA mutant MHV-68 virus lacking the expression of 9 
miRNAs in order to investigate the miRNAs functions in vivo. The final objective 
was to carry out a comprehensive phenotypic analysis of this mutant virus in vitro 
and in vivo in order to examine viral lytic replication, viral latency, ex vivo 
reactivation, viral gene expression, virus-induced B cell activation and proliferation.
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2 Chapter 2: Materials and Methods 
2.1 Cell culture 
 
Baby Hamster Kidney fibroblast 21 (BHK-21) cells were cultured in Glasgow’s 
Modified Eagle’s Medium (GMEM) (Life Technologies, UK) supplemented with 
10% (v/v) fetal calf serum (FCS) (Life Technologies, UK), 10% (v/v) tryptose 
phosphate broth (Life Technologies, UK), 2 mM L-glutamine (Life Technologies, 
UK), and 100 U/ml penicillin and streptomycin (Life Technologies, UK). NIH 3T3 
cells (mouse embryo fibroblasts) were cultured in Dulbecco's Modified Eagle's 
medium (DMEM) (Life Technologies, UK) supplemented with 10% (v/v) FCS (Life 
Technologies, UK), 2 mM L-glutamine (Life Technologies, UK), and 100 U/ml 
penicillin and streptomycin (Life Technologies, UK).  
NS0 cells (murine myeloma) were grown in Rosewell Park Memorial Institute 1640 
(RPMI-1640) medium (Life Technologies, UK) containing 10% (v/v) FCS (Life 
Technologies, UK), 2 mM L-glutamine (Life Technologies, UK), and 100 U/ml 
penicillin and streptomycin (Life Technologies, UK). Cell master stocks (density of 
5x10
6
) were stored as 1 ml FCS with 10% dimethyl sulfoxide (DMSO) in liquid 
nitrogen. In order to make working stocks, the cells were rapidly thawed in water 
bath at 37
o
C. Pre-warmed media was then added drop by drop to the cells followed 
by centrifugation at 470 x g for 5 min at room temperature. The cell pellet was then 
re-suspended in 10 ml media and cultured in T25 sterile flask (Nunc, UK) and 
incubated at 37°C in the presence of 5% CO2. BHK-21 and NIH 3T3 were split when 
they reached 80% confluent growth using 0.25% trypsin (Life Technologies, UK). 
The trypsin was inactivated by addition of an equal amount of medium and the cells 
were pelleted by centrifugation at 470 x g for 5 min at room temperature. The cell 




pellet was re-suspended in medium and a cell aliquot was diluted 1:10 with 0.1% 
trypan blue (Sigma, UK) so that the unstained viable cells could be counted in a 
haemocytometer. The cells were seeded at density of 3 x 10
6
 or 5 x 10
6 
in T80 or 
T175 flasks (Nunc, UK) respectively. 
NS0 cells were grown as suspension and flasks were tilted in the incubator (37
o
C and 
5% CO2) to allow the cells to stick together. These cells were split at ratio of 1:3 
every 3 or 4 days depending on the cell density. 
2.2 In vivo infection 
 
Female BALB/c mice (4-5 weeks old) purchased from Harlan, UK were housed in a 
pathogen-free facility either at the Roslin Institute or the Hugh Robson Building (The 
University of Edinburgh) in accordance with all Home Office and university 
guidelines. Mice were infected with MHV-68 virus intranasally at dose of 4 x 10
5
 pfu 
in 40 µl Phosphate Buffer Saline (PBS) (Life Technologies, UK) under brief 
isofluorane anaesthesia. The infection was carried out by dropping the solution 
containing the virus onto the mouse’s nostrils. Mice were sacrificed by CO2 
asphyxiation. Spleens were harvested and placed in sterile plastic universals 
containing 5 ml RPMI-1640 media. Lungs were kept in cryovials on dry ice 
immediately after harvesting. 
2.3 Virological methods 
 
2.3.1 Preparation of virus stocks 
 
Working stocks of MHV-68 virus were prepared by infection of BHK-21 cells at a 
multiplicity of infection (MOI) of 0.001 pfu/cell. The virus was added to the cells 




and incubated for one hour at 27
o
C with shaking to allow virus adsorption. The cells 
were plated out into T175 flasks at 3x10
6
 cells/flask and incubated for 6 days. The 
cells were subsequently scraped and centrifuged at 1000xg for 20 min at 4
o
C. 
Supernatant was decanted and the cell pellet was re-suspended in PBS, in a volume 
of about third of the number of the flasks used in mls (e.g. 3 ml for 10 flasks). The 
cells were homogenised in a glass dounce homogeniser 20-30 times, sonicated in an 
ice bath for 15 min, and then centrifuged at 1000xg for for 20 min at 4
o
C and the 
supernatant (contains the virus) was collected. The pellet was re-suspended in 1 ml 
PBS and homogenised again, spun down at 1000xg for 20 min at 4
o
C and the 
supernatant was pooled with previous one. The virus suspension was aliquoted into 
cryovials (Nunc) and stored at -80
o
C. 
2.3.2 Plaque assay for virus titration 
 







BHK-21 cells were added to each bijou tube and incubated for 
one hour at 27
o
C with shaking. Each dilution was divided between two 60 mm plates 
resulting in 1 x 10
6 
cells/plate and 3 mls of GMEM was added to each plate. Two 
plates containing uninfected cells were used as a negative control. The plates were 
incubated at 37
o
C in CO2 incubator for 4 days, then the medium was discarded and 
the cells were fixed with 10% (v/v) Neutral Buffered Formaldehyde (Surgipath 
Europe Ltd) for at least 1 hour followed by staining with 0.1% Toluidine blue (BDH 
Laboratory Supplies) for 30 min. Plates were washed in water, left to dry and plaques 
formed by the virus were counted under light microscope. The virus titre was 
calculated as: (average number of plaques) / (lowest dilution x final dilution volume 
added to the plate (2 ml). 




2.3.3 Infection of NIH 3T3 and NS0 cells 
 
NIH 3T3 cells were seeded in a 6-well plates at density of 10
6
 cells per well. Next 
day the wells were infected with MHV-68 virus at MOI of 5 pfu/cell. Uninfected 
wells were used as a control. The 6-well plates were then incubated in CO2 incubator 
for 1 hour at 37
o
C to allow virus attachment then the media was discarded and 2 ml 
of fresh DMEM was added to each well. The plates were incubated for 2, 8 or 24 
hours at 37
o
C followed by cell harvesting and total RNA and DNA extraction. NS0 
cells were counted and 2 x 10
6 
cells were infected with MHV-68 virus at MOI of 5 
and incubated in bijou tubes at 37
o
C for 1 hour while shaking. The cell-virus mixture 
(1 ml) was transferred from the bijou to T25 flasks containing 9 ml of pre-warmed 
RPMI-1640 media. Uninfected cells were used as a control. The flasks were 
incubated for 5 days at 37
o
C followed by cell harvesting and total RNA and DNA 
extraction. 
2.3.4 MHV-68 reactivation induction in vitro 
 
NS0 cells were infected with MHV-68 virus as described above. On day 3 post 
infection, the cells were treated with 20 ng/ml Phorbol 12-myristate 13-acetate 
(PMA) (Sigma-Aldrich). Cells were harvested for RNA and DNA extraction at 2, 4, 
8, 24, and 48 hours post treatment. Untreated cells were used as a control and were 
harvested at 5 days post infection. 
2.3.5 Inhibition of MHV-68 replication in vitro 
 
Two mg/ml solution of the antiviral thionucleoside analogue 2'-deoxy-5-ethyl-beta-
4'-thiouridine (4'-S-EtdU) was prepared in sterile PBS and heated at 60
o
C until 
dissolved. The solution was filtered through a 0.2 µM filter using a syringe. NS0 




cells were infected with MHV-68 virus as described above. On day 3 post infection, 
the cells were treated with 4'-S-EtdU at concentration of 1µg/ml in medium. Cells 
were harvested for RNA and DNA extraction at 0 and 48 hours after treatment. 
Untreated cells were used as a control. 
2.4 Flow cytometry for isolation of mLANA expressing 
cells 
 
2.4.1 Harvesting of spleen cells  
 
A small portion of the spleen was kept in -80
o
C for DNA extraction and 
determination of viral genomic load. The rest of the spleen was teased out of the 
capsule with a scalpel blade into RPMI-1640 medium (with 10% FCS, 2 mM L-
glutamine, and 100 U/ml Pen-Strept). Red blood cells were lysed using RBC Lysis 
Buffer (Biolegend) according to the manufacturer’s instructions. The cells were 
pelleted by centrifugation at 470 x g/ 5 min/ 4
o
C. The cell pellet was re-suspended in 
10 ml fresh medium and left on ice for 5 min to allow settling of any intact portions 
of the tissue out of the fluid. The supernatant was transferred to a new tube and the 
splenocytes were counted and cells were adjusted to a concentration of 5x10
7
 
cells/ml in PBS supplemented with 2% FCS. All of the harvested cells were 
subjected to the flow cytometry. 
2.4.2 β-lactamase detection and isolation of mLANA positive 
splenocytes 
 
The splenocytes were adjusted to a concentration of 5x10
7
 cells/ml in PBS 
supplemented with 2% FCS. The CCF2/AM β-lactamase substrate loading kit (Life 
Technologies) was used according to the manufacturer’s instructions and adapted as 




needed. Freshly prepared CCF2/Am substrate was added to the splenocytes (2 µl 
substrate/100 µl cell suspension) for 5 min at room temperature and light exposure 
was minimised. Cells were then washed in PBS supplemented with 2% FCS in PBS 
twice before being subjected to flow cytometry. Controls including unstained 
splenocytes and splenocytes infected with the wt virus were performed in each 
experiment. The flow cytometry was carried out using a FACS Aria III sorter (BD 
Biosciences) and the results were analysed using FACS Diva software. The mLANA 
positive as well as the mLANA negative populations were collected in RPMI-1640 
medium supplemented with 20% FCS or collected directly in 0.5 ml TRI Reagent
®
 
(Ambion). Splenocytes collected in medium were subjected to centrifugation at 
7000xg / 10 min / 4
o
C. The supernatant was discarded and 0.5 ml TRI Reagent
®
 
(Ambion) was added and samples were kept at 80
o
C for RNA extraction. 
2.5 DNA isolation 
 
DNA extraction was carried out using DNeasy blood and tissue kit (Qiagen) 
according to the manufacturer’s protocol. 
2.6 RNA isolation 
 
Total RNA was extracted using the TRI Reagent
®
 (Ambion). One or 0.5 ml of TRI 
Reagent
®
 was added to cells in 1.5 ml screw capped tubes for 5 min at room 
temperature allowing complete dissociation of the nucleoprotein complex in cells, 
followed by addition of 0.2 volume Chloroform (Sigma-Aldrich, UK). Tubes were 
shaken vigorously for 15 sec and incubated at room temperature for 3 min. Samples 
were then centrifuged at 12,000 xg for 15 min at 4
o
C. The aqueous layer (contained 
the RNA) was then transferred to a new 1.5 ml screw capped tube. Fifteen 




micrograms of GlycoBlue (Ambion) were added to the aqueous phase in order to 
visualise the RNA pellet. Half volume of 100% RNase-free Isopropanol (ACROS 
organics) was added to the aqueous layer and incubated at RT for 10 min. Samples 
were then centrifuged at 12,000 xg/10 min/4
o
C. The supernatant was discarded and 
RNA pellet was washed twice with RNase-free 75% Ethanol (Sigma-Aldrich, UK). 
Samples were vortexed briefly and centrifuged at at 7500 xg/5 min/4
o
C. Ethanol was 
discarded and RNA pellets were air-dried. RNA pellets were then re-suspended in 
appropriate volumes of RNase-free water. Samples were then incubated in a heat 
block set at 55-60
o
C for 10-15 min. RNA samples were stored at -80
o
C. 
2.7 RNA quality control 
 
The quality of the total RNA extracted from splenocytes was determined using an 
RNA 6000 Pico kit on the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa 
Clara, CA) or using the more recent High Sensitivity RNA ScreenTape in 
combination with the 2200 TapeStation system  (Agilent Technologies, Santa Clara, 
CA). RNA integrity was judged by RNA Integrity Number (RIN), which was 
calculated with 2100 Expert Software (Agilent, version B.02.07, eukaryote total 
RNA pico mode). The software algorithm categorises total RNA quality on a scale 
from 1 to 10, in which 10 corresponds to intact RNA and 1 corresponds to highly 
degraded RNA. 
2.8 DNase treatment of RNA 
 
Contaminating genomic DNA was removed from the samples using the TURBO 
DNA-free™ Kit (Ambion, UK). One µl TURBO DNase and 0.1 volume 10x 
TURBO DNase buffer were added to the RNA sample for 30 min at 37
o
C. Following 




the DNase treatment, the reaction was stopped by the addition of 0.1 volume (at least 
2 µl) inactivation reagent and the samples were incubated at room temperature for 5 
min. The inactivation reagent was pelleted by 1.5 min centrifugation at 10,000 xg at 
room temperature and the supernatant was transferred to a fresh RNase free tube. 
2.9 Quantitative reverse transcription polymerase chain 
reaction (qRT-PCR) 
 
2.9.1 miRNA qRT-PCR  
 
2.9.1.1 Reverse transcription 
 
RNA was reverse transcribed into cDNA using miScript II RT Kit (Qiagen, Crawley, 
UK) following the manufacturer’s protocol. The mature miRNAs were 
polyadenylated by poly (A) polymerase and reverse transcribed into cDNA using 
oligo-dT primers, which have a universal tag sequence on the 5' end and a 3' 
degenerate anchor, allowing amplification of mature miRNA in the real-time PCR 
step. The combination of polyadenylation and the universal tag addition ensures that 
the assays do not detect genomic DNA. 
2.9.1.2 Real-time PCR 
 
RT-PCR was performed using miScript SYBR green PCR kit (Qiagen, UK) 
following the manufacturer’s protocol. Specific forward primers identical to the full 
length of the mature miRNAs (200 nM final concentration per reaction) were used 
with the supplied universal reverse primer. The forward miRNA-specific 
oligonucleotides were synthesised by Eurofins MWG Operon (Ebersberg, Germany). 
The primers sequences and the relevant annealing temperatures are shown in table 
2.1. 




2.9.1.3 Relative quantification (∆∆CT method) 
 
Cycle Threshold (CT) is the value where the PCR curve crosses the threshold in the 
linear part of the curve. The qPCR was performed using both the gene of interest and 
the reference gene. A calibrator was also used. A calibrator is the sample which all 
other samples are compared to (e.g. untreated sample). The relative quantification of 
the calibrator is 1 because it does not vary compared to itself.  
∆CTgene of interest = CTgene of interest – CTreference gene  
∆CTcalibrator = CTcalibrator– CTreference gene  
∆∆CT = ∆CTgene of interest - ∆CTcalibrator 























mghv-miR-M1-1-3p TAGAAATGGCCGTACTTCCTTT 58 
mghv-miR-M1-2-3p CAGACCCCCTCTCCCCCTCTTT As indicated 
mghv-miR-M1-3-3p GAGGTGAGCAGGAGTTGCGCTT 62 
mghv-miR-M1-4-5p TCGAGGAGCACGTGTTATTCTA 62 
mghv-miR-M1-5-5p AGAGTTGAGATCGGGTCGTCTC 62 
mghv-miR-M1-6-3p TGAAACTGTGTGAGGTGGTTTT 62 
mghv-miR-M1-7-3p GATATCGCGCCCACCTTTATT 58 
mghv-miR-M1-8-5p AGCACTCACTGGGGGTTTGGTC 58 
mghv-miR-M1-9-3p TCACATTTGCCTGGACCTTTTT 58 
mghv-miR-M1-10-3p TGATTACACGGAAGGTTCTTTT 58 
mghv-miR-M1-12-5p AAGGGTACTCTCATCACCAATGT 62 
mghv-miR-M1-13-3p TATCTCATGTGAGCTCTTCTTT 58 
mghv-miR-M1-14-3p TGCTACAGCGTGCAGAACGTTT 62 
mghv-miR-M1-15-5p AGCTACCCGCGTGGCCGGAGTGTTT 62 
mmu-miR-191-5p CAACGGAATCCCAAAAGCAGCTG 58 
Table ‎2-1 Sequence of the forward miRNA-specific primers used in the 
miRNA qRT-PCR assays. The primers are DNA oligos that are identical to the 










2.9.2 mRNA qRT-PCR  
 
qRT-PCRs for quantification of viral mRNAs were carried out using FastStart 
Universal SYBR Green Master (Roche) following the two-step programme in the 
manufacturer’s protocol. qPCR for viral DNA polymerase, RTA, ORF73, M3 and 
the housekeeping gene SDHA were set up by Ian Bennet in the Dutia/Nash lab (The 
primers sequences and the relevant annealing temperatures are shown in Table 2.2). 
qPCR for ORF65 was set up for this project. The primers were synthesised by 
Eurofins MWG Operon (Ebersberg, Germany). The first step in the ORF65 qRT-
PCR assay set up was to generate a standard template for the qPCR absolute 
quantification. For this reason an ORF65 DNA fragment was amplified by 
conventional PCR using the MHV-68 BAC as a template. Primer sequences are 
shown in Table 2.3. The thermal conditions of the PCR were as follow: 
94
o
C      3 min 
94
o
C      45 sec 
55
o
C      45 sec      
72
o
C      1 min 
72
o
C      7 min    
The PCR product was analysed on 1% agarose gel. The band was excised and DNA 
was extracted using QIAquick Gel Extraction Kit (Qiagen). Then the DNA fragment 
was cloned using TOPO TA Cloning Kit (Invitrogen) for sequencing according to 
the manufacturer’s protocol. After cloning, miniprep plasmid DNA was obtained 
using PureLink® Quick Plasmid Miniprep Kit (Invitrogen). Diagnostic restriction 
endonuclease digestion using EcoRI enzyme was performed to detect positive 
colonies. The plasmid was then sent for sequencing. The sequencing was carried out 
by GenePool (The University of Edinburgh School of Biological Sciences). The 
X 35 cycles 




sequence was analysed and compared to the known sequence using DNASTAR 
Lasergene 10 Core Suite programme. After the correct sequence had been confirmed, 
the plasmid DNA was used as a standard material for the qPCR for making the 
standard curve. The concentration of the DNA plasmid was determined by Nanodrop 
spectrophotometry. The number of copies of the plasmid was calculated using the 
following equation: 
Copy number per µl = 6.032x10
23
 (copies/mol) x plasmid concentration (g/µl) / 
molecular weight (MW) of the whole plasmid (g/mol). 
Plasmid MW (g/mol) = (number of insert base pairs + number of vector base pairs) x 
660 dalton. According to the calculated copy number, the standard plasmid was 
diluted to 10
9




ORF65 qRT-PCR was carried out using FastStart Universal SYBR Green Master 
(Roche) following the two-step programme in the manufacturer’s protocol. The 
optimum conditions for 100% reaction efficiency and detection of the specific 
product were determined. The annealing temperature of 62
o
C was used. ORF65 
transcript qPCR primers were synthesised by Eurofins MWG Operon (Ebersberg, 
Germany). The primer sequences are shown in Table 2.3.  











   
 Fwd  AGAGTGTTTGGGTGAATGTGG 
 




   
  Fwd  CAAAGTCCATAACAGGCATCC 
 





   Fwd  CGTCTGTCTCTCCTACATCTAAACC 
 





    Fwd  TAACAGGCAGATTGCCATTCCC 
 
    Rev  TGGCACTCAAACTTGGTTGTGG 
65 
SDHA 
    
   Fwd  GCTCCTACTGATGAAACCTG 
 
   Rev  AACTCAATCCCTTACAGCAA 
 
62 
Table ‎2-2 Sequence of the primers used for viral mRNAs and cellular SDHA qRT-
PCR assays. 
















Primer Sequence (5’-->3’) 
ORF65 cloning primers 
 
   Fwd GATAACACATTGCCTACATTG 
   Rev CTTTCCATTTCCACTCCTT 
ORF65 qPCR primers 
 
   Fwd  TGTCTTGGGTATCTATCACTTGG 
   Rev   CTCCCTCCGTCAAATGCTC 
Table ‎2-3 Sequence of the primers used for ORF65 cloning and qRT-PCR. 




2.10 Agarose gel electrophoresis 
 
DNA fragments were analysed using 1% agarose gel electrophoresis. The gels were 
prepared by dissolving 1 gram SeaKem
® 
LE agarose (Lonza, USA) in 100 ml TAE 
buffer. To visualize the DNA, 10μl of SYBR
® 
Safe DNA gel stain (Invitrogen, UK) 
was added to 100 ml 1% agarose solution. The DNA was mixed with 6x gel loading 
buffer and electrophoresis was performed at 90 V. The DNA was detected using UV 
light and the size of the DNA was determined using the relevant DNA ladder.  
1L (50X) TAE Buffer 
242 g Tris-base 
57 ml (glacial) Acetic acid 
100 ml (0.5 M) EDTA, pH 8.0 
2.11 Construction of MHV-68.∆miRNAs virus and its WT 
parental counterpart 
 
2.11.1 Cloning of the miRNAs mutated sequence into pORI plasmid 
 
A pUCIDT Ampicilin resistance plasmid carrying the synthetic miRNAs mutated 
sequence flanked by EcoRI sites (GAATTC) was purchased (IDT, UK). Ten 
nanograms of the pUCIDT.∆miRNAs plasmid were transformed into One Shot
®
 
TOP10 competent cells (Life technologies, UK). A pUCIDT.∆miRNAs plasmid 
midi-prep was carried out using Plasmid Midi Kit (Qiagen) according to the 
manufacturer’s instructions. Two µg of the plasmid midi-prep were digested with 20 
units EcoRI restriction enzyme (NEB). The digest was analysed on 1% agarose gel 
and the released DNA fragment was extracted from the gel using QIAquick Gel 
Extraction Kit (Qiagen). The DNA fragment was then ligated to pORI plasmid 
(kindly provided by Prof Jay Nelson, Oregon Health and Science University, USA) 




that carries Kanamycin cassette and FRT sites using T4 DNA ligase kit (Thermo 
Scientific). The ligation mixture was then transformed into chemically competent 
cells. The cells were plated on LB agar supplemented with Kanamycin (50 ug /ml). 
Six colonies were picked and plasmid DNA was isolated using PureLink® Quick 
Plasmid Miniprep Kits (Invitrogen). Positive colonies were determined by restriction 
enzyme (EcoRI) diagnostic digestion. The orientation of the inserted miRNA knock 
out (KO) sequence was determined using restriction enzyme diagnostic digestion. 
Double digestion with XhoI/XbaI (NEB) or SacI/XhoI (NEB) was carried out on the 
pORI.∆miRNAs plasmids extracted from 6 different colonies. The sizes of the 
released fragments determined the orientation of the miRNA KO sequence in the 
plasmid. 
2.11.2 PCR amplification of the DNA fragment that carries the 
miRNAs KO sequence, Kanamycin cassette, and FRT sites  
 
Expand long template PCR system (Roche) was used to amplify a DNA fragment 
carrying the miRNAs KO sequence, kanamycin resistance sequence flanked by FRT 
sites, and MHV-68 homologous sequence for homologous recombination into EL250 
cells.  pORI.∆miRNAs plasmid mini-prep was used as a template (0.5 µl). The PCR 
reaction was carried out in 100 µl final volume. The primers’ sequences were:  
Forward primer 5’ 
GGAGCTAGGCCACGCCCATTTGGAGTTTTCCCCCTCTCCCCTCGCCTGGCT
CTCAGCCCCGAAAAGTGCCACCTGCAGAT -3’ 
 Reverse primer 5’-GCCTGTGGAGCAAAAGGGG -3’.  
Primers concentration used was 500 nM per reaction. Thermal conditions were as 
follow: Hold for 7 min at 95
o
C followed by 45x cycles of 95
 o
C for 30 sec, 55
 o
C for 




30 sec, and 68
 o




C indefinitely. The 
PCR products were analysed on 1% agarose gel, the band was excised and extracted 
from the gel as previously mentioned. The extracted DNA was subjected to ethanol 
precipitation by adding 1/10 volume of 3 M sodium acetate, pH 5.2, mixed well and 
2.5 volume of cold 100% ethanol were added and mixed well again before placing in 
-20
 o
C for 30 min. The mixture was centrifuged at 18000 xg/15 min/4
o
C. Supernatant 
was carefully decanted and DNA pellet was washed twice in 1 ml 70% ethanol. The 
supernatant was decanted after the washes and DNA pellet was air dried. The DNA 
pellet was re-suspended in 25 µl DNase free water. 
2.11.3 Transformation of the WT-MHV-68 BAC into E.coli strain 
EL250 
 
2.11.3.1 Preparation of WT-MHV-68 BAC midi-prep 
 
DH10B cells containing WT-MHV-68 BAC were plated out on LB agar containing 
Chloramphenicol (12.5µg/ml) and incubated o/n at 37
o
C. A single colony was picked 
and dropped in 3 ml LB broth containing 12.5µg/ml Chloramphenicol and incubated 
all day (8 hours) at 37
o
C with vigorous shaking to form the starter culture. This 
culture was added to 500 ml LB broth plus Chloramphenicol (12.5µg/ml) and 
incubated o/n at 37
o
C with vigorous shaking. Midi-prep BAC DNA was then isolated 
using QIAGEN® Plasmid Purification kit (Qiagen) following the very low-copy 
plasmid/cosmid purification protocol. The BAC DNA pellet was re-suspended in 
50µl TE buffer.  
2.11.3.2 Preparation of electrocompetent EL250 cells 
 




A sterile tip was dipped in the frozen EL250 cells and immersed in 3 ml LB broth 
and incubated o/n at 30
o
C with shaking. Next morning, 1 ml of the culture was added 
to 50 ml of LB broth in 250-ml flask and incubated at 30
o
C with shaking until the 
OD600 reached 0.4. The culture was centrifuged at 6000 xg for 10 min at 4
o
C in pre-
chilled autoclaved tubes. The cell pellet was re-suspended in 10 ml of cold 
autoclaved 10% glycerol (made with Milli-Q water). It was then divided between 2 
cold 250 ml centrifuge bottles. The bottles were filled with the 10% glycerol and 
were centrifuged at 6000 xg for 10 min at 4
o
C. After centrifugation, the bottles were 
kept on ice and supernatant was decanted and bottles were inverted briefly to drain. 
The bugs were then re-suspended in the remaining liquid (1-2 ml) and were 
transferred to sterile Eppendorf tubes. The cells were centrifuged at 6000 xg for 10 
min at 4
o
C. The cell pellets were re-suspended in 200µl 10% glycerol and kept as 
100µl volume in -80
o
C. 
2.11.3.3 Electroporation of WT-MHV-68 BAC DNA into electrocompetent 
EL250 cells 
 
One µl of purified WT-MHV-68 BAC DNA was mixed with 50µl electrocompetent 
E-coli strain EL250 (Dy380 derived) that harbours λ prophage, which provides heat-
inducible recombinase enzyme and arabinose-inducible FLP. The mixture was left on 
ice for 5 min and then transferred to 0.1 cm gap cuvette. The Gene Pulser was set at 
2.5k V and the BAC DNA was electroprated into electrocompetent EL250 cells and 
1 ml LB broth was immediately added to the cells. The cells were incubated at 30
o
C 
for 1 hour with shaking (200 rpm). It was then centrifuged for 5 min at 450x g and 
re-suspended in 200µl LB broth, plated on LB agar plate containing 
Chloramphenicol (12.5µg/ml), and incubated at 30
o
C for 2 days. 




2.11.4 Minipreping BAC cultures 
 
Single colonies (EL250 cells containing transformed BAC or DH10B cells 
containing original BAC) were picked and were inoculated into 10 ml LB broth + 
Chloramphenicol (12.5µg/ml) and incubated o/n at 30
o
C with shaking (200 rpm). 
Next morning, the cultures were spun down in 15 ml falcon tubes for 15 min at 3000 
rpm in table top centrifuge. The cell pellet was re-suspended in 300µl of cold P1 
buffer (Qiagen) by dragging along tube rack. It was then transferred to 2 ml 
Eppendorf tubes and 300µl of P2 buffer were added and mixed gently by inverting. 
This was followed by addition of 300µl of P3 buffer and mixed gently again by 
inverting. One ml of Phenol/Chloroform/Isoamyl alcohol, pH6.7 (25:24:1) was 
added to the mixture and rotated in cold room (4
o
C) for 15 min. The mixture was 
then centrifuged at 12000 xg for 10 min at 4
o
C. The upper phase was transferred to a 
new 1.5 ml screw-capped tube using a snipped tip in order not to shear the DNA. 
One tenth volume of 3M sodium acetate (pH 5.2) and 1 ml isopropanol were added 
and incubated at -80
o
C for at least 30 min. The mixture was then centrifuged at 
12000 xg for 10 min at 4
o
C. The supernatant was discarded and BAC DNA pellet 
was washed in 500µl of 70% ethanol followed by centrifugation at 12000 xg for 10 
min at 4
o
C. The ethanol was discarded and the BAC DNA pellet was re-suspended in 
100µl of EB buffer. Miniprep BAC DNA was kept at 4
o
C until used. 
2.11.5 Preparation of electrocompetent, recombination-induced 
EL250 cells  
 
Single colony (EL250 cells carrying MHV-68 BAC) was picked and grown in 3 ml 
o/n culture at 30
o
C with shaking (200 rpm). Next morning, 1 ml of the culture was 
added to 50 ml of LB broth. The culture was incubated in 250-ml flask at 30
o
C with 




shaking until the OD600 reached 0.4. The culture was then induced in water bath at 
42C for 17 min with swirling every couple of minutes for expression of 
recombination proteins. The culture was placed on ice for 5 min, centrifuged at 
6000x g for 10 min at 4C in pre-chilled autoclaved tube. The pellet was re-
suspended in 10 ml of cold, autoclaved 10% glycerol v/v (made with milli-Q water). 
The pellet suspension was divided between 2 cold 250 ml centrifuge bottles. The 
bottles were filled with the 10% glycerol v/v, centrifuged at 6000x g for 10 min at 
4C in pre-chilled autoclaved tubes. The supernatant was discarded and the bottles 
were inverted briefly to drain. The bacterial pellets were re-suspended in the 
remaining fluid (1-2 ml) and were transferred to sterile Eppendorf tubes. The cells 
were centrifuged at 6000 xg for 10 min at 4
o
C. The cell pellets were re-suspended in 
200µl 10% glycerol v/v. The cells were then kept in volumes of 100µl in sterile 
Eppendorf tubes and kept at -80
o
C or used immediately for electroporation. 
2.11.6 Transformation to obtain BAC clones by homologous 
recombination 
 
Approximately 300 ng of the DNA fragment carrying the miRNAs KO sequence, 
Kanamycin cassette, FRT sites, and flanking MHV-68 homology arms designed 
from the target sequence (see section 1.12.2) was electroprated into electrocompetent 
heat-induced EL250 cells carrying the wt-MHV-68 BAC. The Gene Pulser was set at 
2.5k V. One ml LB broth was added to the cells immediately after electroporation. 
The cells were incubated at 30
o
C for 1 hour with shaking (200 rpm). It was then 
centrifuged for 5 min at 450x g and re-suspended in 200µl LB broth then plated on 
LB agar plate containing Chloramphenicol (12.5µg/ml) and Kanamycin (50µg/ml) 
and incubated at 30
o
C for 48 hours. 




2.11.7 FLP recombination 
 
A single colony from the previous transformation was picked and 2 ml o/n culture 
was grown with Chloramphenicol (12.5µg/ml) and Kanamycin (50µg/ml) and 
incubated at 30
o
C while shaking. Next day, the miniculture was added to 98 ml of 
LB with Chloramphenicol (12.5µg/ml) only and was grown at 30
o
C with shaking 
until the OD600 reached 0.5. EL250 cells contain an endogenous L-arabinose-
inducible FLP gene which can excise the kanamycin resistance gene that is flanked 
by FRT sites via FLP-mediated recombination. Therefore, 1 ml of 10% L-arabinose 
(1 g L-arabinose (Sigma Aldrich, Germany) in 10 ml LB broth and sterilised with 
0.2µM filter) was added to the culture and returned to 30
o
C for one hour with 
shaking. Then, the culture was diluted 1/10 in LB and was grown for an additional 
hour at 30
o
C with shaking.  
The culture was centrifuged at 1000xg for 3 min at RT. The pellet was re-suspended 







 dilutions were plated on LB agar with Chloramphenicol (12.5µg/ml) and 
incubated at 30
o
C for 2 days. Antibiotic selection was used to determine the removal 
of the kanamycin cassette. Thirty colonies were picked and each colony was plated 
on LB agar with Chloramphenicol (12.5µg/ml) only and with Kanamycin only 
(50µg/ml). The colonies which grow in the presence of Chloramphenicol, but not in 
the presence of Kanamycin were selected. 
2.11.8 Screening PCR for detection of clones that carry all the 
expected mutations 
 
The following components (Life technologies) were added to a sterile PCR tube 
placed on ice: 0.1 volume of 10x PCR buffer, 0.2 mM dNTP mixture, 1.5 nM MgCl2, 




0.5 µM of each primer, 10 ng BAC DNA template, 1-2 units Taq DNA polymerase 
enzyme, and PCR grade water to final volume. Contents were collected to the bottom 
of the tube by brief centrifugation. The primer sequences were: 
Fwd primer: 5’ GCGCGCCCTGGAGATCCGGG 3’ 
Rev primer: 5’ GCATAGAAACTGAGAGCAAGGC 3’ 
 
The thermal conditions were as follow: hold at at 94°C for 3 minutes followed by 25 
cycles of denaturing at 94°C for 45 s, annealing at 55°C for 30 s, and extension 72°C 
for 1.5 min; followed by additional incubation at 72°C for 10 min and the reactions 
were maintained at 4
o
C. PCR products were analysed by agarose gel electrophoresis 
as described previously (section 2.10) and visualised by SYBR
® 
Safe staining 
(Invitrogen, UK) using UV light.  
 
The PCR product was excised from gel and the DNA was extracted using QIAquick 
Gel Extraction Kit (Qiagen). The DNA fragment was cloned into TOPO vector using 
TOPO TA Cloning Kit (Invitrogen) for sequencing according to the manufacturer’s 
protocol. After cloning, miniprep plasmid DNA was obtained using PureLink® 
Quick Plasmid Miniprep Kit (Invitrogen). Diagnostic restriction endonuclease 
digestion using EcoRI enzyme was performed to detect positive colonies. The 
plasmid was then sent for sequencing. The sequencing was carried out by GenePool 
(The University of Edinburgh School of Biological Sciences). The sequence was 
analysed and compared to the known sequence using DNASTAR Lasergene 9 Core 
Suite programme. 
 




The same protocol was used after the generation of the miRNA mutant virus and its 
WT counterpart except that 100 ng total genomic DNA was extracted from NIH 3T3 
cells infected with the mutant or WT virus at MOI of 5 for 24 hours and used as a 
template. The primer sequences were:  
Fwd primer: 5’ GCACCCCACTATCTCTGGTTCTGC 3’ 
Rev primer: 5’ CCTGTGGAGCAAAAGGGGTA 3’ 
 
2.11.9 Determination of the BAC genomic arrangement by 
restriction endonuclease digestion 
 
Fifty µl of the miniprep BAC DNA from EL250 cells (transformed BAC) or DH10B 
cells (original BAC) were digested with 2µl XhoI enzyme (NEB, 20,000 units/ml) 
using buffer 4 (NEB) in a total reaction volume of 60µl for 1 hour at 37
o
C followed 
by addition of another 2µl of XhoI enzyme and incubated at 37
o
C o/n. The next day, 
6x loading buffer was added to the digested BAC DNA and was analysed on a 0.8% 
agarose gel. The gel electrophoresis was performed at 30V o/n. The next day, the gel 
was immersed in TAE buffer containing SYBR
® 
Safe DNA gel stain (Invitrogen, 
UK) at dilution of 1/1000 and was gently shaken on a rocker for 20 min. The DNA 
fragments were visualised using UV light. 
 
2.11.10 BAC transfection, removal of BAC cassette, and generation 
of the mutant virus and its WT parental counterpart 
 
Parental WT MHV-68 BAC or MHV-68.∆miRNAs BAC (200 ng) were transfected 
into 3T3 cells expressing Cre recombinase that can excise the BAC vector flanked by 
loxP sites. The day before transfection, Cre 3T3 cells were seeded in 24 well plates at 






 cells/ well. The next day, cells were approximately 50% confluent 
and the transfections were carried out using Effectene
®
 Transfection Reagent 
(Qiagen) following the manufacturer’s protocol. Seven days later, widespread of 
CPE was observed and a mix of green (GFP expression) and colourless (BAC vector 
removed) plaques were seen under the fluorescence microscope. The viruses were 
harvested by pipetting up and down. Cre 3T3 cells were seeded in 96 well plates at 
density of 2x10
4
 cells / well. The following day, cells were approximately 50% 
confluent. The viruses were frozen and thawed 3 times and diluted 1/100, 1/200, 
1/500, 1/1000, 1/5000, and 1/50000 for 12 wells of each. The viruses were added to 
the cells and plaque formation was monitored. Single colourless (no GFP expression) 
plaques were harvested. Cre 3T3 cells were set up in 24 well plates and the virus was 
grown in them by adding 1/4 harvest from the 96 well plate after freezing and 
thawing 3 times. The viruses were harvested when there was widespread of CPE.  
MHV-68 miRNAs were detected in the mutant virus, indicating that there is a 
mixture of mutant and wt-viruses. Therefore, the virus was diluted 1/100, 1/200, 
1/500, 1/1000, 1/5000, and 1/50000 and was added to Cre 3T3 cells in 96 well plate 
(12 wells of each dilution). Single plaques were harvested and screened for the 
presence of viral miRNAs by qRT-PCR. A plaque in which the deleted miRNAs 
were absent was used for infecting Cre 3T3 cells in 24 well plate (1/4 harvest from 
the 96 well plate). The mutant and the WT viruses from the 24 well plates were 
titrated and grown at MOI of 0.001 in BHK cells as previously described. 
2.12 One-step growth curve 
 
The day before experiment, BHK-21 cells were seeded in 24 well plates at density of 
10
5
 cells per well in 2 ml GMEM medium. The next day, cells were infected with 




WT parental MHV-68 virus or MHV-68.∆miRNAs virus at MOI of 5. Uninfected 
cells served as a control. Virus was allowed to attach to cells for 1 hour at 37
o
C in 
CO2 incubator. The medium was then removed and cells were washed 3 times with 
medium. One ml of fresh medium was added to each well and zero hour samples 
were taken immediately after the washes. Plates were incubated at 37
o
C in CO2 
incubator and samples (in duplicates) were kept at -80
o
C at appropriate time points 
(6, 12, 18, 24, 30, 36, 48, 60, and 72 hours after infection). Virus was released from 
the cells by freezing and thawing at -80
o
C for 3 times. Virus titration was carried out 
as previously described. 
2.13 Measuring viral titre in the lung 
 
Lung tissues were chopped into small pieces and homogenised in 1 ml of complete 
GMEM medium using TissueLyser (Qiagen) operating for 2 min at 28 Hz (2x). The 
lung homogenate was centrifuged at 2000xg for 5 min at 4
o
C and supernatant was 
kept at -80
o
C until used. Tenfold serial dilution of the homogenate was carried out 
and each dilution was incubated with 2 x 10
6
 BHK-21 cells in bijou tubes at 27
o
C for 
1 hour with continuous shaking (200 rpm). The virus-cells mixture in each bijou tube 
was divided between two 60mm culture plates and 3 ml of GMEM was added to 
each plate and incubated at 37
o
C in CO2 incubator for 4 days. The plaques were 
counted after being fixed and stained as described previously. 
2.14 Infective centre assay 
 
Spleens were harvested and single-cell suspensions were obtained by pressing 
through a 40-µm cell strainer in 5ml of complete RPMI-1640 medium. The cell 
suspensions were transferred to 20ml universal tubes and centrifuged at 450xg for 5 






C. The supernatant was removed and the pellet was re-suspended in 1 ml of 
sterile water for disruption of red blood cells and followed immediately by adding 9 
ml of sterile PBS. Cells were centrifuged at 450xg for 5 min at 4
o
C and the pellets 
were re-suspended in 10 ml RPMI-1640 medium. Cell debris was allowed to settle 
and the cells were transferred to fresh universal tubes. The cells were diluted in 0.1% 







splenocytes were co-cultivated with 10
6
 BHK-21 cells in 60mm 
culture plates (duplicates) in 5 ml RPMI-1640 medium supplemented with 10% FCS, 
2mM L-Glutamin, 100U pen/strept, 50µM 2-mercaptoethanol, 100µM HEPES, and 
0.25µg/ml Fungizone. The cells were incubated at 37
o
C in CO2 incubator for 5 days. 
The infective centres were counted after being fixed and stained as described 
previously. BHK cells only without addition of splenocytes were plated to serve as a 
negative control. Excess splenocytes were kept at -80
o
C to test for the presence of 
free infectious virus. 
2.15 Measuring the produced infectious virus titre in 
splenocytes 
 
Live splenocytes were kept at -80
o
C. These cells were frozen and thawed 3 times to 
disrupt the cells and prevent reactivation of latent virus. Volumes equivalent to 10
7
 
splenocytes were added to 10
6
 BHK-21 cells (in duplicates) and incubated at 27
o
C 
for 1 hour with continuous shaking. The cells were then transferred to 60mm culture 
plates and incubated at 37
o
C in CO2 incubator for 4 days. The plaques were counted 
after being fixed and stained as described previously. Plates containing BHK cell 
only served as a negative control. 




2.16 Flow cytometry for determination of B cell activation 
and proliferation 
 
Spleen cell suspensions were prepared as described above (section 2.14). 
Splenocytes were counted to make 5x10
6
 cells / ml. Fifty µl cells (2.5x10
5
) were 
added to each Polystyrene FACS test tube. The cells were pre-incubated with 25µl 
purified anti-CD16/CD32 antibody (BD Pharmingen Biosciences, USA) for 30 min 
at 4
o
C at final concentration of 1:200 in FACS buffer (PBS containing 1% BSA w/v 
and 0.1% sodium azide w/v). The splenocytes were then labelled with 25 µl of anti-
CD19-PE antibody alone (Invitrogen, UK) (1:200 in FACS buffer), anti-CD69-FITC 
antibody alone (AbD Serotec, UK) (1:50 in FACS buffer), or a combination of both 
and incubated for 15 min at 4
o
C in the dark. FACS buffer (700µl) was added to the 
labelled cells, centrifuged for 5 min at 430xg, supernatant was discarded, and cells 
were washed 2 times with 700µl FACS buffer. If no further staining was required 
200 µl FACS buffer were added followed by addition of 2% formaldehyde (formal 
buffered saline diluted 1:1), mixed, and stored in the dark at 4
o
C until ready to 
analyse.  
For Ki-67 intracellular staining, cells were fixed with 50µl of 1% paraformaldehyde 
for 15 min at RT in the dark and washed 2 times with 700µl FACS buffer. Cells were 
permeabilised with 50µl of 0.5% Tween-20 (diluted in sterile PBS (v/v) for 10 min at 
RT in the dark and then washed as above. Rabbit poly-clonal anti-ki-67 antibody 
(100µl) (Abcam, UK) at a final concentration of 1:200 in FACS buffer were added to 
the cells for 15 min in the dark at 4
o
C. Then the cells were washed as above and 
100µl biotinylated goat anti-rabbit IgG (H+L) (Vector Laboratories, USA) antibody 
(1:300 in FACS buffer) were added and cells were incubated for 15 min at 4
o
C in the 
dark. Cells were washed as above and 100µl Streptavidin 






647(Invitrogen, UK) at a final concentration of 1:500 in FACS buffer 
were added and incubated for 15 minutes in the dark at 4°C. Cells were then washed 
as above and fixed by addition of 200µl FACS buffer followed by addition of 2% 
formaldehyde v/v. Samples were stored in the dark at 4
o
C until ready to analyse.  
PE rat IgG2a (BD Pharmingen Biosciences, USA), FITC hamster IgG1 (BD 
Pharmingen Biosciences, USA), and rabbit IgG (GeneTex) isotype negative controls 
were used at the same concentration of each antibody. Unstained splenocytes before 
and after cell permeabilisation were also used as negative controls. Flow cytometry 
was performed on BD FACSCalibur (BD Bioscience) and analysed with FlowJo 
software. For each sample 10,000 events were counted. 
 
2.17 Statistical analysis and graphs production 
 
Experimental statistical analyses were performed using Minitab 16 statistical 
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One of the aims of this project was to carry out a systematic analysis of the 
expression pattern of the MHV-68 miRNAs during latent infection in vivo. In order 
to do this, it was necessary to establish an assay for quantification of the miRNAs 
expression levels. There are different ways for miRNAs expression profiling such as 
qRT-PCR, microarray, and next-generation sequencing. qRT-PCR technology is 
highly specific, highly sensitive, and has a wide dynamic range. In contrast, miRNA 
microarrays are less sensitive and have lower dynamic range. Next-generation 
sequencing is mainly used for discovery of novel miRNAs. Therefore, qRT-PCR is 
the method of choice for quantification of the expression of previously known 
miRNAs.  
Previous published studies identified at least 15 MHV-68 primary miRNAs by deep 
sequencing (Reese, Xia et al. 2010, Zhu, Strehle et al. 2010). These primary miRNAs 
are expected to be processed into at least 28 mature miRNAs. The mature miRNAs 
are the functional molecules; it is therefore of interest to characterise the expression 
pattern of this class of miRNAs. There are two common priming strategies in the 
commercially available qPCR-based platforms for amplification of mature miRNAs. 
One strategy involves the use of specific stem-loop RT primers for the cDNA 
synthesis (Chen, Ridzon et al. 2005, Kramer 2011). The other strategy depends on 
the use of universal RT primers, where the miRNAs are polyadenylated by a poly 
(A) polymerase enzyme and reverse transcribed into cDNA using oligo-dT primers,   




which have a universal tag sequence on the 5' end and a 3' degenerate anchor (Shi 
and Chiang 2005). Both approaches have advantages and disadvantages. The stem-
loop RT primers are long and bind to the stem-loop region of the miRNA, whereas 
the universal RT primers are short and utilise almost the entire mature miRNA 
sequence; therefore, the stem-loop priming method is more specific than the 
universal RT priming. However, the poly (A) tailing and universal RT reaction 
produce a stable pool of cDNA that can be used to detect different miRNAs and/or 
mRNAs from the same cDNA; thus, this method is convenient when using limiting 
amount of sample. In contrast, the stem-looping requires different RT primers for 
detection of individual miRNAs and only allows for detection of the miRNA of 
interest, but not the mRNA from the same cDNA preparation. This makes stem-loop 
sequence specific RT priming more time-consuming and more expensive than 
universal tailing RT priming.  
Stem-loop qPCR requires the use of an miRNA-specific forward primer, a reverse 
primer, and a probe. This assay does not allow the user to control the reaction 
specificity by melting curve analysis. The qPCR performed using cDNA from the 
universal tailing RT reaction requires a miRNA-specific forward primer and a 
universal reverse primer; therefore, there is little degree in freedom of designing the 
miRNA-specific primer and the assay requires more stringent optimisation measures 
in order to ensure the reaction specificity. This specificity can be observed by 
melting curve analysis. 
In this project, the quantification of the mature MHV-68 miRNAs expression levels 
was performed using the universal tailing RT priming for the cDNA synthesis 
followed by qPCR using miRNA-specific forward primer and a universal reverse 
primer. Optimisation of each miRNA qRT-PCR assay was carried out in order to 




ensure high specificity and high efficiency of the assay. This chapter demonstrates 
the establishment and optimisation of the miRNA qRT-PCR assays and the use of 
these assays to characterise the expression profiles of the mature MHV-68 miRNAs 
in vitro and in vivo.  
3.2  Establishment and optimisation of qRT-PCR assays 
for detection and quantification of the MHV-68 mature 
miRNAs 
 
qRT-PCR assays were used to detect and quantify the mature MHV-68 miRNAs. 
Figure 3.1 shows a workflow diagram of the qRT-PCR reaction. Initially, the total 
RNA was polyadenylated with a poly (A) polymerase enzyme. The polyadenylation 
is a random process and results in addition of Adenine residues to the 3’ end of the 
miRNAs. Subsequently, cDNA molecules were synthesised using reverse 
transcriptase enzyme and oligo-dT primers with universal tag sequence on the 5' end 
and a 3' degenerate anchor. This allows the amplification of the mature miRNAs 
without detection of genomic DNA. A miRNA-specific forward primer and a qPCR 
universal reverse primer were used for the subsequent qRT-PCR reaction. The 
miRNA-specific primer consists of the full-length mature miRNA sequence based on 
the miRBase database (http://www.mirbase.org) (Kozomara and Griffiths-Jones 
2014). The final miRNAs quantifications were carried out by qRT-PCR assays using 
the SYBR Green fluorescence (see Materials and Methods section 2.9.1).. 
Each miRNA has a different sequence and different GC content which can 
significantly affect the specificity and efficiency of the qRT-PCR assays. Therefore, 
optimisation of the individual qRT-PCR assays for each miRNA was carried out, 




aiming at determining the optimum miRNA-specific primer concentration, assay 
annealing temperature, efficiency, and specificity of the reaction. 
The qRT-PCR assays were established using total RNA extracted from BHK-21 cells 
infected with MHV-68 virus for 24 hours at MOI of 5. Analysis and optimisation of 
each miRNA qRT-PCR assay was carried out. As an example of the qRT-PCR assay 
optimisation, figure 3.2 shows the melting curve analyses of the mghv-miR-M1-4-5p 
using different annealing temperatures and primer concentrations in order to 
maximise the specificity of the reaction. A non-specific qPCR product appeared 
when an annealing temperature of 60
o
C and a primer concentration of 250 nM or 200 
nM were used (Figure 3.2A and B). However, this non-specific product disappeared 
when the annealing temperature was increased to 62
o
C (Figure 3.2C and D). 
Increasing the annealing temperature to 63
o
C with the aim of minimising any 
presence of non-specific products led to the decrease in the peak of the melting curve 
and increase in the background noise (Figure 3.2E). Therefore, the annealing 
temperature of 62
o
C and primer concentration of 200 nM were selected as the 
optimum conditions for this assay. Optimisation of some miRNA qRT-PCR assays 
failed, for example, mghv-miR-M1-2-3p showed a non-specific qRT-PCR product 
represented by melting curve at 84
o
C, whereas the qRT-PCR product of the target 
melts at 77.5
o
C (Figure 3.3A). Increasing the annealing temperature failed to 
eliminate the non-specific product in the mghv-miR-M1-2-3p qRT-PCR assay 
(Figure 3.3B-E). Another example is mghv-miR-M1-6-3p qRT-PCR, which 
consistently showed amplification signals in the uninfected negative control (Figure 
3.4). Therefore, these miRNAs were excluded from further analysis. qRT-PCR 
melting curves of different  MHV-68 miRNAs are shown in figure 8.1 in the 
appendix. 
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Figure ‎3.1 Schematic diagram of the qRT-PCR amplification of the MHV-68 
mature miRNAs. qRT-PCR includes 3 steps: polyadenylation, reverse transcription 
and cDNA synthesis, and real-time qPCR. Poly (A) polymerase enzyme adds poly (A) 
tail to the 3’ end of the miRNA. cDNA synthesis is performed by reverse transcription 
using oligo-dT primer carrying a 5’ universal tag and 3' degenerate anchor. A miRNA-
specific primer and a universal qPCR primer complementary to the cDNA molecules 
are used in the qPCR reactions to amplify the target miRNA. 
 




Figure 3.5 shows an example of examining the qRT-PCR assay efficiency and 
specificity using mghv-miR-M1-7-3p specific primer. The efficiency of the 
amplification reaction for each miRNA set of primers was determined using 2-fold 
serial dilution of the cDNAs (Figure 3.5A). The amplification efficiency was 
determined based on the slope of a standard curve with arbitrary values. The standard 
curve is graphically represented as regression line plot of CT values versus log of 
input cDNA. Reaction with 100% efficiency means that the product is doubled each 
cycle with standard curve slope of -3.32 i.e. there is 10-fold increase in the qRT-PCR 
amplicon every 3.32 cycles (log2 10 = 3.3219). Slopes more negative than -3.32 
indicate reaction efficiency less than 100%, whereas slopes more positive than -3.32 
indicate efficiency greater than 100% that can be due to presence of primer dimer, 
non-specific amplicon, or pipetting error. Generally, qRT-PCR amplification 
efficiency between 90-110% is considered acceptable (Life Technologies).  
Table 3.1 shows the efficiency of the qRT-PCR assays of the tested miRNAs. All the 
miRNAs tested showed reaction efficiency in the range of 92% - 105% except mghv-
miR-M1-13-3p that had low reaction efficiency and therefore it was excluded from 
further analysis. The narrow reaction efficiency range between different miRNA 
qRT-PCR assays confirms that any differences in the quantification are real and not 
an artefact. The reaction specificity was determined by melting curve analysis where 
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Figure 3.2 Optimisation of the qRT-PCR assay for detection of mghv-miR-M1-4-5p. 
The graphs show the melting curve analyses of of the mghv-miR-M1-4-5p qRT-PCR 
assay using different annealing temperatures and primers concentrations (indicated). 
The vertical values represent the negative first derivative of the fluorescence and the 
horizontal values represent the melting temperature of the qPCR product(s). The two 
peaks indicate the presence of two qPCR products (A and B), whereas a single peak 
represents one product (C and D). When the annealing temperature increased to 63oC, 
the amount of the specific qRT-PCR product decreased and the non-specific products 
increased (E). The cDNAs were synthesised from the total RNA samples harvested from 














Ann. Temp. = 62oC Ann. Temp. = 63
oC 
Ann. Temp. = 67oC 










Figure 3.3 Melting curve analyses of mghv-miR-M1-2-3p qRT-PCR assay.  
The graphs show the mghv-miR-M1-2-3p qRT-PCR melting curve analyses using 
different annealing temperatures (indicated). The primers concentrations used were 
200 nM. The mghv-miR-M1-2-3p qRT-PCR product melts at 77.5oC while a non-
specific product melts at 84oC (A). Increasing the annealing temperature failed to 
eliminate the non-specific product (B-D). Further increase of the annealing temperature 
at 67oC showed no qRT-PCR product (E). The cDNAs were synthesised from the total 
RNA harvested from infected (Inf) or uninfected (Uninf) BHK- 21 cells (MOI of 5, 24 
hours post-infection). 
 






Figure 3.4 Melting curve analysis of mghv-miR-M1-6-3p qRT-PCR. 
The graph shows the melting curve of the mghv-miR-M1-6-3p qRT-PCR 
assay. The total RNA harvested from infected (Inf) or uninfected (Uninf) 
BHK- 21 cells (MOI of 5, 24 hours after infection) was reverse transcribed 
into cDNA that was subjected to qPCR. NTC = No template control. 




















Table ‎3-1 Reaction efficiency of the MHV-68 miRNA qRT-PCR assays. 
The total RNA harvested from MHV-68-infected BHK- 21 cells (MOI of 5, 24 
hours after infection) was reverse transcribed into cDNA. Two-fold serial 
dilution of the cDNA was carried out and subjected to qPCR in order to 
make a standard curve with arbitrary values. The reaction efficiency was 
calculated via the Rotor-Gene Q series software based on the slope of the 
standard curve. 





Figure 3.5 Determination of the efficiency and specificity of the miRNAs qRT-PCR 
assays.  
BHK-21 cells were infected with MHV-68 at MOI 5 for 24 hours and the miRNAs were detected 
by qRT-PCR. (A) Two fold serial dilution of the cDNA was carried out and subjected to qPCR 
using mghv-miR-M1-7-3p specific primer for determination of reaction efficiency (E). (B) 
Melting curve analysis of mghv-miR-M1-7-3p qRT-PCR for determination of reaction 
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3.3 The MHV-68 miRNAs increase in abundance over time 
during the lytic infection in vitro 
 
The expression kinetics of MHV-68 miRNAs during productive infection were 
determined by infecting NIH 3T3 cells with MHV-68 at MOI 5. The total RNA was 
extracted from uninfected cells or infected cells that were harvested at 2, 8, and 24 
hours post infection (hpi). The total RNA was converted into cDNA that was 
subsequently subjected to qRT-PCR analysis. A reference miRNA was required as a 
normaliser in order to correct for any experimental variability. miR-191 has been 
shown to be the most consistently expressed miRNA among various healthy human 
solid tissues (Peltier and Latham 2008) and it has been found not to be regulated 
following MHV-68 infection (Zhu et al., 2010 and figure 8.2 in the appendix). 
Therefore, mmu-miR-191-5p was used as an endogenous reference control to 
normalise the data in the present study. The viral miRNAs expression levels are 
presented as values relative to the cellular mmu-miR-191-5p expression levels. Ten 
miRNAs were examined and all of them were readily detected at variable levels as 
early as 2 hpi except mghv-miR-M1-4-5p whose expression was below level of 
detection at 2 or 8 hpi, which can be due to either late expression kinetics of this 
miRNA or the limitation of the assay (Figure 3.6). The amplification signals in the 
uninfected controls were below the cycle threshold (data not shown). It was found 
that mghv-miR-M1-7-3p, mghv-miR-M1-1-3p, mghv-miR-M1-3-3p, mghv-miR-
M1-8-5p, mghv-miR-M1-5-5p, mghv-miR-M1-15-5p, and mghv-miR-M1-9-3p are 
the most abundant miRNAs at 24 hpi (Figure 3.6 A). In contrast, mghv-miR-M1-14-
3p, mghv-miR-M1-10-3p, and mghv-miR-M1-4-5p are the least abundant miRNAs 
(Figure 3.6 B).  




The tested miRNAs showed a slight decrease in expression at 8 hpi and then 
accumulated over the course of infection. The abundance of mghv-miR-M1-7-3p, 
mghv-miR-M1-1-3p, mghv-miR-M1-5-5p, mghv-miR-M1-8-5p, mghv-miR-M1-9-
3p, mghv-miR-M1-14-3p, mghv-miR-M1-15-5p, and mghv-miR-M1-10-3p at 24 hpi 
was increased by approximately 84.2, 17.5, 13.2, 7.2, 4.4, 4.2, 3, and 2.6-fold, 
respectively, as compared to their abundance at 2 hpi. Interestingly, mghv-miR-M1-
3-3p expression level at 2 hpi and 24 hpi was almost the same and its abundance at 2 
hpi was higher than the other miRNAs at the same time point, indicating that this 
miRNA may play a role during the early stage of lytic infection.  
3.4 Expression of MHV-68 miRNAs during latent infection 
 
3.4.1 Profiling of MHV-68 miRNAs expression during latency in 
vitro 
 
In order to investigate the miRNAs expression profiles during latent infection in vitro 
and compare it to that of the lytic infection, NS0 cells were infected with MHV-68 
virus at an MOI five for five days. The NS0 cell line is derived from a mouse 
myeloma and it supports latent infection; however, approximately 5% of the infected 
cells undergo reactivation and express lytic proteins (Nash, Dutia et al. 2001). The 
infected or uninfected NS0 cells were harvested and total RNA was extracted and 
analysed by qRT-PCR for determination of the expression levels of the MHV-68 
miRNAs (Figure 3.7A). The amplification curves of the uninfected controls were 
below the threshold (data not shown).  
 
  














































Figure ‎3.6 Expression kinetics of the MHV-68 miRNAs during lytic infection. 
NIH 3T3 cells were infected with MHV-68 virus at MOI of 5 and total RNA was harvested 
from infected cells at 2, 8, and 24 hours post-infection (hpi). qRT-PCR was carried out using 
specific forward primers (see Materials and Methods) for quantification of the mature 
miRNAs. (A) Expression levels of the miRNAs with relatively high abundance. The relative 
expression was calculated as 2-∆CT x 102 where ∆CT = CTmiRNA of interest – CTreference miRNA. The 
mmu-miR-191-5p miRNA was used as a cellular reference miRNA in order to correct for any 
experimental variability. (B) Expression levels of the miRNAs with relatively low abundance. 
Error bars represent standard deviation from the mean values of 3 experiments. 




In general, the miRNAs were detected during both lytic and latent infection in vitro 
(Figure 3.6 and 3.7A). It was found that the expression pattern of the miRNAs in 
NS0 cells was similar but not identical to that in the NIH 3T3 cells (Figure 3.6 and 
figure 3.7A). For example, mghv-miR-M1-9-3p was ranked the 7
th
 in terms of 
abundance among the tested miRNAs in NIH 3T3 cells at 24 hpi, whereas it is the 3
rd
 
most abundant miRNA in NS0 cells (Figure 3.6A and figure 3.7A). The expression 
level of mghv-miR-M1-7-3p was approximately 6.3-fold higher than mghv-miR-M1-
1-3p in 3T3 cells at 24 hpi, but it was approximately 2-fold less than mghv-miR-M1-
1-3p in NS0 cells (Figure 3.6A and figure 3.7A). mghv-miR-M1-14-3p, mghv-miR-
M1-10-3p, and mghv-miR-M1-4-5p were the least abundant miRNAs in NS0 and 
NIH 3T3 cell lines, whereas mghv-miR-M1-1-3p and mghv-miR-M1-7-3p were the 
most abundant miRNAs in both cell lines. Collectively, these findings suggest that 
the regulation of the expression of some MHV-68 miRNAs can differ depending on 
the phase of infection. 
3.4.2 MHV-68 miRNAs expression during the peak of viral latency 
in vivo 
 
After detecting the MHV-68 miRNAs during latent infection in vitro, the expression 
levels of the miRNAs during latency were examined in vivo at 14 dpi, a time point 
that coincides with the peak latent viral load in the spleen (Cardin, Brooks et al. 
1996, Weck, Kim et al. 1999, Marques, Efstathiou et al. 2003). BALB/c mice were 
infected intranasally with 4x10
5
 PFU of MHV-68 virus. Fourteen days post infection, 
mice were sacrificed and spleens were harvested. The total RNA was extracted from 
splenocytes and cDNAs were synthesised for qRT-PCR analysis and quantification 
of the MHV-68 miRNAs. In general terms, the miRNAs expression levels were 
higher in cell lines than in splenocytes (Figure 3.6 and 3.7). This is expected because 




of the higher percentage of infected cells in the cell culture (approximately 100%) as 
compared to the percentage of infected splenocytes during the peak expansion of 
latently infected cells, which is approximately 0.5 – 1% (Nealy, Coleman et al. 
2010).  
It was found that mghv-miR-M1-1-3p and mghv-miR-M1-9-3p were expressed at 
relatively high levels as compared to other viral miRNAs during latency in vitro and 
in vivo (Figure 3.7A and B). Surprisingly, mghv-miR-M1-10-3p and mghv-miR-M1-
14-3p, which are expressed at low levels in NS0 cells, were expressed at relatively 
higher levels in vivo when compared to the expression levels of the other miRNAs 
(Figure 3.7A and B). Although the percentage of infected splenocytes in vivo is much 
lower than the infected cells in vitro as mentioned above, the mghv-miR-M1-10-3p 
abundance in splenocytes was 3.5-fold higher than NS0 cells and 16.9-fold higher 
than NIH 3T3 fibroblasts at 24 hpi (Figure 3.6B and  
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Figure ‎3.7 MHV-68 miRNAs expression during latent infection. 
qRT-PCR was carried out to quantify the mature miRNAs expression levels. Viral 
miRNA expression levels are presented as values relative to the endogenous 
cellular miRNA mmu-miR-191-5p. Relative expression is 2-∆CT x 102. (A) NS0 cells 
were infected with MHV-68 virus at MOI of 5 for 5 days. Total RNA was extracted 
and qRT-PCR was performed. Error bars represent standard deviation from the 
mean of 2 independent experiments. (B) BALB/c mice were infected intranasally 
with 4 x 105 PFU WT MHV-68 virus. At day 14 post-infection, mice were sacrificed 
and total RNA from splenocytes was extracted for determination of mature 
miRNAs expression levels by qRT-PCR. Error bars represent means ± SD from 5 
individual mice. 
 




figure 3.7A and B). In addition, mghv-miR-M1-14-3p expression level in 
splenocytes was 2.2-fold more abundant than NIH 3T3 cells at 24 hpi (Figure 3.6B 
and figure 3.7B).Although mghv-miR-M1-4-5p is the least abundant miRNA in NIH 
3T3 cells, NS0 cells, and splenocytes, its abundance during latency in splenocytes 
was 5.6-fold higher than NS0 cells and 14.4-fold higher than 3T3 cells. mghv-miR-
M1-8-5p was detected in NIH 3T3 cells and NS0 cells at relatively high levels; 
however it was one of the least abundant miRNAs during latency in vivo. Taken 
together, these results demonstrate that the expression of MHV-68 encoded miRNAs 
depends on the phase of virus infection and it highlights the importance of the in vivo 
model for studying gammaherpesviruses miRNAs. 
3.5 Expression kinetics of MHV-68 miRNAs during virus 
reactivation in vitro 
 
3.5.1 The stimulation of NS0 cells with PMA results in a robust 
induction of virus reactivation 
 
In order to examine the kinetics of MHV-68 miRNAs during in vitro reactivation, 
NS0 cells were infected with MHV-68 virus at MOI of 5. Three days after infection, 
the cells were treated with Phorbol 12-myristate 13-acetate (PMA) at concentration 
of 20ng/ml. The cells were harvested at 2, 4, 8, 24, and 48 hours post treatment (hpt). 
Total RNA and genomic DNA were extracted in order to look at viral gene 
expression and viral genomic load. Before investigating the viral miRNAs expression 
kinetics following reactivation, viral transcripts and viral genome load were analysed 
by qRT-PCR and qPCR. Immediate early ORF50 (RTA), early DNA polymerase 
(DNA pol), and late ORF65 (M9) as well as the latency associated ORF73 
expression kinetics were analysed after the PMA-induced reactivation. As expected,  
















  Figure ‎3.8 MHV-68 mRNAs expression kinetics during in vitro reactivation.  
Murine myeloma NS0 cells were infected with MHV-68 virus at MOI 5. At 3 days 
post- infection, the cells were treated with PMA at concentration of 20 ng/ml in 
medium. The cells were harvested at 2, 4, 8, 24, or 48 hours post-treatment (hpt). 
Untreated cells were used as a control. Total RNA and genomic DNA were extracted 
and the viral mRNA expression and viral genomic load were examined by qRT-PCR 
and qPCR, respectively. The mRNAs copy numbers as well as the genome copy 
numbers were determined using serial dilution of a Plasmid DNA standard curve. 
The expression kinetics of the immediate-early ORF50 (RTA) (A), the early viral DNA 
polymerase (B), the late ORF65 (C), and the latency associated ORF73 (D) 
transcripts were analysed by qRT-PCR over time after PMA treatment. The viral 
mRNAs copy numbers were normalised against the endogenous cellular SDHA copy 
numbers. The viral genomic load was determined following PMA treatment by qPCR 
using 100 ng genomic DNA per reaction (E). The viral genome copy numbers were 
normalised against the cellular genome copy numbers. RTA and SDHA primers were 
used for determination of the viral and cellular genome copy numbers, respectively.  
The data represent 2 independent experiments. Error bars represent mean ± SD. 




the viral mRNAs expression was strongly induced after reactivation (Figure 3.8). 
RTA, DNA pol, and ORF73 mRNAs reached peak levels at 48 hpt with 
approximately 51.4, 73.2, and 121.9 copies per 10
3
 SDHA copies, respectively, and 
with fold increases of approximately 13.2, 14.9, and 5.5-fold, respectively, as 
compared to the untreated control (Figure 3.8A, B, and D). ORF65 mRNA 
expression reached peak level at 24 hpt with approximately 30,078 copies/10
3
 SDHA 
copies and a fold increase of 61.8-fold as compared to the untreated control (Figure 
3.8C). The viral genomic load reached peak levels at 48 hpt with approximately 27.8 
copies/cellular genome copies and a fold increase of approximately 4-fold higher 
than the untreated control (Figure 3.8E). These results indicate that PMA-induced 
reactivation of MHV-68-infected NS0 cells is efficient. 
3.6 MHV-68 miRNAs are differentially expressed following 
PMA-induced virus reactivation in vitro 
 
After confirming the efficient PMA-induced virus reactivation in NS0 cells, the next 
step was to evaluate the expression kinetics of MHV-68 miRNAs. Seven out of 10 
tested miRNAs were induced following PMA treatment, however, at variable levels 
(Figure 3.9). The expression levels of these miRNAs reached peak levels at 48 hpt 
except mghv-miR-M1-8-5p that reached peak levels at 24 hpt. mghv-miR-M1-3-3p, 
mghv-miR-M1-14-3p, and mghv-miR-M1-15-5p showed the highest expression 
induction levels with approximately 9.4, 9.5, and 14.4-fold increase over the 
untreated control at 48 hpt, respectively. Interestingly the expression of 3 miRNAs 
(mghv-miR-M1-4-5p, mghv-miR-M1-9-3p, and mghv-miR-M1-10-3p) was not 
induced after PMA treatment to a level that is substantially higher than the untreated 
control (Figure 3.9). These results indicate that the MHV-68 miRNAs are 
differentially expressed following PMA-induced reactivation in vitro. 




3.6.1 Expression of MHV-68 mRNAs and miRNAs following in vitro 
PMA-induced reactivation after standardisation against the 
viral genomic DNA levels 
 
 In order to determine the rate of viral mRNAs and miRNAs expression during the 
lytic reactivation, the normalised mRNAs or miRNAs expression levels were 
standardised against the normalised levels of viral genomic DNA levels and 
presented as fold change of PMA-treated versus untreated  (Figures 3.10 and 3.11). 
The rate of RTA transcript expression was approximately 3.6-fold higher than in the 
untreated sample as early as 2 hpt and reached peak levels at 8 hpt with an 
expression rate that is 6-fold higher than the untreated control (Figure 3.10A). The 
DNA pol transcript was also induced as early as 2 hpt with an approximately 2.4-fold 
higher than the untreated control with peak of expression at 48 hpt that was 4.4-fold 
higher than the untreated control (Figure 3.10B). ORF65 transcript showed increase 
in the expression rate only after 8 hpt, which is consistent with its late expression 
kinetics (Ebrahimi, Dutia et al. 2003), with expression level that is approximately 14-
fold higher than the untreated control at 24 hpt (Figure 3.10C). The latency-
associated ORF73 transcript showed a modest increase in the expression rate with 
approximately 1.8-fold higher than untreated control at 8 hpt and almost stayed the 
same after this time-point (Figure 3.10E).  
In terms of the expression kinetics of the miRNAs after standardisation against the 
viral genomic loads, there was differential expression of the miRNAs (Figure 3.11). 
mghv-miR-M1-3-3p, mghv-miR-M1-14-3p, and mghv-miR-M1-15-5p were up-
regulated at 48 hpt with approximately 2.5-, 2.7-, and 4-fold higher than the 
untreated control. In contrast, the expression rate of the other miRNAs was either 
down-regulated or stayed unchanged. mghv-miR-M1-1-3p, mghv-miR-M1-4-5p, 




mghv-miR-M1-9-3p, and mghv-miR-M1-10-3p were down-regulated following 
PMA treatment with peak of down-regulation at 24 hpt, showing expression rate of 
approximately 3.3-,  5-, 14.3-, and 5-fold less than untreated control. mghv-miR-M1-
8-5p was down-regulated as early as 2 hpt with approximately  2-fold decrease in the 
expression rate as compared to untreated control and this down-regulation continued 
at same level over the reactivation time-course. The expression rate of mghv-miR-
M1-5-5p did not change after PMA treatment at any time-point when compared to 
the untreated control. Taken together, the differential expression of different 
miRNAs during reactivation suggest a differential regulation of the expression of 
these miRNAs, which may play different roles in modulating reactivation. It is 
important to note that during lytic reactivation not all of the viral genomic DNA is 
used for gene transcription because a proportion of this DNA is packaged within the 
newly formed virions. However, the expression pattern of the well-characterised 
MHV-68 mRNAs was determined and it showed the expected expression kinetics 
following PMA-induced reactivation, which validates this system.   
3.7 MHV-68 DNA replication is not a requirement for the 
miRNAs expression 
 
In order to determine whether the inhibition of MHV-68 DNA replication may affect 
the expression profiles of the miRNAs, NS0 cells were infected with MHV-68 of 
MOI 5. Three days after infection, the cells were treated with the antiviral 
thionucleoside analogue 2'-deoxy-5-ethyl-beta-4'-thiouridine (4'-S-EtdU) at 
concentration of 1µg/ml in the medium. 4'-S-EtdU can inhibit MHV-68 replication 
due to its nucleoside analogue activity; however it does not inhibit latency 
establishment (Barnes, Dyson et al. 1999). The cells were harvested at 0 or 48 hpt. 
Viral transcript expression and viral miRNA expression levels were analysed by 




qRT-PCR. There were no significant changes in RTA and ORF73 expression levels 
(Figure 3.12A and D), however, DNA pol showed a decrease in expression by 4-fold 
as compared to the untreated control at 48 hpt (Figure 3.12 B).  
Notably, the expression level of ORF65, which is a late transcript proposed to 
express a capsid protein (Ebrahimi, Dutia et al. 2003, Martinez-Guzman, Rickabaugh 
et al. 2003), was decreased by 17.9-fold at 48 hpt as compared to the untreated 
control (Figure 3.12C). The viral genomic load was decreased by approximately 3.5-
fold at 48 post 4'-S-EtdU treatment (Figure 3.12E).  This indicates that the inhibition 
of virus replication was efficient. Next, the expression profiles of the viral miRNAs 
were determined. None of the miRNA tested showed significant decrease in 
expression level after 4'-S-EtdU treatment at 48 hpt (Figure 3.13). These results 





MHV-68 provides a unique tractable model for investigating the potential roles of a 
gammaherpesvirus-encoded miRNAs in the virus life cycle and pathogenesis within 
the natural host. In order to investigate the potential functions of MHV-68 encoded 
miRNAs, it is important to characterise their expression pattern during lytic and 
latent infection. qRT-PCR assays were established and optimised for quantification 
of MHV-68 mature miRNAs expression levels.  
 
 









Figure ‎3.9 MHV-68 miRNAs expression kinetics following in vitro reactivation.  
Murine myeloma NS0 cells were infected with MHV-68 virus at MOI of 5. Three days 
after infection, the cells were treated with PMA at concentration of 20 ng/ml. The cells 
were harvested at 2, 4, 8, 24, or 48 hpt. Untreated cells were used as a control. The total 
RNA was extracted from treated or untreated infected cells and the viral miRNA 
expression kinetics were analysed by qRT-PCR. The miRNAs expression levels were 
normalised against the reference cellular miRNA mmu-miR-191-5p. Data are presented 
as fold expression change in the treated over the untreated samples based on the 
comparative 2-∆∆CT method (see Materials and Methods section 2.9.1.3). Error bars 
represent mean ± SD. The data were compiled from 2 independent experiments. 











Figure ‎3.10 Expression kinetics of MHV-68 transcripts standardised 
against viral genomic loads following in vitro PMA-induced 
reactivation.  
This is the same experiment described in figure 3.8, but here the 
normalised MHV-68 mRNA expression levels in the PMA-treated samples 
are presented as fold change from that of the untreated samples after 
standardisation against the viral genomic DNA loads. The data represent 2 
independent experiments. Error bars represent mean ± SD. 
 












Figure ‎3.11 miRNAs expression kinetics following in vitro reactivation 
after standardisation against viral genomic DNA levels. 
This is the same experiment described in figure 3.9, but the normalised 
MHV-68 miRNA expression levels in the PMA-treated samples are 
presented as fold change from that of the untreated samples after 
standardisation against the viral genomic DNA loads. The data represent 2 
independent experiments. Error bars represent mean ± SD. 




The current study has shown that the MHV-68 miRNAs expression is dependent on 
the stage of virus life cycle and the infection model employed. This is consistent with 
a recent published study that investigated the MHV-68 miRNAs expression in vitro 
and in vivo using stem-loop qRT-PCR (Feldman, Kara et al. 2014), suggesting that 
the regulation of the MHV-68 miRNAs expression is dependent on the stage of 
infection. In the present study it has been shown that the abundance of the MHV-68 
mature miRNAs increases over time in the lytically infected NIH 3T3 cells. mghv-
miR-M1-14-3p, mghv-miR-M1-10-3p, and mghv-miR-M1-4-5p were the least 
abundant miRNAs among the tested miRNAs during this lytic infection. It has also 
been shown that mghv-miR-M1-8-5p expression level is very low during latent 
infection in vivo, whereas it is relatively high during latent infection in vitro. These 
results are consistent with Feldman’s study. However, although mghv-miR-M1-1-3p 
and mghv-miR-M1-7-3p were among the most abundant miRNAs during lytic and 
latent infection in the present study and showed high read frequency in NIH 3T3 and 
S11 cell lines by deep sequencing (Zhu, Strehle et al. 2010), they were of low 
abundance in Feldman’s study. These differences are likely due to the different 
approaches used for the miRNAs quantifications. Stem-loop primers and TaqMan 
assays, which are very sensitive to miRNA sequence specificity, were used in the 
Feldman’s study and thus the alternate miRNA isoforms cannot be detected using 
these assays. On the other hand, SYBR Green qRT-PCR was used in the current 
study and it allows for detection of different miRNA isoforms.  
While mghv-miR-M1-9-3p is one of the most highly expressed miRNAs during 
latent infection in vitro and in vivo, it is one of the least abundant miRNAs during 
lytic infection in NIH 3T3 cells. Interestingly, the expression of this miRNA was not 
induced following PMA-induced virus reactivation in NS0 cells. This suggests that 




mghv-miR-M1-9-3p may play a role in promoting latent infection. The difference in 
miRNAs expression may reflect differential regulation and functions of these 
miRNAs. It is plausible that some miRNAs may have more fundamental roles during 
latency by facilitating inhibition of productive  infection and lytic reactivation as 
well as increasing the longevity of infected cells (reviewed in section 1.5), whereas, 
other miRNAs may play roles in supporting lytic replication. Indeed, the observation 
that the MHV-68 miRNAs, mghv-miR-M1-3-3p, mghv-miR-M1-14-3p, and mghv-
miR-M1-15-5p, are upregulated during the PMA-induced lytic reactivation in 
latently infected NS0 cells suggests that these miRNAs may play a role in MHV-68 
lytic reactivation. This finding is consistent with a previous published study showing 
the upregulation of kshv-miR-K12-10 and kshv-miR-k12-12 during PMA-induced 
lytic reactivation of KSHV (Umbach and Cullen 2010). MHV-68 miRNAs are 
located adjacent to the unique latency-associated M genes within the genome, 
suggesting that MHV-68 miRNAs predominately promote latent infection.  
  



















Figure ‎3.12 Expression of MHV-68 mRNAs after inhibition of lytic virus replication in 
NS0 cells.  
NS0 cells were infected with MHV-68 virus at MOI of 5. Three days after infection, the cells 
were treated with 4'-S-EtdU (concentration 1µg/ml in medium). The cells were harvested at 0 
and 48 hours post treatment (hpt). Untreated cells were used as a control. Total RNA and 
genomic DNA were extracted and viral mRNA expression and viral genomic load were 
examined by qRT-PCR and qPCR, respectively.  The mRNAs copy numbers were 
determined using serial dilution of Plasmid DNA standard curve. The expression levels of 
RTA (A), DNA pol (B), ORF65 (C), and ORF73 (D) were determined as copy numbers 
normalised against reference cellular SDHA copy numbers. The viral genomic load is 
presented as viral genome copy numbers normalised against the cellular genome (SDHA) 
copy numbers (E). The data represent 2 independent experiments. Error bars represent 
mean ± SD. 










Figure ‎3.13 Expression profiles of MHV-68 miRNAs following inhibition of virus 
lytic replication in NS0 cells. 
Murine myeloma NS0 cells were infected with MHV-68 virus at MOI of 5. Three days 
after infection, the cells were treated with 4'-S-EtdU at concentration of 1µg/ml in 
medium. The cells were harvested at 0 or 48 hours post-treatment (hpt). Untreated cells 
were used as control. Total RNA was extracted and viral miRNA expression kinetics were 
analysed by qRT-PCR. The miRNAs expression levels are presented as values relative 
to the reference cellular miRNA mmu-miR-191-5p. Relative expression is 2-∆CT x 102. 
Error bars represent standard deviation from the mean of 2 independent experiments. 




 In general, the expression levels of the miRNAs were higher in cell lines than in 
splenocytes which is likely due to higher number of infected cells in vitro than in 
vivo.  
Interestingly, mghv-miR-M1-1-3p and mghv-miR-M1-10-3p whose primary 
miRNAs are transcribed from the same vtRNA promoter sequence (vtRNA1) have 
different expression profiles. For instance, the expression level of mghv-miR-M1-1-
3p is higher than the expression level of mghv-miR-M1-10-3p by approximately 
331-, 450-, and 11-fold in NIH 3T3 cells (24 hpi), NS0 cells (5 dpi), and splenocytes 
(14 dpi), respectively. This suggests a post-transcriptional regulation of these 
miRNAs such as miRNA processing and/or stability. 
The kinetics of MHV-68 miRNAs expression were evaluated after stimulation of 
NS0 cells for virus reactivation. There was strong reactivation induction evidenced 
by the increase of viral mRNAs expression levels and the increase of viral genomic 
load over time. The expression level of RTA, which is a key regulator of lytic 
infection and reactivation (Liu, Pavlova et al. 2000, Pavlova, Virgin et al. 2003), was 
increased by 13.2-fold at 48 hpt. The viral DNA pol was also increase by 14.9-fold at 
48 hpt. Interestingly, the expression level of ORF73, which is a latency-associated 
transcript, was increased by 5.5-fold at 48 hpt, suggesting that ORF73 may play an 
important role in facilitating MHV-68 reactivation in a manner similar to that 
described during viral lytic replication in the fibroblasts (Forrest, Paden et al. 2007).   
The kinetics of MHV-68 miRNAs expression were investigated following PMA-
induced virus reactivation in NS0 cells. It was found that the MHV-68 miRNAs were 
differentially expressed during reactivation, suggesting different roles played by 
these miRNAs during lytic reactivation. Interestingly, the mghv-miR-M1-9-3p 
expression was down-regulated, whereas the expression of mghv-miR-M1-15-5p was 




up-regulated following the PMA-induced reactivation; although, their primary 
miRNAs are transcribed from the same promoter in association with vtRNA8, 
suggesting that the differential regulation of the MHV-68 miRNAs expression during 
reactivation can occur at the post-transcriptional level such as miRNA processing or 
stability. 
When the MHV-68 infected NS0 cells were treated with 4'-S-EtdU, which inhibits 
MHV-68 DNA replication, there were no substantial changes in expression levels of 
the tested miRNAs, indicating that the MHV-68 DNA replication is not essential for 
the miRNAs expression, a feature that is required during latent infection when the 
viral DNA replication is restricted.  
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4 Chapter 4: Expression kinetics of MHV-68 





The hallmark of herpesviruses infection is their ability to establish and maintain 
latency within the natural host (Speck and Ganem 2010). Following the primary lytic 
infection in lung epithelial cells, MHV-68 establishes latent infection mainly in B 
cells where it exploits B cell biology to gain access to the long-lived memory B cells 
through germinal centre reactions (Flano, Kim et al. 2002, Collins and Speck 2012). 
During latency, the viral gene expression is restricted and the production of 
infectious virus is absent; however, the virus possesses the ability to reactivate and 
produce infectious virus under certain conditions in order to disseminate the virus 
and infect new host. The molecular mechanisms behind the establishment, 
maintenance, and reactivation from latency are not fully understood.  
 
Since their discovery, there has been growing evidence that miRNAs encoded by 
herpesviruses can play important roles during virus latency (reviewed in Grey F, 
2015). The gamma-herpesvirus  miRNAs are readily expressed and detected during 
the latent infection and their genes are clustered within regions of the genome 
characterised by latent gene expression, suggesting that these miRNAs might be 
involved in regulating the viral latent state (Cai, Lu et al. 2005, Pfeffer, Sewer et al. 
2005, Umbach, Kramer et al. 2008, Cosmopoulos, Pegtel et al. 2009, Grundhoff and 
Sullivan 2011). Furthermore, KSHV miRNAs were found to play roles in inhibiting 
lytic viral gene expression during latency in order to inhibit virus productive 





replication and to help the virus lay low (Bellare and Ganem 2009, Lei, Bai et al. 
2010, Lu, Stedman et al. 2010).  
The human gamma-herpesviruses, EBV and KSHV, are oncogenic viruses that 
establish and maintain latency in immunocompetent individuals; however, the 
viruses can reactivate and develop malignant tumours in immunocompromised 
individuals. KSHV causes Kaposi’s sarcoma, primary effusion lymphoma, and some 
types of multicentric Castleman's disease (Cesarman, Chang et al. 1995, Boshoff and 
Weiss 2002). EBV is involved in Hodgkin's lymphoma, Burkitt's lymphoma, and 
nasopharyngeal carcinoma (Niedobitek, Meru et al. 2001). It is therefore important to 
investigate the potential roles of the viral miRNAs during latent gamma-herpesvirus 
infection in the immunocompetent host.  
 
Due to strict species specificity of herpesviruses, the roles played by the miRNAs 
encoded by human gamma-herpesviruses during latency cannot be directly assessed 
in vivo. MHV-68 is genetically related to the human gamma-herpesviruses (Virgin, 
Latreille et al. 1997, McGeoch, Gatherer et al. 2005) and provides a tractable small 
animal model to investigate the establishment and maintenance of gamma-
herpesvirus latency and other pathologic features that are difficult to assess in 
humans. MHV-68 causes a productive infection of the lung following intranasal 
infection, followed by establishment of splenic latent infection mainly in B cells, 
which peaks 14 days post-infection and is characterised by prominent splenomegaly 
and activation and clonal expansion of B cells (Sunil-Chandra, Efstathiou et al. 1992, 
Sunil-Chandra, Efstathiou et al. 1993, Weck, Barkon et al. 1996, Flano, Husain et al. 
2000). Three weeks after infection,  there is reduction in the CD4+ T-cell mediated B 
cell proliferation and expansion of CD8+ T-cells (Tripp, Hamilton-Easton et al. 





1997, Flano, Hardy et al. 2004, Evans, Moser et al. 2008). These pathological 
features are reminiscent of the infectious mononucleosis induced by EBV virus 
(Nash and Sunil-Chandra 1994, Doherty, Tripp et al. 1997). MHV-68 virus then 
maintains lifelong latent infection within the host. 
 
Quantification of the MHV-68 miRNAs expression and determination of their 
expression kinetics during the latency in vivo can allow us to better define the 
possible biological roles of these miRNAs. This chapter shows evaluation of the 
expression kinetics of MHV-68 miRNAs during different stages of MHV-68 splenic 
latency.  
 
Investigation of viral miRNAs expression pattern in latently infected cells requires 
detection and isolation of those cells during the course of infection because they exist 
in small numbers. There have been a number of attempts to construct MHV-68 
marked viruses. Bennett et. al. constructed an MHV-68 recombinant virus expressing 
enhanced green fluorescent protein (eGFP), which was co-expressed with mLANA 
by insertion of an internal ribosome entry site downstream of the ORF73 coding 
region (Bennett, May et al. 2005, Smith, Rosa et al. 2006). This virus showed similar 
lytic replication and establishment of latency to that of the WT virus, but it was 
attenuated during long-term latency in BALB/c mice. Collins and colleagues 
constructed a transgenic virus that expresses enhanced yellow fluorescent protein 
(MHV68-YFP) (Collins, Boss et al. 2009), where the human cytomegalovirus 
immediate-early promoter was used for the expression. This virus replicated and 
established latency to comparable levels to that of the WT virus. However, the 
expression of the transgene was significantly reduced during late latency, suggesting 





that a latency associated promoter may be required for marking infected B cells 
during late latency.  
 
Another approach to isolate latently infected cells involved the use of a recombinant 
MHV-68 virus expressing Cre-recombinase under the control of an RSV promoter 
(Dutia, Reid et al. 2009). However, this virus was attenuated in vivo and in vitro as 
compared to the WT virus. (mLANA), a protein that has sequence homology to 
KSHV LANA and plays a central role in maintaining the viral genome as an extra 
chromosomal episome in dividing cells . Published data indicated that the 
MHV68.ORF73βla virus replicated lytically and established latency at similar levels 
to that of the wild-type virus.  
 
In the current study,  for the purpose of isolating latently infected splenocytes in a 
mouse model by flow cytometry, with the aim of determining the kinetics of MHV-
68 miRNAs expression in these cells, an initial attempt involved the use of a 
recombinant MHV-68 virus carrying a β-lactamase gene inserted in-frame 
downstream of ORF73 (designated MHV68.ORF73βla), which was constructed by 
Nealy and co-workers (Nealy, Coleman et al. 2010). This recombinant virus allowed 
for quantification of MHV-68 miRNAs expression in the isolated latently infected 
splenocyte population at 14 and 21 dpi, despite the unpredicted attenuation of this 
virus in establishing latency, which was evidenced in this study by significantly 
lower MHV68.ORF73βla splenic genomic loads as compared to that of the wild-type 
virus, in disagreement with Nealy’s study. Therefore, this virus was not used for 
further profiling of MHV-68 miRNAs expression at later time-points. Alternatively, 
the determination of the latent miRNAs expression kinetics in total splenocytes 





throughout latency was performed using wild-type MHV-68. This involved 
quantification of the miRNAs expression levels during the course of latent infection 
and normalisation of these levels to the respective levels of the viral DNA genomic 
loads, aiming to eliminate the possibility that any changes in the miRNAs expression 
levels are not merely due to changes in the viral genomic load.  
It was found that the standardised miRNAs expression levels are high during the 
early stage of latency (10 or 14 dpi) and then decrease over time until day 21 post-




4.2 Detection and isolation of latently infected splenocytes 
using the MHV68.ORF73βla virus 
 
One challenge in studying MHV-68 infection is the very low frequency of latently 
infected cells in vivo. Therefore, evaluation of the MHV-68 encoded miRNAs 
expression kinetics during different stages of virus latency in vivo requires detection 
and isolation of individual latently infected cells, aiming at enriching these cells. 
MHV68.ORF73βla virus was used for this purpose. This virus carries β-lactamase 
gene that is fused in-frame downstream of ORF73 (Figure 4.1A). The Fluorescence 
Resonance Energy Transfer (FRET)-based substrate, CCF2, allows the use of β-
lactamase as a reporter for ORF73 (mLANA) expression in latently infected 
splenocytes. The lipophilic esterified form of this substrate (CCF2-AM) enters the 
cells via passive diffusion. The endogenous cytoplasmic esterases cleave the AM 
ester from the CCF2-AM, converting it into its negatively charged form (CCF2) that 
is retained in the cytoplasm (Figure 4.1B). In the absence of β-lactamase, excitation 





of the coumarin in the intact CCF2 at 405 nM by violet laser causes FRET to the 
fluorescein that emits a green light at 520 nM. When the β-lactamase is expressed in 
the cell, it cleaves the CCF2 and disrupts FRET; therefore, excitation of the coumarin 
at 405 nM now produces a blue fluorescence signal at 447 nM (Zlokarnik, Negulescu 
et al. 1998) (Figure 4.1B). 
 
A previous published study has shown that the MHV68.ORF73βla virus allowed for 
detection and isolation of rarely infected mouse splenocytes expressing β-
lactamase/mLANA by flow cytometry. For example, the frequency of splenocytes 
from MHV68.ORF73βla-infected mice was 1 in 1,120, 1 in 18,600, and 1 in 30,800 
at 16, 42, and 90 days post intranasal infection, respectively (Nealy, Coleman et al. 
2010). 
  













Figure 4.1 The β-lactamase reporter system.  
(A) Schematic diagram showing the insertion of the β-lactamase gene in-frame 
downstream of ORF73 in the MHV68.ORF73βla virus. The recombinant virus was 
constructed from the parental MHV-68 bacterial artificial chromosome (BAC) 
using allelic exchange (Nealy, Coleman et al. 2010). (B) A diagram showing the β-
lactamase reporter system. The FRET based substrate, CCF-AM, is loaded into 
splenocytes by incubation at 37
o
C for 5 min in dark place. The AM ester is cleaved 
from the CCF2 by the cytoplasmic esterases, producing a fluorescence dye that 
emits a green signal when excited at 405 nM. The β-lactamase cleaves the CCF2 
causing a change in emission to 447 nM when excited at 405 nM. 





In order to isolate latently MHV-68 infected splenocytes by flow cytometry-based 
cell sorting, female BALB/c mice were infected intranasally with 4x10
5
 PFU of 
MHV68.ORF73βla virus or WT-MHV-68 virus. The spleens were harvested at 14 
and 21 dpi and single cell suspensions were prepared and loaded with CCF2-AM β-
lactamase substrate. The splenocytes were subsequently subjected to flow cytometry 
that allowed for distinguishing the cells expressing mLANA from the cells not 
expressing mLANA (see Materials and Methods section 2.4). Splenocytes from WT 
MHV-68 infected mice and unloaded splenocytes (untreated with CCF2-AM) were 
used as negative controls for adjusting the flow cytometry gates.  
 
At 14 dpi, approximately 0.2% of the splenocytes from MHV68.ORF73βla infected 
mice were β-lactamase/mLANA positive, whereas 0.0% of splenocytes from WT 
MHV-68 infected mice were mLANA positive (Figure 4.2 upper panels). At 21 dpi, 
approximately 0.06% of the splenocytes were β-lactamase/mLANA positive (Figure 
4.2 lower panels). The decrease in number in mLANA positive cells is due to the 
drop of the number of MHV-68 infected splenocytes over time (Nealy, Coleman et 
al. 2010). The mLANA positive cells were isolated for RNA extraction and viral 
miRNAs expression profiling by qRT-PCR. At least 10
5
 mLANA negative cells were 
also isolated to be used as a negative control in the qRT-PCR. The mLANA negative 
splenocytes are present in a very high frequency; therefore, a small portion of this 
cell population was gated as a representative of the mLANA negative cells.  





4.3 Quality control of the RNA extracted from sorted 
splenocytes 
 
Effective extraction and processing of the RNA from mLANA positive cell 
populations is crucial for the subsequent qRT-PCR assays. RNA is very sensitive to 
degradation by the ubiquitous RNases. This problem is further enhanced during the 
process of RNA extraction   from the sorted mLANA positive splenocytes because 1) 
these cells are rare and exist in very low numbers (a range of 3,000 to 20,000 cells at 
14 dpi and less than 1,000 to 5,000 cells at 21 dpi) and 2) the passage of the cells 
through the nozzle of the flow cytometer can stress the cells by shearing forces.  
 
At the beginning of this study, several attempts for isolating intact RNA from the 
mLANA positive cells were not successful when the routine flow cytometry and 
RNA extraction procedures were used. This was evidenced by the highly degraded 
RNA when analysed by the Agilent bioanalyzer. Collecting the sorted cells in 
RNAlater
®
 did not overcome this problem. Although RNAlater
® 
can stabilise and 
protect the RNA from degradation, loss of the cells during the centrifugation step 
before the RNA extraction dramatically decreased the RNA yield from the small 
number of the sorted cells. Therefore, more stringent measures were taken in order to 
recover RNA of acceptable quantity and quality for the qRT-PCR assays. These 
measures included cleaning the FACS machine thoroughly with RNase 
decontamination solution prior to the cell sorting and sorting the cells directly into 
Trizol or foetal calf serum-rich medium rather than the FACS buffer or RNAlater
®
. 
This significantly improved the RNA yield and quality following RNA extraction. 
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Figure 4.2 Detection of the mLANA expressing splenocytes by flow cytometry. 
Spleens were harvested at 14 dpi (upper panels) or 21 dpi (lower panels). WT MHV-68 (left) or MHV68.ORF73βla 
(right) virus was used for the infections. Single-cell suspensions were loaded or unloaded with CCF2-AM substrate 
followed by flow cytometric analysis. β-lactamase/mLANA positive cells (blue) and a representative cell population of 
the β-lactamase/mLANA negative cells (purple) are indicated by the boxed gates. The data are representative of 2 
independent experiments, using 5 mice per time-point per group per experiment. 









mLANA+ mLANA- mLANA+ mLANA- 
14 dpi  21 dpi 
28s 
18s 
RNA conc. (pg/µl) 1,420       836        3,400     1,250      556       1,470                
 
RIN   6.8          9.5           9.7        6.5         7.2         8.1              
 
Figure ‎4.3 Quality control of the RNA extracted from the sorted 
splenocytes. 
Agilent High Sensitivity RNA ScreenTape® gel image showing RNA 
extracted from mLANA positive (mLANA+) and mLANA negative (mLANA-) 
splenocytes at 14 or 21 dpi. RNA integrity numbers (RIN) and RNA 
concentrations (RNA conc.) are given at the bottom. The 28 and 18s rRNA 
bands are indicated by arrows. L, Ladder. 
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The quality of the RNA samples from sorted cells was determined using the Agilent 
bioanalyzer or the Agilent High Sensitivity ScreenTape
®
 in combination with the 
2200 TapeStation system. The RNA quality in these systems is based on the integrity 
of the 18s and 28s subunits of the ribosomal RNA (rRNA). This integrity was judged 
by RNA Integrity Number (RIN). The scale of RIN ranges from 1 to 10 where 10 
corresponds to intact RNA and 1 corresponds to highly degraded RNA. Only the 
samples with intact RNA were included in the qRT-PCR analyses. Figure 4.3 shows 
a representation of the samples subjected to Agilent RNA analyses, which were 
selected for the qRT-PCR analyses. The 28s and 18s rRNA bands in the RNA from 
the sorted cells were intact with no signs of degradation and absence of low 
molecular weight RNA bands (Figure 4.3). 
 
The RNA concentrations from mLANA positive cells were very low; therefore, the 
maximum volume of RNA was required for cDNA synthesis and qRT-PCR 
reactions. However, increasing the volume of the RNA also increases the amount of 
the cDNA synthesis inhibitors in the samples such as phenol and guanidine 
thiocyanate salt. This problem is further enhanced because the RNA concentrations 
are very low. In order to determine the optimum RNA volume for the cDNA 
synthesis, different volumes of RNA (1µl, 2µl, 4µl, and 8 µl) from 2 x 10
4
 sorted 
mLANA negative cells were used in the cDNA synthesis and qRT-PCR reactions for 
detection of the cellular miRNA mmu-miR-191-5p and the cellular transcript SDHA. 
It was found that the qRT-qPCR reactions were inhibited when 8µl RNA were used 
for the qRT-PCR, whereas the lowest CT values, which corresponds to the highest 
abundance of the target, were observed when 4µl RNA were used in the qRT-PCR 
(Figure 4.4). 




4.4 The mLANA positive splenocytes are latently infected 
 
In order to confirm that the isolated mLANA positive splenocytes were latently 
infected, the expression profiles of viral gene transcripts were investigated using 
qRT-PCR. RTA (ORF50), an immediate early viral protein, is essential for lytic 
MHV-68 replication during de novo lytic infection or reactivation (Wu, Tong et al. 
2001). The viral DNA polymerase (DNA pol) is an early viral protein and it is 
responsible for viral DNA synthesis during virus replication (Rochford, Lutzke et al. 
2001). Therefore, RTA and DNA pol mRNAs were selected as markers for lytic viral 
replication. Although ORF73 (mLANA) is expressed during both latent and lytic 
infection, its function is mainly associated with latency; and thus, it was used as a 
marker for viral latency (Rochford, Lutzke et al. 2001, Fowler, Marques et al. 2003). 
The RNA isolated from the mLANA positive or mLANA negative splenocytes at 14 
dpi or 21 dpi were reverse transcribed into cDNA and subjected to qRT-PCR for 
detection of RTA, DNA pol, and ORF73. The viral gene expression during latency 
was compared to that of the lytic replication in NIH 3T3 cells by running the qRT-
PCR products on agarose gel (Figure 4.5).  
 
The latent viral gene expression was very close to or below the limit of detection by 
qRT-PCR (~32-35 cycles) and thus an accurate quantification using the CT values 
was difficult. Therefore, the qRT-PCR products were analysed by gel electrophoresis 
(Figure 4.5). The ORF73 qRT-PCR product (129 bp) was detected across all the 
mLANA positive samples, but not in the mLANA negative samples (Figure 4.5). 
This does not only confirm the high efficiency of the splenocytes sorting based on 
mLANA expression, but also indicates that mLANA positive splenocytes isolated at 
both 14 and 21 dpi express ORF73 transcripts that are essential for viral latency. The  
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Figure ‎4.4 Optimisation of the RNA volume used in the cDNA synthesis. 
RNA was extracted from 2x104 sorted mLANA negative cells. Different RNA 
volumes (1, 2, 4, or 8µl) were used for cDNA synthesis in a final reaction volume 
of 20µl. cDNAs were diluted 1/10 and subjected to qRT-PCR for determination of 
the abundance of the cellular miRNA mmu-miR-191-5p (A) or the cellular 
transcript SDHA (B). The CT values represent the abundance of the target gene 
transcript. The lower the CT value, the higher the abundance of the target. Error 
bars represent standard deviation of triplicate qRT-PCR reactions. 
 
 
Figure ‎4.5 Agarose gel image showing MHV-68 mRNAs expression during 




overall expression of RTA and DNA pol was higher at 14 dpi than at 21 dpi; 
however, it is much lower than NIH 3T3 cells as indicated visually by the intensity 
of the qRT-PCR product bands and the inconsistency of detection across individual 
mice.  
At 14 dpi, which coincides with the highest latent virus titre in the spleen, the lytic 
gene transcripts RTA and DNA pol qRT-PCR products (138 bp and 107 bp 
respectively) were occasionally detected in some of the tested mLANA positive 
samples. In contrast, these transcripts were rarely detected at 21 dpi, which is 
expected as a result of viral latency programme and restriction of viral gene 
expression (Figure 4.5). These results indicate that the mLANA positive cells are 
latently infected. The occasional presence of RTA and DNA pol at 14 dpi in 
mLANA positive cells can be a result of sporadic reactivating virus that seeds new 
uninfected B cells in order to enhance the latency establishment and viral latent 
amplification. This explanation is consistent with a previous published study that 
showed that virus reactivation in vivo increases the frequency of latently infected 
splenocytes (Gargano, Forrest et al. 2009). 
4.5 Latent expression profiles of MHV-68 encoded miRNAs 
in mLANA positive splenocytes  
 
In order to investigate the expression levels of MHV-68 miRNAs in the latently 
infected splenocytes, qRT-PCR assays were carried out using miRNA specific 
primers. miRNAs expression levels at 14 and 21 dpi were determined (Figure 4.6) 
and normalised against the cellular miRNA mmu-miR-191-5p. The expression levels 
of the mmu-miR-191-5p represented by CT values at the 2 time-points are shown in 
figure 4.7. The expression levels of all of the miRNAs tested were higher at 14 dpi 
than at 21 dpi; however, to a varying degree.  




Figure 4.5 Agarose gel image showing MHV-68 mRNAs expression during latent infection in vivo. Four µl of 
total RNA from mLANA positive (mLANA +) or mLANA negative (mLANA-) splenocytes at 14 dpi (4 mice) or 21 dpi (3 
mice) were reverse transcribed into cDNA and subjected to qRT-PCR for detection of the indicated transcripts. The 
qRT-PCR products were analysed on 3% agarose gel. Five ng of RNA from NIH 3T3 infected with MHV-68 at MOI of 5 
were used for similar qRT-PCRs as a representative of lytic infection. No reverse transcription controls (NoRT) were 
used to confirm the absence of contaminating genomic DNA in the RNA samples. SDHA was used as a cellular 
housekeeping gene. M, marker. bp, base pair. 




The expression levels of mghv-miR-M1-1-3p, mghv-miR-M1-3-3p, mghv-miR-M1-
5-5p, mghv-miR-M1-7-3p, mghv-miR-M1-8-5p, mghv-miR-M1-9-3p, and mghv-
miR-M1-15-5p were 2-, 2.4-, 1.9-, 3.8-, 2.7-, 2.2-, and 2.3-fold higher at 14 dpi than 
at 21 dpi respectively (Figure 4.6). The higher miRNAs expression levels at 14 dpi 
were not statistically significant except for mghv-miR-M1-1-3p, mghv-miR-M1-7-
3p, and mghv-miR-M1-8-5p, suggesting that these miRNAs in particular may play 
roles during the establishment of latency. Given the small changes in the miRNAs 
abundance levels, these roles can be subtle and involve fine tuning and slight 
adjustment of the expression of certain cellular and/or viral genes in order to 
optimise the virus microenvironment for establishment of latency.  
4.6 Kinetics of MHV-68 miRNAs expression during 
different stages of latent infection in vivo 
 
Although MHV68.ORF73βla can provide a tool for detection and isolation of 
latently infected cells in vivo, the pathogenicity of this virus was different from the 
wild-type virus in vivo under the experimental conditions of this study. For example, 
the splenomegaly in the WT-MHV-68 infected mice was more prominent than that 
of the MHV68.ORF73βla infected mice at 14 dpi by approximately 1.6-fold, which 
was statistically significant and consistent in independent experiments (Figure 4.8B). 
The bigger sizes of the spleens from the WT-MHV-68 infected mice at 14 dpi can be 
observed visually (Figure 4.8A). When the viral DNA genomic loads were 
determined by qPCR, it was found that the viral genomic DNA load in splenocytes 
from WT-MHV-68 infected mice was significantly higher than that of the 
MHV68.ORF73βla infected mice by approximately 16.1 and 21.6-fold at 14 and 21 
dpi, respectively (Figure 4.8C). This suggests that the MHV68.ORF73βla virus is 
attenuated during the establishment of latent infection in vivo.  
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Figure ‎4.6 Expression of MHV-68 miRNAs during latency.  BALB/c mice were infected 
with 4x105 pfu MHV68.ORF73βla virus. The mLANA positive cells were isolated at 14 or 21 
dpi and total RNA was extracted. Four µl RNA were converted into cDNA and the viral 
miRNAs expression levels were determined by qRT-PCR. The relative expression was 
calculated as 2-∆CT x 102 where ∆CT = CTmiRNA of interest – CTreference miRNA. mmu-miR-191-5p was 
used as a cellular reference miRNA in order to correct for any experimental variability. The 
error bars represent mean ± SD of 2. The data were compiled from 2 independent 
experiments, with 3-5 mice were used per time-point per experiment. qRT-PCR was carried 
out in triplicates. P-values were calculated based on student’s t test. 
 
Figure ‎4.7 The expression levels of mmu-miR-191-5p in mLANA positive cells. mmu-
miR-191-5p was used as a reference miRNA for the relative quantification of MHV-68 miRNAs 
in mLANA positive cells during latency (see figure 4.6). The mmu-miR-191-5p expression at 
14 or 21 dpi was determined by qRT-PCR and presented as CT values. Error bars represent 
standard deviation of the mean of 2 independent experiments with 3-5 mice per time-point per 
experiment. qRT-PCR was performed in triplicates.Figure ‎4.6 Expression of MHV-68 
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qRT-PCR. The relative expression was calculated as 2-∆CT x 102 where ∆CT = CTmiRNA of interest – 
CTreference miRNA. mmu-miR-191-5p was used as a cellular reference miRNA in order to correct 
for any experimental variability. The error bars represent mean ± SD of 2. The data were 
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Figure 4.7 The expression levels of mmu-miR-191-5p in 
mLANA positive cells. mmu-miR-191-5p was used as a 
reference miRNA for the relative quantification of MHV-68 
miRNAs in mLANA positive cells during latency (see figure 4.6). 
The mmu-miR-191-5p expression at 14 or 21 dpi was determined 
by qRT-PCR and presented as CT values. Error bars represent 
standard deviation of the mean of 2 independent experiments with 
3-5 mice per time-point per experiment. qRT-PCR was performed 
in triplicates. 
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Figure ‎4.8 The MHV-68.ORF73βla virus is attenuated during latent infection in vivo. 
BALB/c mice were infected with 4x105 WT-MHV-68 or MHV-68.ORF73βla virus 
intranasally. (A) At 14 or 21 dpi, mice were sacrificed and the spleens were harvested and 
the splenomegaly was observed. (B) The spleen weights were determined at 14 dpi as a 
measurement of splenomegaly. (C) The genomic DNA was extracted from the splenocytes 
of infected mice and the absolute copy numbers of the viral genomic loads were 
determined by qPCR using RTA primers and 100 ng genomic DNA as a template. The 
viral genomic copy numbers were normalised to 103 copies of the cellular genomic load 
using the SDHA primers. The error bars represent the mean ± SD. Data represent two 
independent experiments, using 2-5 mice per group per time-point. P-value was 
determined using unpaired student’s t test. 
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The rationale of using the MHV68.ORF73βla virus was to enrich for latently 
infected splenocytes by selectively isolating them from the uninfected population, 
aiming to facilitate the quantification of viral miRNAs. However, the small numbers 
of the isolated mLANA positive splenocytes, which is most likely due to the small 
numbers of MHV-68 ORF73βla-infected cells, caused difficulty in recovering RNA 
of good quality and quantity for the qRT-PCR analysis. This observed attenuation of 
MHV68.ORF73βla virus during latency in vivo, made us decide to use the WT-
MHV-68 virus for expression profiling of the viral miRNAs during latent infection. 
This can allow for further confirmation of the findings obtained from the 
MHV68.ORF73βla virus using an independent virus as well as investigating the 
miRNA expression levels at earlier and later time-points post-infection, during which 
the numbers of infected cells are very small.  
In order to evaluate the expression kinetics of MHV-68 miRNAs during the course of 
latent infection in vivo using the WT virus, BALB/c mice were infected intranasally 
with 4x10
5
 pfu WT-MHV-68 virus. The spleens were harvested at 10, 14, 21, and 32 
dpi. The use of WT-MHV-68 virus for profiling the viral miRNAs during different 
stages of latency in vivo is possible; however, the potential changes of the miRNAs 
expression can be merely due to the changes of the viral genomic loads during the 
course of latent infection. For this reason parallel RNA and DNA samples were 
extracted for quantification of viral miRNAs as well as viral DNA genomic loads. 
The levels of viral miRNAs expression were then standardised against the levels of 
viral genomic loads.  















Figure ‎4.9 The expression kinetics of MHV-68 encoded miRNAs and viral genomic load 
during latent infection in vivo. BALB/c mice were infected intranasally with 4x105 WT-MHV-
68 virus. Spleens were harvested at 10, 14, 21, and 32 dpi and single-cell suspensions were 
prepared and parallel RNA and DNA extractions were carried out on the same animal. Total 
RNA (500 ng) was converted into cDNA and subjected to qRT-PCR using miRNA specific 
primers. The viral miRNAs expression levels were quantified relative to the reference miRNA 
mmu-miR-191-5p (A and B). The viral DNA genomic loads (RTA primers) were quantified 
relative to the cellular genomic levels (SDHA primers) using 100 ng template DNA (C and D). 
Error bars in A and C represent the mean ± SEM from 5 mice per group per time-point. Error 
bars in B and D represent mean ± SD of the CT values from 5 mice per group per time-point. 
qRT-PCR reactions were carried out in triplicates. 
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Figure ‎4.10 The  kinetics of MHV-68 miRNAs expression normalised against 
the genomic viral load during latent infection in vivo. The data shown in this 
figure are from the same experiment as figure 4.9, but here the normalised levels of 
miRNAs expression were standardised against the normalised viral genomic loads. 
Error bars represent mean ± SEM. The means that do not share a letter are 
significantly different (P<0.05). The statistical significance was determined by one-
way ANOVA and Tukey’s comparison test on log-transformed data using Minitab 16 
statistical software. Data were compiled from 5 mice per time-point per group. The 
qRT-PCR reactions were performed in triplicates.  




Interestingly, all of the tested miRNAs showed similar expression kinetics pattern 
(Figure 4.9A). The miRNAs expression levels are shown as relative expression to the 
cellular reference miRNA mmu-miR-191-5p (Figure 4.9B). The viral genomic loads 
were normalised to the cellular genomic loads (Figure 4.9D). The miRNAs 
expression levels increased between 10 and 14 dpi relative to the expression of the 
cellular miRNA mmu-miR-191-5p, which coincides with increase of the viral latent 
genomic load in the spleen detected by qPCR (Figure 4.9C). The relative miRNAs 
expression levels decreased between 14 and 21 dpi. Surprisingly, despite the 
decrease of the viral genomic DNA load between 21 and 32 dpi by approximately 
9.5-fold, there was slight increase of the miRNAs expression levels by approximately 
2-3-fold at 32 dpi over 21 dpi (Figure 4.9A and C). The normalised miRNAs 
expression levels were standardised against the normalised viral genomic levels in 
order to rule out the effect of the viral load differences between different time-points 
on the changes of the viral miRNAs expression levels. Although, there was a non-
significant decrease in the abundance of the viral miRNAs between 10 dpi and 21 
dpi, except for mghv-miR-M1-4-5p, this decrease was consistent among all the tested 
miRNAs (Figure 4.10). 
Due to the large variation between individual mice, a larger experiment will be 
needed to detect possible statistically significant differences at these time points. The 
miRNAs expression levels increased over time between 21 and 32 dpi. This increase 
in expression was statistically significant in all of the miRNAs tested (Figure 4.10). 
These findings suggest that the regulation of the expression of MHV-68 miRNAs 
expression may differ at different stages of latent infection and that the miRNAs may 
play different roles during latency. Due to time constraints this experiment was done 
once and another experiment will be needed to confirm these results. 






The roles of the gamma-herpesviruses encoded miRNAs during the latent infection 
are not fully understood. Characterisation of the expression patterns of these 
miRNAs during latency can be helpful to further dissect their functions. In this study, 
a marked virus, MHV68.ORF73βla, that carries a β-lactamase gene fused in-frame 
downstream of the mLANA expressing gene ORF73 was used to detect and isolate 
latently infected splenocytes (mLANA positive splenocytes) at 14 dpi and 21 dpi by 
flow cytometry, aiming at quantifying the viral miRNAs expression levels during the 
early establishment of latency and during latency maintenance. The MHV-68 
miRNAs expression levels were quantified in the mLANA positive cells at 14 and 21 
dpi. It was found that the expression levels of all of the miRNAs tested showed 
decrease in the expression levels over time between 14 and 21 dpi. This is consistent 
with the findings in the current study, where The WT-MHV-68 virus was used to 
evaluate the expression kinetics of the MHV-68 miRNAs at 10, 14, 21, and 32 dpi in 
total splenocytes. The miRNAs expression levels of the WT-MHV-68 decreased over 
time between 10 and 21 dpi. Interestingly, the miRNAs expression levels then 
increased between 21 and 32 dpi, suggesting that the MHV-68 latency is a complex 
dynamic process. It is plausible that there are different stages of MHV-68 latency: (i) 
the stage of early establishment of latency in spleen (between 10 to 21 days post 
infection) when the miRNAs can play an important role in silencing viral gene 
expression and inhibiting lytic infection possibly by targeting viral transcription 
activators, particularly RTA, in a way similar to that of the KSHV miRNA, miR-
K12-9*, which targets a sequence in the 3’ UTR of KSHV RTA (Bellare and Ganem 
2009). MHV-68 miRNAs can also possibly down-regulate expression of cellular 
genes involved in supporting lytic infection. This strategy has been reported for other 




gamma-herpesvirus miRNAs.  For example, the KSHV-encoded miR-K12-1 has 
been shown to down-regulate IκBα, a suppressor of NF-κB complexes resulting in 
promoting NF-κB-dependent viral latency (Lei, Bai et al. 2010).  Furthermore, the 
EBV miRNA, BART-miR-18-5p, has been shown to  down-regulate the expression 
of the cellular protein MAP3K2 leading to decreased viral lytic gene expression and 
virus production (Qiu and Thorley-Lawson 2014). 
 The MHV-68 miRNAs expression decreased over time between 10 and 21 dpi 
possibly to allow for basal expression levels of lytic genes particularly RTA in order 
to allow for a minimal level of reactivation, resulting in virus spread to neighbouring 
uninfected cells; (ii) the stage of latency maintenance which  involves increase of 
miRNAs expression (after 21 dpi in spleen) in order to suppress any lytic reactivation 
beyond the basal level and possibly to increase the longevity of infected cells through 
anti-apoptotic functions.  
 
In the present study, each animal was analysed individually and samples from 
different animals were not pooled in order to get an insight into individual variations 
between animals. In a previous published study involving the use of 
MHV68.ORF73βla virus for evaluating the kinetics of mLANA expression in B cell 
subsets the samples from different mice were pooled and analysed (Nealy, Coleman 
et al. 2010). This possibly facilitated the gene expression analysis in that study. In the 
same study the MHV68.ORF73βla virus showed a significant decrease in virus 
spread among cells during the multi-step growth curve analysis, approximately 2 log 
difference in virus titre at 24 and 48 hours post infection in NIH 3T12 cells as 
compared to the WT virus, a phenotype that is observed in the MHV-68 mutant virus 
lacking mLANA expression (Moorman, Willer et al. 2003, Forrest, Paden et al. 




2007), suggesting that the C-terminal fusion of β-lactamase can affect the mLANA 
function. However, in contrast to the current study, no attenuation was reported 
during latent infection in vivo in Nealy et. al. study (Nealy, Coleman et al. 2010).  
 
It would have been interesting if the miRNA expression levels were assayed in the 
latently infected splenocyte population at time points later than 21 dpi; however, very 
small numbers of infected splenocytes are expected to be isolated later than 21 dpi 
using the MHV68.ORF73βla virus because of its attenuation and it was thought to be 
not worth trying. Future experiments can involve the use of a marked MHV-68 virus, 
which can establish and maintain latency at levels similar to that of the WT virus, for 
isolation of latently infected splenocytes during late latency and for determination of 
the miRNAs expression after 32 days post infection in these cells.
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An important feature of gammaherpesvirus latency is the restricted gene expression 
that allows the virus to evade the immune system and to remain in the host 
throughout its lifetime. However, the viruses need to encode functions which 
modulate the viral gene expression and the cellular environment to maintain latent 
infection.   Protein expression in latently infected cells can be a target of the immune 
system, hence expression of miRNAs provides the gammaherpesviruses with a 
powerful tool to manipulate the cell and maintain latency.  A number of  studies have 
used cross-linking immunoprecipitation (CLIP) of the RNA-induced silencing 
complex (RISC) and validation of miRNAs targets to identify potential functions of 
the miRNAs encoded by the human gammaherpesviruses EBV and KSHV  (Dolken, 
Malterer et al. 2010, Haecker, Gay et al. 2012, Ramalingam, Kieffer-Kwon et al. 
2012, Riley, Rabinowitz et al. 2012, Skalsky, Corcoran et al. 2012, Zhu, Haecker et 
al. 2013). These studies have identified viral miRNAs targets that are involved in cell 
cycle regulation, apoptosis, and immune recognition and thus enhance viral latency 
and survival in the host. Some viral miRNAs have also been proposed to directly 
target the viral transcripts in order to suppress lytic genes and promote latency 
(Kincaid and Sullivan 2012, Riaz, Dry et al. 2014).  
 
Although some of these studies indicate that the miRNAs encoded by the human 
gammaherpesviruses can target both cellular and viral targets, the functions of these 
miRNAs remain not fully characterised in the context of natural host infection due to 




the strict host specificity of gammaherpesviruses. MHV-68 is genetically related to 
the human gammaherpesviruses, EBV and KSHV (Barton, Mandal et al. 2011), and 
it provides a tractable small animal model for studying the potential functions of 
gammaherpesvirus miRNAs during the natural course of infection (primary lytic 
infection, establishment of latency, maintenance of latency, and reactivation).  
The aim of this chapter was to investigate the potential roles played by the MHV-68 
miRNAs in the virus pathogenesis. For this purpose, an MHV-68 mutant virus, 
lacking 9 miRNAs associated with vtRNAs1-5, was constructed using homologous 
recombination within the MHV-68 bacterial artificial chromosome (BAC). This 
miRNA mutant virus (designated MHV-68.ΔmiRNAs) was used along with its wild-
type counterpart to investigate:  
1- The role of the miRNAs in virus productive replication in vitro and in vivo 
2- The kinetics of latency establishment in vivo 
3- The efficiency of virus reactivation  from latency ex vivo 
4- The ability of the virus to maintain long-term latency in the spleen 
5- The virus-induced B cell activation and proliferation in spleen 
The construction of the MHV-68.ΔmiRNAs virus was successful and the virus 
lacked the expression of the deleted miRNAs in vitro and in vivo. Although the 
miRNA mutant virus and its wild-type counterpart showed similar ability to replicate 
productively, to establish latent infection in vivo and to reactivate ex vivo during 
early latency and as late as 28 dpi, the MHV-68.ΔmiRNAs virus showed higher ex 
vivo reactivation efficiency than the WT virus during late latency (49 dpi). At this 
time point,  an increase in the expression levels of the viral lytic mRNAs in the 
spleens of MHV-68.ΔmiRNAs virus infected mice, particularly the M3 transcript 
that is abundantly expressed during lytic infection and encodes a chemokine-binding 




protein (Parry, Simas et al. 2000, Rochford, Lutzke et al. 2001), demonstrated a key 
role for MHV-68 miRNAs in maintaining long-term latency and control of the 
transition from latent state to lytic state during late latency.  
 
While this study was underway, two groups published papers using a similar 
approach. These studies suggested that the MHV-68 miRNAs are dispensable for the 
productive virus infection and the establishment of latency in vivo and that they can 
be involved in increasing the numbers of the MHV-68-infected memory B cells and 
in the development of lethal pneumonia in IFNγ-deficient mice (Feldman, Kara et al. 
2014, Diebel, Oko et al. 2015). 
5.2 Construction of an MHV-68 mutant virus lacking the 
expression of 9 miRNAs 
 
In order to investigate the potential roles of the MHV-68 miRNAs during the virus 
life cycle, a recombinant virus carrying mutations that deleted 9 miRNAs, designated 
MHV-68.ΔmiRNAs, was constructed (Figure 5.1). The WT-MHV-68 BAC (Adler, 
Messerle et al. 2000) was used as a backbone for generating the MHV-68.ΔmiRNAs 
virus by two-step lambda red-mediated recombination (Tischer, von Einem et al. 
2006). The mutations targeted the deletion of 9 miRNAs (mghv-mir-M1-1, mghv-
mir-M1-10, mghv-mir-M1-2, mghv-mir-M1-3. mghv-mir-M1-4, mghv-mir-M1-5, 
mghv-mir-M1-6, mghv-mir-M1-7, and mghv-mir-M1-12), while keeping intact the 
vtRNA genes and putative open reading frames. The positions of the nucleotide 
mutations within the MHV-68 genome are shown in Table 5.1. 
 
After cloning and recombination, the generated miRNA mutant MHV-68 BAC 
clones were screened by PCR in order to determine whether the mutated region 




showed the expected size by gel electrophoresis followed by Sanger sequencing of 
this region (see Materials and Methods). All the expected mutations were present and 
the intact sequences between the mutations were correct when aligned against the 
wild-type sequence (Figure 5.2). In order to confirm that the genome structure within 
the MHV-68.ΔmiRNAs BAC is similar to that of the parental WT-MHV-68 BAC 
and that there is no genomic rearrangement in the MHV-68.ΔmiRNAs BAC, the 
anatomy of the viral genomic structure within the intact BAC DNA was determined 
by restriction enzyme digest using XhoI and EcoRI enzymes (Figure 5.3A). It was 
found that the genomic structure of the MHV-68.ΔmiRNAs BAC was similar to that 
of the WT-MHV-68 BAC. Having confirmed the correct mutant sequence and the 
proper genomic structure, the MHV-68.ΔmiRNAs BAC DNA and its wild-type 
counterpart were transfected into NIH 3T3 cells expressing Cre recombinase in order 
to remove the BAC vector sequences by Cre-loxp recombination and to produce 
MHV-68.ΔmiRNAs virus and its parental WT-MHV-68 virus (see Materials and 
Methods).  
In order to confirm that the generated miRNA mutant virus carried all the miRNAs 
deletions, NIH 3T3 cells were infected with MHV-68.ΔmiRNAs virus or WT-MHV-
68 virus at MOI of 5 for 24 hours. Total genomic DNA was extracted and PCR 
amplification of the DNA fragment containing the miRNAs mutations was carried 
out. Uninfected cells were used as a negative control. As expected, when the PCR 
products were analysed by agarose gel electrophoresis, it was found that the 
amplified DNA fragments showed the expected sizes of 1,719 bp and 1,360 bp for 
the WT-MHV-68 and the MHV-68.ΔmiRNAs-infected samples, respectively. This 
corresponds to a difference of 359 bp between the wild-type and miRNA mutant 
sequences due to deletion of the miRNAs (Figure 5.3B).  















Figure ‎5.1 Schematic of the genomic organisation of the MHV-68 tRNAs and 
its associated miRNAs within the genomes of WT-MHV-68 and MHV-
68.ΔmiRNAs viruses. The vtRNA genes are represented as black triangles. The 
miRNA WT sequences are represented as grey rectangles. The miRNA mutant 
sequences are represented as white rectangles. The names of the genes are 
indicated. The miRNA genes are named according to the miRBase nomenclature. 
TR, terminal repeat. 
        
  
 






Position of deleted or  
mutated sequences 
  Deleted feature 
vtRNA1 127-196 - - 
mghv-mir-M1-1 197-260 
197-316 
  mghv-mir-M1-1 
  mghv-mir-M1-10 261-322    mghv-mir-M1-10 
vtRNA2 488-561 - - 
mghv-mir-M1-2 562-627 607-614    mghv-mir-M1-2 
mghv-mir-M1-3 638-698 
Point mutations: C673A, G676C,  
    G679A, A682C, A685C, A688C, T691A, 
and G694A 
   mghv-mir-M1-3 
  mghv-mir-M1-11 759-811 - - 
vtRNA3 894-955 - - 
mghv-mir-M1-4 956-1049 1029-1036    mghv-mir-M1-4 
vtRNA4 1182-1254 - - 
mghv-mir-M1-5 1255-1314 
1255 – 1373 
  mghv-mir-M1-5 
mghv-mir-M1-6 1319-1381   mghv-mir-M1-6 
EcoRI site 1517-1522 A1518T EcoRI site 
EcoRI site 1570-1575 A1571T EcoRI site 
vtRNA5 1588-1659 - - 
mghv-mir-M1-7 1660-1719 
1660 – 1764 
  mghv-mir-M1-7 
  mghv-mir-M1-12 1720-1789     mghv-mir-M1-12 
 
Table ‎5-1 MHV-68 vtRNAs and miRNAs genomic locations and the positions of 
the deleted sequences in the MHV-68.∆miRNAs virus. 
  




CLUSTAL 2.1 multiple sequence alignment 
 
 
WT  GCGCGCCCTGGAGATCCGGGGCTGATGCTGGGTTCAGGAGTTCAGGGCGGCCGACCATTC 60 
Mut GCGCGCCCTGGAGATCCGGGGCTGATGCTGGGTTCAGGAGTTCAGGGCGGCCGACCATTC 60 
    ************************************************************ 
 
WT  GATGCAAATGTTGGGTGTGTGCACCCCACTATCTCTGGTTCTGCAAAGCTTGCTTTTTGT 120 
Mut GATGCAAATGTTGGGTGTGTGCACCCCACTATCTCTGGTTCTGCAAAGCTTGCTTTTTGT 120 
    ************************************************************ 
 
WT  GCTGGTGCCAGAGTAGCTCAATTGGTAGAGCAACAGGTCACCGATCCTGGTGGTTCTCGG 180 
Mut GCTGGTGCCAGAGTAGCTCAATTGGTAGAGCAACAGGTCACCGATCCTGGTGGTTCTCGG 180 
    ************************************************************ 
 
WT  TTCAAGTCCGAGCTCTGGTCGAGGAAGTGGGTCCAACTTTATCCCTATAGTGTGATAGAA 240 
Mut TTCAAGTCCGAGCTCT-------------------------------------------- 196 
    ****************                                             
 
WT  ATGGCCGTACTTCCTTTATAATTAAGAACCCTCAGTGCAATCACTTGTCTGCATTTGGAG 300 
Mut ------------------------------------------------------------ 
                                                                             
 
WT  TGATTACACGGAAGGTTCTTTTGTTTTGGGACTTGCTGCTTTGATATAGCCCAGGCTTTT 360 
Mut ----------------TCTTTTGTTTTGGGACTTGCTGCTTTGATATAGCCCAGGCTTTT 240 
                    ******************************************** 
 
WT  ATGTGCAACTTTCTATTTTTCTACTATGCAAAAGACCCTTGATTATTGAGAGTCTAGCAA 420 
Mut ATGTGCAACTTTCTATTTTTCTACTATGCAAAAGACCCTTGATTATTGAGAGTCTAGCAA 300 
    ************************************************************ 
 
WT  CCTCATGCAAATTGTCCTTTTAAAGACCCGTAGGTTCATCAAGCCCAACAGATACTATTT 480 
Mut CCTCATGCAAATTGTCCTTTTAAAGACCCGTAGGTTCATCAAGCCCAACAGATACTATTT 360 
    ************************************************************ 
 
WT  ACATAAGGCCAGGGTAGCTCAATCGGTAGAGCAGCGGTTCCTGGAGTCCGCTGGTTCTCG 540 
Mut ACATAAGGCCAGGGTAGCTCAATCGGTAGAGCAGCGGTTCCTGGAGTCCGCTGGTTCTCG 420 
    ************************************************************ 
 
WT  GTTCAAGCCCGAGCCCTGGTTGAGAGGGGGAGTGTGTGGTCTGTAGAGAGACATGAGTTG 600 
Mut GTTCAAGCCCGAGCCCTGGTTGAGAGGGGGAGTGTGTGGTCTGTAGAGAGACATGAGTTG 480 
    ************************************************************ 
 
WT  ATCGGCAGACCCCCTCTCCCCCTCTTTCCCTCTTTACGAAGTAGCGAACCTCTGCTCACT 660 
Mut ATCGGC--------TCTCCCCCTCTTTCCCTCTTTACGAAGTAGCGAACCTCTGCTCACT 532 
    ******        ********************************************** 
 
WT  GCCCGGGCCCTCCGGGAGGTGAGCAGGAGTTGCGCTTTTCTTTCTCTGTTTTGTTTTTGC 720 
Mut GCCCGGGCCCTCAGGCAGATGCGCCGGCGTAGCACTTTTCTTTCTCTGTTTTGTTTTTGC 592 
    ************ ** ** ** ** ** ** ** ************************** 
 
WT  CATACCCAAGTCTATTGGCACGCTGCCAATCTCACCCTGACAGCTGTCAGGGGTTACATG 780 
Mut CATACCCAAGTCTATTGGCACGCTGCCAATCTCACCCTGACAGCTGTCAGGGGTTACATG 652 
    ************************************************************ 
 
WT  AGAGAACTTCATGTAACCCCTGACAGCTGTCAACCTAATCCTGACCGTGAGAACTTTTCA 840 
Mut AGAGAACTTCATGTAACCCCTGACAGCTGTCAACCTAATCCTGACCGTGAGAACTTTTCA 712 
    ************************************************************ 
 
WT  GACTCATATCGAAAATGGGTAACAACTCTGAAGGAACTGTGTCTTTTTACAGCGTCGGGG 900 
Mut GACTCATATCGAAAATGGGTAACAACTCTGAAGGAACTGTGTCTTTTTACAGCGTCGGGG 772 
    ************************************************************ 
 
WT  TAGCTCAAATGGTAGAGTGGCAGGCCAACATAGCCAGCAGATCTCGGTTCAAACCCGAGC 960 
Mut TAGCTCAAATGGTAGAGTGGCAGGCCAACATAGCCAGCAGATCTCGGTTCAAACCCGAGC 832 
    ************************************************************ 
 















Mut CCTGACCA--------CACGTGTTATTCTAGACCTCTCTTCCAGCTAAGATAGCATGTGC 884 
    ********        ******************************************** 
 
WT  CGTCCTCTTTGTTTCCCAAGTCAGTATTCAAGCGCAGACCATCGCTGCCTGGTGGCTCAG 1080 
Mut CGTCCTCTTTGTTTCCCAAGTCAGTATTCAAGCGCAGACCATCGCTGCCTGGTGGCTCAG 944 
    ************************************************************ 
 
WT  CTACCGTGGAGTGTTTCCTCCCCATCACCCCGTCATAAGAGTATGCAAATCACAGTCAGT 1140 
Mut CTACCGTGGAGTGTTTCCTCCCCATCACCCCGTCATAAGAGTATGCAAATCACAGTCAGT 1004 
    ************************************************************ 
 
WT  GAAAGCAAGCTCTAAAGCTCTGGTCTGCTGATTGCCCCTCCGTCGGGGTAGCTCAATTGG 1200 
Mut GAAAGCAAGCTCTAAAGCTCTGGTCTGCTGATTGCCCCTCCGTCGGGGTAGCTCAATTGG 1064 
    ************************************************************ 
 
WT  TAGAGCGGCAGGCTCATCCCCTGCAGGTTCTCGGTTCAATCCCGGGTCCCGACGCAGAGT 1260 
Mut TAGAGCGGCAGGCTCATCCCCTGCAGGTTCTCGGTTCAATCCCGGGTCCCGACG------ 1118 
    ******************************************************       
 
WT  TGAGATCGGGTCGTCTCCCCCTGGCGGAAGGAGGCAAACCCGAGCTCCTCCTTCTTTTCA 1320 
Mut ------------------------------------------------------------ 
                                                                             
 
WT  ACCACCTCCCACAATTTCAGAGTCTTAGCCAGATTATCTGAAACTGTGTGAGGTGGTTTT 1380 
Mut -----------------------------------------------------TGGTTTT 1125 
    ******* 
 
WT  TTCTTTTCCCAGACCCCCAGATGTCCCAAGTCTTTTTCTTTTGGTGGAAACGCTTGCGAT 1440 
Mut TTCTTTTCCCAGACCCCCAGATGTCCCAAGTCTTTTTCTTTTGGTGGAAACGCTTGCGAT 1185 
    ************************************************************ 
 
WT  GGTCTAAACTCTTCGACCCACCCAGTGCCTTTCAAGCAGCGCACAGCCGCTTATGTACCC 1500 
Mut GGTCTAAACTCTTCGACCCACCCAGTGCCTTTCAAGCAGCGCACAGCCGCTTATGTACCC 1245 
    ************************************************************ 
 
WT  AGAAGACCATGTCTGGGAATTCCCCAATGACGCCAAAGTCTAAGTCCCTGTACAGGCTTA 1560 
Mut AGAAGACCATGTCTGGGTATTCCCCAATGACGCCAAAGTCTAAGTCCCTGTACAGGCTTA 1305 
    ***************** ****************************************** 
 
WT  ACTTTTTTAGAATTCCCTAAAACACTTGCCAGGGTAGCTCAATTGGTAGAGCATCAGGCT 1620 
Mut ACTTTTTTAGTATTCCCTAAAACACTTGCCAGGGTAGCTCAATTGGTAGAGCATCAGGCT 1365 
    ********** ************************************************* 
 
WT  AGTATCCTGTCGGTTCCGGTTCAAGTCCGGGCCCTGGTTAAAGGTGGAGGTGCGGTAACC 1680 
Mut AGTATCCTGTCGGTTCCGGTTCAAGTCCGGGCCCTGGTT--------------------- 1404 
    ***************************************                      
 
WT  TCCTAAGATTACTGTTGGGATATCGCGCCCACCTTTATTGTAAGGGTACTCTCATCACCA 1740 
Mut ------------------------------------------------------------ 
                                                                             
 
WT  ATGTAAATTAATATGTAGCAAACTTTGGTGTGGGAGTCCTACCCCTTTTGCTCCACAGGC 1800 
Mut -----------------------TTTGGTGTGGGAGTCCTACCCCTTTTGCTCCACAGGC 1441 



















Figure ‎5.2 Clustal 2.1 multiple sequence alignment.  
Alignment of the consensus sequence of the MHV-68.ΔmiRNAs BAC (Mut) 
against the WT-MHV-68 sequence (WT). All the non-aligned sequences are 
indicated including the 9 miRNAs and EcoRI sites. The vtRNA sequences in the 
MHV-68.ΔmiRNAs BAC were identical to that of the WT-MHV-68. 
 
























Figure 5.3 Analysis of BAC stability and miRNAs deletion. 
(A) Agarose gel electrophoresis of restriction digests of the parental WT MHV-68 and 
the MHV-68.ΔmiRNAs BACs. BAC DNA was digested with either XhoI or EcoRI 
enzyme overnight at 37oC followed by analysis of the resultant DNA fragments on 
0.8% agarose gel at 30 volt for 16 hours. (B) Agarose gel electrophoresis of the 
amplified PCR products that carries either WT miRNA sequence or miRNA sequence 
with deletion mutations. NIH 3T3 cells were infected with MHV-68.ΔmiRNAs virus or 
its wild-type counterpart at MOI of 5 for 24 hours. Genomic DNA (100 ng) from 
infected cells was used as a template. DNA extracted from uninfected cells was used 
as a negative control. NTC, no template control. Molecular size markers (M) are 
shown beside each gel. bp, base pairs. kb, kilobase pairs. 
 




5.3 The MHV-68.ΔmiRNAs virus lacks the expression of 
the deleted miRNAs 
 
In order to confirm that the miRNA mutations within the MHV-68.ΔmiRNAs 
genome eliminated the miRNAs expression, NIH 3T3 were infected with MHV-
68.ΔmiRNAs or WT-MHV-68 viruses at MOI of 0.001 for 6 days. qRT-PCR was 
carried out for detection of virus encoded miRNAs (Figure 5.4A). The mutations 
resulted in elimination of the mature miRNAs expression in cells infected with 
MHV-68.ΔmiRNAs virus. The miRNAs expression in these cells was comparable to 
the background level in the uninfected cells. The melting curve analysis showed that 
the apparent expression of low levels of some deleted miRNAs in the MHV-
68.ΔmiRNAs-infected cells and uninfected cells is due to non-specific products 
when compared to the melting curves of the WT-MHV-68-infected cells (Figure 8.3 
in the appendix). 
Notably, the intact miRNAs such as mghv-miR-M1-9-3p, mghv-miR-M1-13-3p, 
mghv-miR-M1-14-3p, and mghv-miR-M1-15-5p showed similar expression levels in 
cells infected with MHV-68.ΔmiRNAs or WT-MHV-68 virus (Figure 5.4A). qRT-
PCR was also carried out for detection of mature MHV-68 miRNAs in spleen at 14 
days following infection of BALB/c mice intranasally with 4x10
5 
PFU of MHV-
68.ΔmiRNAs or WT-MHV-68 viruses (Figure 5.4B). None of the deleted miRNAs 
were detected in splenocytes from the mouse infected with the MHV-68.ΔmiRNAs 














Figure ‎5.4 miRNA deletion mutations within the MHV-68.ΔmiRNAs virus genome 
resulted in elimination of miRNAs expression.  
(A) qRT-PCR for detection of mature miRNAs was carried out using RNA from NIH 3T3 cells 
infected with WT-MHV-68 or MHV-68.ΔmiRNAs viruses for 6 days at MOI of 0.001. 
Uninfected cells were used as a negative control. mmu-miR-191-5p was used as an 
endogenous cellular miRNA for normalisation. (B) qRT-PCR was performed for detection of 
MHV-68 miRNAs in spleens of BALB/c mice 14 dpi. The mice were infected intranasally with 
4x105 PFU of WT-MHV-68 or MHV-68.ΔmiRNAs viruses. The viral miRNAs expression were 
normalised to the cellular miRNA mmu-miR-191-5p. Splenocytes from an uninfected mouse 










Figure ‎5.4 miRNA deletion mutations within the MHV-68.ΔmiRNAs virus genome 
resulted in elimination of miRNAs expression. (A) qRT-PCR for detection of mature 
miRNAs was carried out using RNA from NIH 3T3 cells infected with WT-MHV-68 or MHV-
68.ΔmiRNAs viruses for 6 days at MOI of 0.001. Uninfected cells were used as a negative 
control. mmu-miR-191-5p was used as an endogenous cellular miRNA for normalisation. (B) 
qRT-PCR was performed for detection of MHV-68 miRNAs in spleens of BALB/c mice 14 dpi. 
The mice were infected intranasally with 4x105 PFU of WT-MHV-68 or MHV-68.ΔmiRNAs 
viruses. The viral miRNAs expression were normalised to the cellular miRNA mmu-miR-191-
5p. Splenocytes from an uninfected mouse were used as a negative control. 















Figure ‎5.5 The deleted miRNAs are dispensable for virus lytic replication. 
(A) Single-step virus replication growth curve was analysed by infecting NIH 3T3 cells at 
MOI of 5 with WT-MHV-68 or MHV-68.ΔmiRNAs viruses. Cells and supernatants were 
harvested at the indicated time-points post-infection and subjected to 3 cycles of freezing 
and thawing in order to disrupt the cells and release the virus. Viral titres were determined by 
plaque assay. The error bars represent SD ± mean of 2 experiments with 2 replicates per 
experiment. *, P<0.05 calculated by unpaired student’s t-test. (B) Viral titres in the lung were 
measured by plaque assay 5 days after infecting BALB/c mice intranasally with 4x105 PFU 
with WT-MHV-68 or MHV-68.ΔmiRNAs viruses. Each symbol represents individual animal. 
The error bars represent SD ± mean. 




5.4 The deleted miRNAs are not essential for lytic 
replication in vitro and in vivo 
 
In order to determine whether the MHV-68 miRNAs play a role during productive 
infection, a single-step analysis of virus replication was carried out using NIH 3T3 
cells infected with WT-MHV-68 or MHV-68.ΔmiRNAs virus at MOI of 5 for time 
intervals from 0-72 hours post-infection (Figure 5.5A). Viral titres were assessed by 
plaque assay.  There was a slight but statistically significant increase in the titres of 
MHV-68.ΔmiRNAs virus as compared to that of the WT-MHV-68 virus during some 
intermediate time-points; however, the replication of the miRNA mutant virus was 
almost identical to the WT-MHV-68 virus at early time-points and during the peak of 
viral titres (Figure 5.5A). 
 
This indicates that the deletion of the miRNAs did not interfere with the ability of the 
virus to replicate productively in vitro. In order to determine whether the miRNAs 
may alter virus replication in vivo, BALB/c mice were infected intranasally with 
4x10
5
 PFU WT-MHV-68 or MHV-68.ΔmiRNAs viruses. The viral titres in the lungs 
of infected mice 5 dpi were assessed using plaque assay (Figure 5.5B). It was found 
that the replication of the miRNA mutant virus was comparable to the WT virus in 
the lungs of the infected animals, indicating that the deleted miRNAs are not 
essential for lytic replication in vivo at this time-point post infection. 
 
5.5 Investigating the potential functions of the MHV-68 
miRNAs during the latent virus infection in vivo 
 




In order to evaluate the MHV-68.ΔmiRNAs virus ability to establish, maintain, and 
reactivate from latency, splenocytes harvested at different time points during latency 
from mice infected with WT-MHV-68 or MHV-68.ΔmiRNAs viruses were subjected 
to parallel assays. These assays were aimed at determining the ability of the virus to 
reactivate from la Published data indicate that expression of CD69 on B cells is 
significantlytency ex vivo, detecting the presence of produced infectious virus, 
measuring the viral DNA genomic load, and measuring the level of viral lytic and 
latency-associated mRNA expression. 
5.5.1 MHV-68 miRNAs are not essential for establishment of 
latency, but control the virus reactivation during late latency 
 
In order to determine the ability of the MHV-68.ΔmiRNAs virus to reactivate from 
latency, infective centre assays were performed and spontaneous ex-vivo reactivation 
was measured. For this purpose, BALB/c mice were infected intranasally with 4x10
5
 
PFU of WT-MHV-68 or MHV-68.ΔmiRNAs viruses. Splenocytes were harvested at 
5, 10, 14, 21, 28, and 49 dpi and were co-cultivated with BHK-21 cells for 5 days to 
allow virus reactivation from splenocytes. The number of infective centres (virus 
plaques) was determined by plaque assay as a measurement of the number of the 
cells containing reactivatable virus (Figure 5.6A). During early latent infection and 
the establishment of latency, the number of infective centres in splenocytes from 
MHV-68.ΔmiRNAs-infected mice was comparable to that of the WT-MHV-68-
infected mice except at day 21 post infection when there was a slight (2.7-fold) but 
significant increase in the number of the infective centre with the MHV-
68.ΔmiRNAs virus as compared to the WT-MHV-68 virus; however, this difference 
disappeared at 28 dpi (Figure 5.6A). Interestingly, at 49 dpi, during late latency, 
there was a statistically significant (P=0.024) increase in the reactivation level in the  























      
  
Figure ‎5.6 MHV- 68 miRNAs are not essential for establishment of latency, but can 
control reactivation during long-term latency. 
BALB/c mice were infected with 4x105 PFU of MHV-68.ΔmIRNAs virus or WT-MHV-68 
virus intranasally. Four to five mice were used per group per time-point. (A) Infective 
centre assays were carried out using single-splenocyte suspensions at the indicated time-
points post-infection. Different numbers of splenocytes (105, 106, and 107) from mice 
infected with WT-MHV-68 virus or the miRNA deletion mutant virus at the indicated time-
points were co-cultivated with 106 BHK-21 cells for 5 days at 37oC as described in the 
materials and methods. The virus infective centres were counted and data are presented 
as infective centres per 107 infected splenocytes, Error bars represent mean values ± SD. 
(B) The presence of produced infectious virus was determined by disruption of parallel 
splenocyte by 3 freeze-thaw cycles and adding an equivalent volume of 107 splenocytes to 
106 BHK-21 cells for 4 days at 37oC before counting the virus plaques. (C) Viral DNA 
genomic load was determined at the indicated time-points by qPCR. Genomic DNA was 
extracted from infected splenocytes and 100 ng DNA was used as a template for 
quantification of the viral genome levels using ORF50 (RTA) primers. The data are 
presented as viral genome copy numbers normalised against 103 cellular genome copy 
numbers (SDHA primers). The error bars represent mean values ± SD. The Statistically 
significant differences from the WT virus were determined by Mann-Whitney test and are 
indicated by an asterisk. *, P<0.05. 
 




splenocytes from mice infected with the MHV-68.ΔmiRNAs virus by approximately 
18.2-fold higher than that of the mice infected with the WT-MHV-68 virus (Figure 
5.6A). Parallel splenocyte samples were disrupted by 3 cycles of freezing and 
thawing and were used to measure the amount of any produced infectious virus 
(Figure 5.6B). Disruption of the splenocytes prevents the virus from reactivation 
without damaging the intact virus particles (Weck, Kim et al. 1999). No virus 
plaques were detected in samples from any group at any time-point (Figure 5.7B). In 
order to determine the viral DNA genomic load in the infected splenocytes, qPCR 
was carried out using DNA extracted from splenocytes from mice infected with WT-
MHV-68 or MHV-68.ΔmiRNAs viruses at 10, 14, 21, 28, and 49 dpi (Figure 5.6C). 
There was no statistically significant difference between the viral genomic loads in 
the spleens of mice infected with the WT-MHV-68 virus or the MHV-68.ΔmiRNAs 
virus at any time-point; however, there was a trend towards higher viral genomic 
load in the mice infected with the miRNA mutant virus than those infected with the 
WT virus (approximately 6-fold difference). These results indicate that the MHV-68 
miRNAs are not essential for the establishment of latency, but suggest they may play 
a role in controlling reactivation and promoting latency maintenance at later time-
points (e.g. 49 dpi). 
 
5.5.2 The lack of MHV-68 miRNAs resulted in increased levels of 
viral lytic gene expression during late latency 
 
Because the ex vivo reactivation level of MHV-68.ΔmiRNAs virus was higher than 
that of the WT-MHV-68 virus at 49 dpi, it was important to compare the expression 
levels of the lytic genes of the two viruses at this time-point. During latency, 
particularly late latency, the viral gene expression is highly restricted and the basal 




expression levels are usually below or close to the detection limit of the qRT-PCR 
assays (~ 32-35 cycles); therefore, accurate quantification by directly measuring the 
absolute mRNA copy numbers is difficult. In order to quantify viral gene expression 
at 49 dpi, the level of viral mRNA expression in splenocytes from mice infected with 
MHV-68.ΔmiRNAs or WT-MHV-68 were determined as fold change compared to 
the qRT-PCR background signal in splenocytes from uninfected mice (Figure 5.7). 
Expression levels of the immediate-early RTA, early DNA pol, and late ORF65 
transcripts were determined (Figure 5.7A, B, and C). In addition, the expression 
levels of the latency-associated mRNA ORF73 (mLANA) and the M3 transcript 
were also determined (Figure 5.7D and E).  
 
Strikingly, the expression level of the M3 transcript, that encodes a secreted broad 
spectrum chemokine-binding protein that is abundantly expressed during lytic 
infection and early latency (Parry, Simas et al. 2000, Rochford, Lutzke et al. 2001), 
in mice infected with MHV-68.ΔmiRNAs virus was 4.7-fold higher than the 
background level and 5.5-fold significantly higher than its expression in mice 
infected with the WT-MHV-68 virus (Figure 5.7E). Although the difference in 
expression levels of RTA, DNA pol, ORF65, and ORF73 between the mice infected 
with MHV-68.ΔmiRNAs or WT-MHV-68 viruses were not statistically significant, 
the abundance of these transcripts was always higher in the mice infected with the 
miRNA mutant virus. For example, in 2 mice infected with MHV-68.ΔmiRNAs 
virus, the expression level of ORF65 mRNA, a late transcript that is proposed to 
encode a capsid protein (Wu, Tong et al. 2001), was approximately 7- and 9-fold 
higher than the background level, whereas none of the mice infected with the WT-
MHV-68 showed expression of ORF65 mRNA higher than the background level  




































Figure ‎5.7 Expression of viral mRNAs at 49 dpi in the spleen. 
qRT-PCR was carried out in order to detect the presence of lytic and latency-
associated viral gene expression during late latency (49 dpi). RNA from splenocytes 
recovered from mice infected with WT-MHV-68 virus (n=5) or MHV-68.miRNAs virus 
(n=4) were extracted and 500 ng RNA were used for cDNA synthesis. qRT-PCR 
assays were carried out following 1:10 dilution of the cDNAs as described in Materials 
and Methods using primers specific for RTA (A), viral DNA pol (B), ORF65 (C), ORF73 
(D), and M3 (E). qRT-PCR using RNA from splenocytes of an uninfected mouse was 
used to determine the CT values for any non-specific products produced Data are 
presented as fold change of expression levels in infected samples as compared to the 
background level in the uninfected samples that is considered 1 (dotted line) based on 
the 2-ΔΔCT method. In cases when the qRT-PCR amplification curve did not cross the 
cycle threshold, the CT value was considered 40. The cellular reference mRNA, SDHA, 
was used as an endogenous control for normalisation of any experimental variability. 
Each symbol represents an individual animal. Error bars represent mean values ± SD. 
Statistical significance was determined by Mann-Whitney test. *, p<0.05. 
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Figure 5.8 Viral mRNA expression and detection of viral genomic DNA during late 
latency (49 dpi) in the spleen. 
qRT-PCR products of the assays described in figure 5.8 and qPCR products of the assays 
described in figure 5.7C (49 dpi) were analysed by agarose gel electrophoresis. qRT-PCR and 
qPCR reactions were carried out in triplicates in 20 µl final volume per reaction. The qRT-PCR 
or qPCR products were pooled from the 3 reactions and 20 µl were loaded on 3% NuSieve gel. 
The expected qRT-PCR product sizes are as follow: RTA (138 bp), ORF73 (129 bp), DNA pol 
(107 bp), ORF65 (84 bp), M3 (381 bp), and SDHA (157 bp). The numbers above the gel 
represent individual mice. M, marker. NTC, no template control. Uninf, uninfected. NoRT, no 
reverse transcriptase control. RNA aliquots from spleens from each group were pooled and 
500ng RNA were used to synthesise the NoRT controls. Colour was inverted for clarity. 
 




(Figure 5.7D). These experiments were done once and further work is needed to 
confirm these results and a larger number of animals may be required to establish 
statistically significant differences. 
 
In order to confirm that the qRT-PCR CT values of the above mentioned viral 
transcripts were representing true qRT-PCR targets, the qRT-PCR products of these 
transcripts were analysed by agarose gel electrophoresis (Figure 5.8). The agarose 
gel electrophoresis analysis showed  
the expected sizes of the qRT-PCR products for the mRNAs and it was consistent 
with the qRT-PCR relative quantification in terms of mRNAs abundance. These 
results indicate that the splenocytes from mice infected with the miRNA mutant virus 
were undergoing lytic cycle infection at 49 dpi and that the lytic genes were 
expressed at levels higher than the basal levels in the splenocytes from mice infected 
with the WT virus at 49 dpi. The lack of produced infectious virus at this time-point 
is most likely due to the fact that the level of lytic infection is very low and therefore 
beyond the limit of detection of the conventional plaque assay or because the 
majority of lytically infected cells would be rapidly eliminated by the immune 
system.  
 
Increased reactivation of MHV-68 virus in the spleen was previously shown to be 
accompanied by increased virus replication in the lung (Gargano, Forrest et al. 2009). 
In order to determine whether the increased virus reactivation in the splenocytes 
from mice infected with 
MHV-68.ΔmiRNAs virus was accompanied by increase in the level of virus 
replication in the lung, the lungs were harvested from the mice infected with MHV-




68.ΔmiRNAs or WT-MHV-68 viruses and qPCR assays were carried out using 
genomic DNA extracted from theses lungs for quantification of viral genomic loads. 
Interestingly, the MHV-68.ΔmiRNAs genomic load was significantly higher than 
that of the WT-MHV-68 by approximately 2.6-fold (Figure 5.9). Collectively, these 
results indicate that the MHV-68 miRNAs are important for controlling unwanted 
reactivation and initiation of virus lytic cycle during the maintenance of latency. 
5.5.3 The lack of MHV-68 miRNAs did not alter viral mRNA 
expression during the establishment of latency in spleen at 14 
dpi and as late as 28 dpi 
 
In order to determine whether the MHV-68 miRNAs may change the viral mRNA 
expression pattern during the establishment of latency and later time-points of 
latency, qRT-PCR was performed on RNA extracted from mice infected with the 
miRNA mutant virus or its WT counterpart at 14, 21, and 28 dpi for quantification of 
RTA, ORF73, ORF65, and M3 transcripts (Figure 5.10). It was found that the 
differences between tested viral mRNAs expression levels in splenocytes from mice 
infected with the MHV-68.miRNAs or WT-MHV-68 viruses were not statistically 
significant at any time-point. 
 
5.5.4 Investigating B lymphocyte activation and proliferation in 
spleens from mice infected with the MHV-68.ΔmiRNAs virus 
 
In order to determine whether the MHV-68 miRNAs are involved in the virus-
induced B cell activation in the spleen, BALB/c mice were infected with 4x10
5
 PFU 
of MHV-68.ΔmiRNAs or the WT virus and spleens were harvested at 5, 10, 14, 21, 
or 28 dpi. Single-cell suspensions were prepared and B lymphocytes were labelled 




with the anti-CD19 antibody and anti-CD69 antibody was used as a marker of B cell 
activation for the flow cytometric analysis (Figure 5.11). Mediastinal lymph nodes 
(MLN) were harvested from 3 mice at 5 dpi and the cells were pooled and used as a 
positive control for B cell activation. There were no significant differences in B cell 
activation between in B cells from mice infected with the miRNA mutant virus or the 
WT virus at any time-point post infection (Figure 5.12). The percentage of activated 
B cells (CD19+CD69+) was approximately 11% of total B cells in the MLN at 5 dpi 
(Figure 5.12). However, the percentage of activated B cells in spleens of wild type 
and MHV-68.ΔmiRNAs virus infected mice during the peak of viral latency (14 dpi) 
was approximately 1.8% of the total B cells analysed and was statistically non-
significant relative to that of the uninfected (approximately 1.3 % of total B cells).    







Figure ‎5.9 Viral DNA genomic load in the lung at 49 dpi. 
DNA (100ng) extracted from lungs of mice infected with WT-MHV-68 or 
MHV-68.ΔmiRNAs viruses were used to quantify the viral genomic load 
by qPCR. The data are presented as viral genome copy numbers (RTA 
primers) per 103 cellular genome copy numbers (SDHA primers). Error 
bars represent means ± SD. Each symbol represents individual animal. 








   
Figure ‎5.10 Viral mRNA expression during latent infection in the spleen. 
qRT-PCR assays were carried out to quantify the expression of RTA, ORF73, ORF65, 
and M3 transcripts in the spleens of mice infected with WT-MHV-68 or MHV-
68.ΔmiRNAs viruses at 14, 21, and 28 dpi. RNA (500ng) extracted from the splenocytes 
of infected animals were reverse transcribed into cDNA for the qRT-PCR. The data are 
presented as viral transcript copy numbers per 103 endogenous transcript SDHA copy 
numbers. Error bars represent mean values ± SD. Five mice per group per time-point 
were used. 
 




Published data indicate that expression of CD69 on B cells is significantly elevated 
compared to uninfected mice at this time point  (Stevenson and Doherty 1999).  This 
suggests that the CD69 antibody was not used at optimum concentration or under 
optimum conditions and casts doubt on the reliability of the data.  Therefore further 
work is needed to evaluate the role role of the miRNAs in B cell activation. MHV-68 
miRNAs are not essential for the virus-induced B lymphocyte proliferation in vivo. 
  
In order to determine whether the MHV-68 miRNAs may play a role in the virus-
induced B cell proliferation in the spleen, BALB/c mice were infected with 4x105 
PFU of the MHV-68.ΔmiRNAs virus or the WT virus and spleens were harvested at 
5, 10, 14, or 28 dpi. A single-cell suspension was prepared and B lymphocytes were 
labelled with the anti-CD19 antibody and anti-ki67 antibody which is a marker of 
cellular proliferation (Figure 13.A). There was a small but statistically significant 
increase in the B cell proliferation in mice infected with the MHV-68.ΔmiRNAs 
virus as compared to mice infected with the WT virus at 14 dpi, this difference 
disappeared at 28 dpi and was not detected at the earlier time-points (Figure 5.13.B). 
The weight of the spleens was used as a measurement of splenomegaly (Figure 
5.13.C). There were no statistically significant differences between the weights of the 
spleens from mice infected with the WT-MHV-68 or the MHV-68.ΔmiRNAs viruses 
at any time-point. As splenomegaly is due to the increase in cell numbers of both T 
and B cells in the spleen it is possible that measurement of spleen weight is not 
sensitive enough to detect differences in B cell proliferation.  
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Figure ‎5.11 Representative flow cytometric analysis for measurement of B cell 
activation in mice spleens at 14 days following WT-MHV-68 or MHV-68.ΔmiRNAs 
infections (n=5). 
Single-cell suspensions from spleens or lymph nodes from infected mice were 
labelled with anti-CD19-PE antibody (B cell marker) and ant-CD69-FITC antibody (B 
cell activation marker) for detection of activated B cells (CD19+CD69+) in the 
lymphocyte population. The small plots on the right side of the main plots show the 
gating for the lymphocyte population in single cell suspensions (boxed gates) based 
on forward and side scatter of laser light.  Isotype antibodies were used with cells 
pooled from all the samples as a negative control for detection of non-specific 
background signals caused by the primary antibodies. Splenocytes from uninfected 
mice were used as a negative control for B cell activation (n=2). The mediastinal 
lymph nodes (MLN) from mice infected with WT-MHV-68 at 5 dpi were used as a 
positive control for B cell activation (n=3, pooled). 
 





Figure ‎5.12 B cell activation in the spleen. 
Expression of CD69 on CD19+ B cells as a measurement of B cell activation 
following infection of BALB/c mice with the miRNA mutant virus or its WT 
counterpart at the indicated time-points. The data represent the per cent of 
CD69+CD19+ cells of the total CD19+ B cells. Cells from mediastinal lymph 
nodes (MLN) of 3 mice infected with the WT-MHV-68 virus at 5 dpi were 
harvested at 5 dpi, pooled, and used as a positive control for B cell activation 
(grey bar). Cells harvested from spleens of uninfected mice were used as a 
negative control for B cell activation (black bar). 
 






MHV-68 provides a unique small animal model for studying the possible functions 
of gammaherpesvirus miRNAs during the natural course of infection. Such functions 
are difficult to assess in the human gammaherpesviruses due to the narrow host range 
of herpesviruses. In order to examine the potential roles of MHV-68 miRNAs during 
the virus life cycle, a recombinant virus lacking 9 pre-miRNAs was constructed 
using homologous recombination on the backbone of the MHV-68 wild-type BAC. 
The miRNAs expression was successfully abolished and the miRNAs were not 
detected by qRT-PCR in NIH 3T3 fibroblasts and in splenocytes from mice infected 
with the miRNA mutant virus. In order to determine the potential roles of MHV-68 
miRNAs in the virus life cycle, a series of in vitro and in vivo assays were carried 
out. 
 
The MHV-68.ΔmiRNAs virus replicated productively in vitro to levels that are 
similar to that of the WT virus; however, there was minor but statistically significant 
increase in MHV-68.ΔmiRNAs virus titres in some intermediate time-points in the 
single-step growth curve. The exact reason for that is not clear, but it is possible that 
there was increased MHV-68.ΔmiRNAs virus release at these time-points possibly 
because the miRNAs may play roles in restricting lytic infection. During in vivo lytic 
infection in the lung, the MHV-68.ΔmiRNAs virus replicated to levels comparable to 
that of the WT virus. These results indicate that the MHV-68 miRNAs are not 
essential for the lytic replication. 
 
It was found that the lack of MHV-68 miRNAs did not alter the ability of the virus to 
establish latent infection in vivo. In addition, the ex vivo reactivation of the 




splenocytes infected with the MHV-68.ΔmiRNAs virus was comparable to that 
infected with the WT virus during early latency and at 28 dpi and the viral genomic 
loads of both viruses were similar at these splenocytes infected with the MHV-
68.ΔmiRNAs virus was comparable to that infected with the WT virus during early 
latency and at 28 dpi and the viral genomic loads of both viruses were similar at 
these time-points. However, during late latency (7 weeks post-infection), the 
reactivation level of the MHV-68.ΔmiRNAs-infected splenocytes was significantly 
higher (P=0.024) than the WT-MHV-68-infected splenocytes.   
 
The mRNA levels of RTA, DNA pol, ORF65, and ORF73 in the splenocytes from 
mice infected with the MHV-68.ΔmiRNAs were higher than that of the mice infected 
with the WT MHV-68 at 49 dpi, although statistically non-significant. Notably, M3, 
which is an early-late transcript that encodes a secreted chemokine-binding protein 
(Parry, Simas et al. 2000, Rochford, Lutzke et al. 2001, Ebrahimi, Dutia et al. 2003), 
was the most highly expressed transcript among the tested viral mRNAs during 
MHV-68.ΔmiRNAs virus infection at 49 dpi, whereas its expression was below level 
of detection during the WT-virus infection at the same time-point. It has been 
previously shown that the 600 bp of the sequence upstream of the M3 TATA box 
contain an RTA responsive element and that M3 is regulated by RTA in the absence 
of other viral factors (Martinez-Guzman, Rickabaugh et al. 2003). The same study 
also showed that M3 was one of the most highly expressed transcripts in BHK-21 
cells infected with a recombinant MHV-68 virus overexpressing RTA This may 
explain why M3 was the transcript whose expression increased the most at 49 dpi in 
the splenocytes from mice infected with the MHV-68.ΔmiRNAs virus, which were 
undergoing an increased level of reactivation and lytic cycle progression.  



















  Figure ‎5.13 B cell proliferation in the spleen. 
(A) Representative flow cytometric analysis for measurement of B cell proliferation in 
mice spleens at 14 days following WT-MHV-68 or MHV-68.ΔmiRNAs infections (n=5). 
Single-cell suspensions from spleens of infected mice were labelled with anti-CD19-
PE antibody and ani-ki67 antibody (B cell proliferation marker) for detection of 
proliferating B cells (CD19+ki-67+) in the lymphocyte population. The small plots on 
the right side of the main plots show the gating for the lymphocyte population in single 
cell suspensions (boxed gates). Splenocytes from uninfected mice were used as a 
negative control for B cell proliferation (grey bar, n=2). (B) Measurement of B cell 
proliferation using anti-ki-67 antibody for labelling proliferating CD19+ B cell following 
mice infection at the indicated time-points with either MHV-68.ΔmiRNAs or WT-MHV-
68 viruses. Data represent the per cent of CD19+ki67+ cells of the total CD19+ cells. 
P-value was determined by Student’s t test. *, P<0.05. (C) BALB/c mice were infected 
intranasally with 4x 105 PFU of WT-MHV-68 or MHV-68.ΔmiRNAs viruses. Spleens 
were harvested and weighed at the indicated time-points. Data are represented as 
mean ± SD. Four to five mice were used per group per time-point. 




In support of this, the results also show an increase in the MHV-68.ΔmiRNAs viral 
genomic load. No infectious virus was detected by plaque assay in these spleens but 
this may be because the levels are too low to be detected by this method or because 
the immune system had rapidly cleared the lytically infected cells. Taken together, 
the increased level of reactivation and the higher levels of lytic mRNA expression 
support the hypothesis that the miRNAs play a role in control of latent-lytic switch at 
this late time point. This finding is consistent with a recently published study in 
which an MHV-68 lacking all the miRNAs and vtRNAs showed higher viral 
genomic load in the spleen at 42 dpi by qPCR; however, the authors could not detect 
ex-vivo reactivation (Steer B et al., 2016).  
 
Interestingly, when the viral genomic loads in the lungs from mice infected with 
either the MHV-68.ΔmiRNAs virus or its WT counterpart virus at 49 dpi were 
determined, there was significant increase in MHV-68.ΔmiRNAs genome load 
compared to that of the WT-virus. It is not clear whether the reactivating virus in the 
spleen re-infected the lung or the latently infected cells in the lung underwent 
reactivation. Measuring the level of infectious virus, if any, and determining the viral 
mRNA expression profiles in the lung at this time-point could be helpful in gaining 
further insight into this. Given the higher reactivation rate and the presence of lytic 
transcripts at higher levels during MHV-68.ΔmiRNAs infection than during WT-
virus infection in spleen at 49 dpi, it is reasonable to assume that the miRNAs can 
function as control valves that prevent precocious reactivation and control exit from 
long-term latency. 
 




When the expression levels of the viral mRNAs, ORF50, ORF73, ORF65, and M3, 
were determined at earlier time-points than 7 weeks post-infection such as 14, 21, 
and 28 dpi in the splenocytes from mice infected with the miRNA mutant or WT 
viruses, there were no significant differences in the expression of these mRNAs at 
any time-point. Although, the similar mRNA levels does not guarantee similar 
protein levels because the miRNAs may target mRNAs via translational repression 
rather than mRNA degradation, the absence of a prominent phenotype at these time-
points suggests that either the tested mRNAs are not targeted by the miRNAs that 
were deleted from the MHV-68.∆miRNAs virus or the miRNA-mediated 
translational inhibition, if any, is too slight to cause a pronounced phenotype. 
One of the prominent features of MHV-68 infection is the virus-induced B 
lymphocyte proliferation. It has been shown that EBV-encoded miRNAs can 
promote cell cycle progression and induce proliferation of primary human B cells 
(Seto, Moosmann et al. 2010, Vereide, Seto et al. 2014). In this study, the B cell 
proliferation was examined in splenocytes of mice infected with the WT or the 
miRNA mutant virus during various time-points of latency. It was found that the 
deleted miRNAs are dispensable for the virus-induced B cell proliferation in vivo at 
days 5, 10, and 28 post infection; however, there was slight but statistically 
significant increase in B-cell proliferation in splenocytes from mice infected with the 
miRNA mutant virus as compared to that of the WT virus at 14 dpi. This is a 
surprising finding because it was thought that the MHV-68 miRNAs may play a role 
in enhancing B cell proliferation in a manner similar to that of the EBV miRNAs 
(Seto, Moosmann et al. 2010). miRNAs from the same virus can have contradictory 
functions. For example, EBV-miR-BART15-3p has been shown to inhibit cell 
proliferation and to induce apoptosis in a gastric cancer cell line, whereas the 




majority of the BART miRNAs promote proliferation in this cell line (Choi, Lee et 
al. 2013), but the total effect of the EBV miRNAs is towards increased cell 
proliferation. It is possible that one or more miRNAs that were deleted in the MHV-
68.ΔmiRNAs virus may play a role in inhibiting B cell proliferation in a manner 
similar to that of EBV-miR-BART15-3p miRNA. In the MHV-68.ΔmiRNAs virus, 9 
miRNAs were deleted while the other 6 miRNAs were intact and this may have 
slightly shifted the total effect towards more B cell proliferation in the mice infected 
with this mutant virus. It important to note that due to time constraints the in vivo 
experiments using the MHV-68.ΔmiRNAs virus were carried out once and further 
work is needed to confirm the role of the miRNAs during the latent infection.  
 
Whilst it is tantalising that the miRNA mutant virus displayed a hyper-reactivation 
phenotype at 49 dpi, a revertant virus will be needed in order to confirm that this 
phenotype is due to the miRNAs deletions and not any other random mutation within 
the virus genome. Alternatively, a whole-genome high-throughput sequencing of the 
MHV-68.ΔmiRNAs genome could confirm that the MHV-68.ΔmiRNAs genome 
does not carry any unintended mutations. When the leftmost end of the original BAC 
derived WT MHV-68 genome was sequenced, it was found that the first 56 bp are 
missing. It would therefore be useful to use WT-MHV-68 field strain as an additional  
control in future experiments.  
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6   Chapter 6: Discussion 
 
6.1 Expression of MHV-68 encoded miRNAs 
 
To establish a qRT-PCR platform for detection and quantification of the MHV-68 
mature miRNAs expression during latency in vivo, expression of a defined set of 
previously confirmed or predicted mature miRNAs was first determined in cells lytically 
or latently infected in vitro.  In this study, it was shown that the pattern of miRNAs 
expression depends on both the phase of infection and the infection model employed. 
For instance, mghv-miR-M1-9-3p was among the least abundant miRNAs during lytic 
infection NIH 3T3 cells, but it was one of the most abundant miRNAs during latent 
infection in NS0 cells and in splenocytes from infected mice, suggesting that this 
miRNA may play a more fundamental role during latent infection. Although mghv-miR-
M1-14-3p was one of the least expressed miRNAs in latently infected NS0 cells, it was 
one of the highly expressed miRNAs in splenocytes, suggesting that cell lines are not 
necessarily valid models for characterisation of miRNAs that are expressed in vivo. 
These differences can be due to differential processing of the miRNAs transcripts. This 
is consistence with the presence of post-transcriptional regulatory pathways that control 
cell type-specific maturation of viral and cellular miRNAs (Dolken, Perot et al. 2007, 
Michlewski, Guil et al. 2008). In addition, the stability of the miRNAs can be influenced 
by the protection by the RISC Argonaute proteins and the presence of the target mRNAs 
(Chatterjee and Grosshans 2009, Kai and Pasquinelli 2010), which may be present at 
levels that are different between NS0 cells and splenocytes. 
 





All the tested miRNAs were detected as early as 2 hpi except mghv-miR-M1-4-5p, 
indicating that the miRNAs are transcribed early after infection. This is consistent with 
previous published studies that demonstrated the immediate early transcription kinetics 
of the vtRNAs, which contain RNA pol III promoters that drive the miRNAs expression 
(Ebrahimi, Dutia et al. 2003, Marques, Efstathiou et al. 2003, Pfeffer, Sewer et al. 2005, 
Cliffe, Nash et al. 2009). It can also be speculated that MHV-68 miRNAs may be 
packaged within the virion particles in a similar way to that of the vtRNAs (Cliffe AR et 
al., 2009). Although MHV-68 miRNAs are thought to play a major role during latency, 
the detection of MHV-68 miRNAs early after lytic infection suggests a role played by 
these miRNAs during this stage of infection. This role is not yet clear. It is possible that 
the miRNAs can counteract innate immunity immediately after infection by targeting 
signaling pathways involved in cellular sensing of viral DNA.  
 
Interestingly, there was a large variation in the expression levels of individual miRNAs 
within the same cell type. For example, the expression level of the most abundant 
miRNA in infected NIH 3T3 cells, mghv-miR-M1-7-3p, was approximately 10,400-fold 
higher than the expression level of the least abundant miRNA, mghv-miR-M1-4-5p in 
the same cell line. The expression level of the most abundant miRNA, mghv-miR-M1-1-
3p, in infected NS0 cells and splenocytes from infected mice was approximately 4,460- 
and 68-fold higher than that of the least abundant miRNA, mghv-miR-M1-4-5p, 
respectively. This large variation in miRNAs expression levels could be due to 
differences in the stability of individual miRNAs within the same cell type and/or 
variation in the efficiency of miRNA maturation from the primary transcript.  





Interestingly, miRNAs that are associated with the same vtRNA and are transcribed by 
from the same RNA pol III promoter showed different expression profiles. For example, 
the expression level of mghv-miR-M1-1-3p, which is processed from a primary miRNA 
that is associated with vtRNA1, was 331-, 450-, and 11-fold higher than that of mghv-
miR-M1-10-3p, which is processed from a primary miRNA that is associated with the 
same vtRNA, in NIH 3T3 cells at 24 hpi, NS0 cells at 5 dpi, and splenocytes at 14 dpi 
respectively. This suggests that these miRNAs may undergo regulation at the post-
transcriptional level. 
 
While this work was in progress, Feldman and colleagues described a similar 
quantitative study of MHV-68 miRNAs expression in a number of cell lines and in 
splenocytes from infected mice (Feldman, Kara et al. 2014). Their overall conclusions 
are broadly similar to those of the present work. For example, they showed that the 
MHV-68 miRNAs expression is dependent on cell type and stage of infection and that 
the individual miRNAs expression levels varied widely within the same cell line. The 
authors also showed that the expression of the majority of the 17 tested mature miRNAs 
was induced after lytic infection of NIH 3T12 fibroblasts with peak of expression at 16, 
24, or 48 hpi.  
 
Despite these similarities, there were a number of discordant results between the two 
studies. For instance, mghv-miR-M1-7-3p and mghv-miR-M1-1-3p were the most 
abundant miRNAs during NIH 3T3 fibroblasts lytic infection in the current study, 
whereas they were among the least abundant miRNAs during NIH 3T12 fibroblasts lytic 
infection in their study. In addition, although the mghv-miR-M1-1-3p and mghv-miR-





M1-9-3p were the most highly expressed miRNAs in splenocytes from infected mice at 
14 dpi in the present study, they were among the least abundant miRNAs in splenocytes 
from infected mice at 16 dpi in their study. These differences are likely due to the 
different qRT-PCR platforms used in these studies. The TaqMan stem loop PCR assays 
were used in their study for quantification of the mature MHV-68 miRNAs, whereas the 
poly (A) tailing followed by universal RT reaction and qPCR assays were used in the 
present study for this purpose. The stem-loop PCR assays cannot detect previously 
unpublished alternate mature miRNAs sequences and miRNA isoforms (isomiRs) that 
may be present as a result of post-transcriptional modification. In contrast, the SYBR 
green qRT-PCR assays can detect previously unpublished alternate mature miRNAs 
sequences, particularly 3’ isomiRs. It is also likely that the different mouse strains used 
in the 2 studies (C57BL6/J mice in Feldman study and BALB/c mice in the current 
study) may lead to differences in miRNAs expression levels; possibly as a result of 
differential miRNAs processing between the 2 mouse strains.  
 
6.2 MHV-68 miRNAs and in vitro reactivation 
 
PMA is a potent inducer of MHV-68, KSHV, and EBV reactivation in latently infected 
cells through induction of protein kinase C activity and RTA expression (Davies, Grand 
et al. 1991, Renne, Zhong et al. 1996, Miller, Heston et al. 1997, Zhu, Cusano et al. 
1999, Wang, Wu et al. 2004, Forrest and Speck 2008). Interestingly, the expression of 
the latency associated ORF73 mRNA was induced after PMA treatment, which is 
consistent with a previous finding that ORF73 expression was induced following PMA-
induction in latently infected murine B cell line (Forrest and Speck 2008). In support of 





these findings, Forrest and colleagues (Forrest, Paden et al. 2007) found that an ORF73-
null MHV-68 virus was deficient in lytic infection in murine fibroblasts and in lungs 
from infected mice, indicating a role played by mLANA protein during lytic infection. 
The same study proposed that this role may be played through the mLANA dependent 
regulation of p53 transcription factor that enhances MHV-68 gene expression and lytic 
replication. It is therefore likely that mLANA may play similar roles following PMA-
induced reactivation of latently infected NS0 cells. 
 
The expression kinetics of the MHV-68 encoded miRNAs were evaluated following 
PMA-induced virus reactivation in NS0 cells. Determination of the ratio of the miRNAs 
expression level to the viral genome level over time following reactivation revealed that 
a number of the miRNAs was down-regulated, while others were up-regulated after the 
PMA-induced reactivation, indicating that the expression of the MHV-68 miRNAs is 
differentially regulated during virus reactivation in vitro and that the miRNAs may have 
various roles in modulating virus reactivation.   
 
6.3 The expression of MHV-68 miRNAs is independent of 
virus DNA replication 
 
There has been evidence that the MHV-68 vtRNAs that are associated with the miRNAs 
have immediate-early expression kinetics (Ebrahimi, Dutia et al. 2003). The MHV-68 
mature miRNAs could be detected as early as 2 hpi during lytic infection in NIH 3T3 
cells (chapter 3). In the present study, an antiviral thionucleoside analogue that can 
inhibit MHV-68 viral DNA replication without interfering with viral latency, 4'-S-EtdU 





(Barnes, Dyson et al. 1999), was used to inhibit productive viral DNA replication in 
MHV-68-infected NS0 cells followed by evaluation of viral mRNAs and miRNAs 
expression. Although the NS0 cell line supports MHV-68 latent infection, approximately 
5 % of the infected cells undergo reactivation and lytic gene expression (Nash, Dutia et 
al. 2001).  
 
It was found that the miRNAs expression levels in the 4'-S-EtdU-treated and untreated 
MHV-68 infected NS0 cells at 48 hours post-treatment were similar, indicating that the 
expression of the MHV-68 miRNAs is independent of viral DNA synthesis. It is 
therefore plausible to suggest that these miRNAs may play roles during latent virus 
infection when the viral DNA replication is highly restricted. It is important to note that 
NS0 cells predominantly support latent infection and there are only approximately 5% of 
the cells that may undergo lytic replication. It is possible that the inhibition of lytic 
replication in infected NS0 cells by 4'-S-EtdU may not be sufficient for detecting 
differences in miRNAs expression due to the small proportion of lytically infected cells. 
However, the decrease of viral genomic load level and the late transcript, ORF65, 
expression level following 4'-S-EtdU treatment of infected NS0 cells indicates that this 
approach can be valid. 
 
6.4 Kinetics of MHV-68 mature miRNAs expression during 
latency in vivo 
 
A recombinant MHV-68 virus that carries a β-lactamase gene fused to ORF73, MHV-
68.ORF73βla, was used to detect and isolate latently infected spleen cells (β-lactamase 





positive/mLANA positive) in vivo by flow cytometry, allowing for assessing the 
expression levels of the viral miRNAs in these cells. Although, this virus was shown to 
establish latency at comparable levels to that of the wild-type virus (Nealy, Coleman et 
al. 2010). In the current study, MHV-68.ORF73βla latent genomic load and 
splenomegaly were significantly lower than that of the wild-type virus.  
 
Given the latency attenuation of MHV-68.ORF73βla virus and the difficult, albeit 
successful, recovery of enough mLANA+ cells for the qRT-PCR analyses at day 14 and 
21 post infection, it was thought that the attenuation of MHV-68.ORF73βla virus latency 
would hamper the assessment of viral miRNAs expression levels at time-points later 
than 21 dpi because the viral genomic load drops dramatically over time after 
establishment of latency and it was expected that the frequency of infected splenocytes 
from mice infected with MHV-68.ORF73βla virus would be lower than those of the 
wild-type virus. Therefore, the WT-MHV-68 virus was used to evaluate the expression 
kinetics of MHV-68 miRNAs at 10, 14, 21, and 32 dpi during latency in the spleen.  
At the early stage of latency (10 dpi), MHV-68 miRNAs were expressed at high levels 
as compared to day 14 and 21 post-infection. It can be speculated that the MHV-68 
miRNAs are expressed at high levels during this early stage of latency in order to help 
establish latent infection by shutting down lytic viral gene expression and possibly by 
down-regulating cellular gene expression involved in supporting lytic infection. The 
MHV-68 miRNAs expression was down-regulated over time (between 10 and 21 dpi) 
possibly to allow for some level of reactivation and spread of virus to the adjacent 
uninfected cells. At a later stage of latency (between 21 and 32 dpi) the miRNAs 
expression levels increased again possibly to inhibit unwanted lytic reactivation and to 





maintain cell survival. This explanation is consistent with the finding that splenocytes 
from mice infected with MHV-68.ΔmiRNAs virus exhibited higher ex-vivo reactivation 
than the WT-MHV-68 (section 5.5.1).  
The increase of miRNAs abundance after 21 dpi can possibly be due to selective 
expression of the miRNAs in certain splenocyte subpopulations whose distribution 
increases over time. It was previously reported that the MHV-68 latent gene 
transcription is dependent on the differential stage of B cells and the spleen cell type and 
that the MHV-68 genome was only detected in newly formed and germinal-centre B 
cells beyond 21 dpi (Marques, Efstathiou et al. 2003). Another study which investigated 
the expression of the latency associated mLANA protein in mature B cell subsets (naïve 
follicular, germinal-centre, and memory B cells) throughout a 90-day infection course 
showed that the memory B cells constituted the vast majority of mLANA-expressing 
cells at 16 dpi, whereas the germinal-centre B cells represented the majority of the 
mLANA-expressing cells from 28 dpi to 90 dpi and that the naïve follicular B cells 
constituted a small proportion of the mLANA-expressing cells at all the time-points  
(Nealy, Coleman et al. 2010). 
 
It can be speculated that the MHV-68 miRNAs act as fine-tuners of gene expression 
during different stages of virus latency. It is also suggested that the regulation of MHV-
68 miRNAs expression is dependent on the stage of latent infection and that the day 32 
post infection constitutes a previously uncharacterised important stage for establishing a 
long-term latency. The latter suggestion is reminiscent of the observation that the highest 
frequency of genome-positive cells expressing the latency-associated mLANA protein 
occurred at 28 dpi in a 90 day-infection course experiment (Nealy, Coleman et al. 2010). 





6.5 MHV-68 encoded miRNAs are dispensable for productive 
virus replication 
 
Since the discovery of viral miRNAs, the assessment of their functions has been a field 
of extensive research, particularly in the herpesvirus field. However, few studies have 
investigated these functions in natural host. The engineered miRNA deletion mutant 
viruses, lacking the miRNAs expression, provide a very powerful tool to examine viral 
miRNAs function both in vitro and in vivo. The first in vivo study of a phenotype for a 
recombinant miRNA mutant virus revealed that a miRNA mutant murine 
cytomegalovirus, lacking 2 viral miRNAs, exhibited virus production attenuation in the 
salivary glands of the infected mice (Dolken, Krmpotic et al. 2010), highlighting the 
importance of the natural host infection model. MHV-68 provides an authentic natural 
host-virus infection system for studying potential gammaherpesvirus miRNAs functions 
during the different aspects of in vivo infection (primary lytic infection, latency 
establishment, latency maintenance, and reactivation). In the present study, a 
recombinant MHV-68 virus lacking 9 miRNAs, MHV-68.ΔmiRNAs, was constructed in 
order to investigate the potential functions of the miRNAs with specific focus on the 
latent infection in vivo. 
The lytic replication of the MHV-68.ΔmiRNAs virus was comparable to that of the WT-
MHV-68 virus in vitro and in vivo. This is consistent with previous studies that 
demonstrated that a spontaneous MHV-68 deletion mutant virus (MHV-76) lacking ~9.5 
kb in the left end of the genome, which includes the unique genes M1, M2, M3, M4, and 
the vtRNAs and their associated miRNAs, exhibited normal productive replication in 
vitro and in vivo, but it was cleared more rapidly from the lung and showed attenuation 





in the latency establishment in spleen (Macrae, Dutia et al. 2001, Clambey, Virgin et al. 
2002).These results are also consistent with recent published studies that showed that 
miRNA mutant viruses lacking all of the miRNAs exhibited similar levels of lytic 
replication to that of the WT virus (Feldman, Kara et al. 2014, Diebel, Oko et al. 2015). 
Nevertheless, these findings do not exclude any potential role of these miRNAs in post-
transcriptional regulation of lytic transcripts. The miRNAs may functions as rheostats 
that fine-tune gene expression levels; indeed, a number of herpesvirus miRNAs suppress 
leaky lytic transcripts expression during latent infection (Ebert and Sharp 2012, Kincaid 
and Sullivan 2012, Grey 2015). These functions may not be relevant during virus 
productive replication that is associated with high levels of lytic gene expression. 
 
6.6 MHV-68 miRNAs and B-cell proliferation 
 
It was found that the spleens from MHV-68.ΔmiRNAs-infected mice developed 
splenomegaly that is comparable to that of the spleens from mice infected with the WT 
virus during latency establishment. This was evidenced by the weight of the spleens 
(Figure 5.13). It is important to note the spleen weight is not a very sensitive method for 
determining subtle changes in B lymphocyte proliferation because it also measures T 
lymphocytes and other cell types besides B cells. FACS analysis showed that although 
there was a slight but statistically significant increase (1.5-fold) in proliferation of B 
cells from the mice infected with the miRNA mutant virus at 14 dpi, which coincides 
with maximal B cell proliferation, there was no significant difference at earlier and later 
time-points. This was unexpected finding as it was hypothesised that MHV-68 miRNAs 
may play roles in promoting B-cell proliferation in a way reminiscent of EBV miRNAs 





(Seto, Moosmann et al. 2010) . It was reported that the unique M2 protein of MHV-68 
was able to induce B cell proliferation and differentiation of infected B cells in an IL-10 
dependent manner (Siegel, Herskowitz et al. 2008). Therefore, the proliferation of 
MHV-68-infected B cells is likely induced by viral proteins rather than viral miRNA, 
not to mention the important role of CD4+ T cells in inducing B cell proliferation and 
splenomegaly (Usherwood, Ross et al. 1996).  
 
6.7 MHV-68 miRNAs are not essential for latency 
establishment, but help the virus lay low during the 
maintenance of long-term latency in vivo 
 
The MHV-68.ΔmiRNAs virus established in vivo latent infection comparable to that of 
the WT virus, indicating that the deleted miRNAs are not required for latency 
establishment. These findings are consistent with recent published studies (Feldman, 
Kara et al. 2014, Diebel, Oko et al. 2015). 
Strikingly, although the ex vivo reactivation of the miRNA mutant virus was identical to 
that of the WT virus during the establishment of latency (14 dpi), it was approximately 
18-fold higher than that of the WT virus during the maintenance of latency (49 dpi) 
despite the similar viral DNA genomic loads for both viruses at all the time points, 
indicating that the ex vivo reactivation was representing the ability of the infected cells 
to reactivate from latency rather than the amount of latent virus. Consistent with this 
hyper-reactivation phenotype, there was an increase of the MHV-68.ΔmiRNAs lytic 
gene expression as compared to that of the WT virus at 49 dpi, indicating the presence of 
viral lytic cycle. Future experiments may be required to investigate the proportions of 





episomal and linear forms of the virus genome at this time-point and later time-points in 
order to determine the ratio between latent and lytic replication. The presence of lytic 
transcripts also raises the question as to whether latent infection is maintained in the 
long term or whether on-going reactivation eventually leads to disease in infected 
animals.  This could be investigated by maintaining infected animals for longer periods 
or by infecting transgenic mice with compromised immune systems such that they might 
be more susceptible to infection.  It would also be of interest to investigate the ability of 
MHV-68.ΔmiRNAs virus to establish latency in cell lines. 
There was no difference in the gene expression levels, viral DNA genomic loads, or ex 
vivo reactivation at earlier time-points (14, 21, and 28 dpi) except a slight increase in the 
ex vivo reactivation of the MHV-68.ΔmiRNAs-infected splenocytes over that of the WT-
MHV-68-infected splenocytes at 21 dpi. Taken together, it is suggested that the MHV-
68 miRNAs are not required for latency establishment, but they play a key role in 
controlling virus reactivation and exit from latency during the maintenance of latency. 
 
The similar mRNA levels of RTA, ORF73, ORF65, and M3 between the miRNA mutant 
virus and the WT virus at time-points earlier than 49 dpi suggest that the mRNAs of 
these genes may not be targets for the deleted viral miRNAs; however, it is important to 
note that the protein expression levels of these genes were not determined and the 
miRNAs may exert their functions via translational repression leaving intact target 
mRNA rather than mRNA degradation (Filipowicz, Bhattacharyya et al. 2008); indeed, 
the work of Riaz et. al. has revealed that Ovine herpesvirus-2 miRNAs reduced the 
target ORF20 and ORF73 protein levels without affecting their mRNA levels (Riaz, Dry 
et al. 2014). 





Despite the accentuated reactivation of the MHV-68.ΔmiRNAs-infected splenocytes at 
49 dpi, no produced infectious virus was detected by plaque assay. It is possible that the 
immune system had cleared the lytically infected splenocytes or that the plaque assay is 
not sensitive enough to detect very low level of infectious virus. Interestingly, the DNA 
genomic load of MHV-68.ΔmiRNAs virus was significantly higher than that of the WT 
virus in the lung at 49 dpi. The lung was reported as an important site for MHV-68 
persistent infection in intact and B cell deficient mice (Stewart, Usherwood et al. 1998). 
It is therefore suggested that MHV-68 miRNAs control virus reactivation from latency 
in both spleen and lung during late latency. It is possible that the increase in MHV-
68.ΔmiRNAs genomic load in the lung at 49 dpi is due to the transfer of reactivating 
virus from the spleen to infect the lung or due to increase in the reactivation of latently 
infected epithelial cells, or both. Additional experiments are required to examine the 
presence of infectious virus as well as the levels of lytic gene expression in the lungs 
from the mice infected with MHV-68.ΔmiRNAs at 49 dpi and compare it to that of the 
WT virus.  
 
The finding that the MHV-68 miRNAs control virus reactivation and enhance long-term 
latency is not surprising. Lei et. al.  demonstrated that an miRNA encoded by KSHV, 
miR-k1, directly inhibited the expression of IκBα and thus increased the NF-κB activity 
that led to inhibition of lytic viral gene expression and productive replication, a function 
that is important for promoting latency (Lei, Bai et al. 2010). Consistent with these 
findings, another study showed that overexpression of miR-K3 in KSHV latently 
infected cells caused an increase in RTA expression and that miR-K3 directly targets 
NF-κB inhibitor for suppression (Lu, Li et al. 2010). In addition, in the same study, it 





was demonstrated that blocking miRNAs biogenesis in KSHV latently infected cells 
through knocking down the Dicer or Argonaute proteins led to increased lytic viral gene 
expression, indicating the importance of KSHV miRNAs in controlling reactivation and 
promoting latency. 
 
Lu et. al. reported that a KSHV miRNA mutant virus lacking 10 miRNAs displayed 
comparable numbers of KSHV-positive cells to that of the WT virus. Latency gene 
transcription and viral DNA genome copies were also similar to that of the WT virus. 
However, the mRNA expression levels of the key lytic switch, RTA, were significantly 
lower in cells infected with the miRNA mutant KSHV than those infected with the WT 
virus due to targeting of the RTA mRNA by miR-K12-5 miRNA (Lu, Stedman et al. 
2010). The work of Bellare et. al. showed that the KSHV miR-K9* down-regulated 
RTA expression and helped inhibit virus lytic reactivation (Bellare and Ganem 2009). 
Additionally, it was reported that a KSHV miRNA deletion mutant virus lacking miR-
K12-3 and miR-K12-11 miRNAs showed increased reactivation and more sensitivity to 
reactivation inducers as compared to the WT virus, a phenotype resulting from the 
miRNA-induced inhibition of cellular transcription factors that activate KSHV RTA  
(Plaisance-Bonstaff, Choi et al. 2014). The miRNA BART-miR-18-5p of the human 
gamma herpesvirus EBV was reported to suppress the expression of the cellular MAP 
kinase kinase kinase 2 (MAP3K2), which is involved in signalling pathways that 
facilitate viral lytic infection, and thus inhibit virus reactivation from latency (Qiu and 
Thorley-Lawson 2014). 
 





While this work was in progress, 3 studies investigating the phenotype of a miRNA 
mutant MHV-68 virus lacking 14 miRNAs with intact vtRNAs (Feldman, Kara et al. 
2014) and the phenotype of a mutant MHV-68 virus lacking all the vtRNAs and their 
associated miRNAs (Diebel, Oko et al. 2015) were published. Consistent with the results 
in the present study, they found that the mutant viruses have similar levels of lytic 
replication to that of the WT virus and that the miRNAs are non-essential for the 
development of splenomegaly and the establishment of latent infection in vivo. They 
reported that deletion of the miRNAs from the MHV-68.ORF73βla virus led to modest 
decrease in the number of mLANA+ memory B cells as compared to that of the WT 
MHV-68.ORF73βla virus, whereas the opposite effect was observed in naïve B cells 
during the establishment of latency. They also reported that deletion of the miRNAs 
caused significant reduction in the virus pathogenicity in a viral pneumonia model using 
interferon gamma deficient mice. Diebel et. al. showed that expression of vtRNA1 alone 
in the absence of its associated miRNAs and other vtRNAs and miRNAs partially 
restored the lethal pneumonia phenotype seen in the immunodeficient mice infected with 
the WT virus, indicating that vtRNAs can play a role in virus pathogenicity. Consistent 
with the hyper-reactivation phenotype of the miRNA mutant virus, Steer et al. have 
shown that the viral genomic load of a mutant MHV-68 virus lacking all viral miRNAs 
and vtRNAs in splenocytes from infected mice was higher than that of the WT virus-









What are the molecular mechanisms behind the hyper-reactivation phenotype of 
the MHV-68.ΔmiRNAs virus during late latency in vivo? 
 
The exact molecular mechanisms behind this phenotype are unknown. However, it can 
be speculated that the MHV-68 miRNAs may hijack cellular signalling pathways in a 
manner reminiscent of that of the miRNAs encoded by KSHV and EBV viruses, 
particularly the activation of the NF-κB pathway, which has an important role in 
maintaining gamma-herpesvirus latency and suppression of lytic reactivation (Brown, 
Song et al. 2003, Bellare and Ganem 2009, Krug, Collins et al. 2009, Lei, Bai et al. 
2010, Lu, Li et al. 2010, Lu, Stedman et al. 2010, Plaisance-Bonstaff, Choi et al. 2014, 
Qiu and Thorley-Lawson 2014). Members of the NF-κB family of transcription factors 
have low activity in various cell types due to their association with the NF-κB family of 
inhibitors that promote their retention in the cytoplasm; however, upon suppression of 
the NF-κB inhibitor, NF-κB is activated and accumulated in the nucleus (Hayden and 
Ghosh 2008). 
 
Intriguingly, NF-κB is particularly active in the mature murine B lymphocytes, which 
are the major reservoir of MHV-68 latency, and constitutively present in the nucleus due 
to the instability of the NF-κB inhibitor in these cells (Miyamoto, Chiao et al. 1994, 
Flano, Kim et al. 2002). Following gammaherpesvirus infection, NF-κB is further 
elevated in the latently infected B lymphocytes by the latency associated viral proteins 
(Hammarskjold and Simurda 1992, Laherty, Hu et al. 1992, Schwarz and Murphy 2001, 
Guasparri, Keller et al. 2004, Gewurz, Mar et al. 2011, Lavorgna and Harhaj 2012, 
Ersing, Bernhardt et al. 2013). It is therefore plausible to hypothesise that over time 





during latent infection when the MHV-68 protein levels decrease dramatically, the viral 
miRNAs expression levels increases (see chapter 4) in order to compensate for the loss 
of the roles played by the viral proteins in exploiting host cell pathways in order to 
maintain long-term latency and prevent undesired reactivation. By this way the virus can 
evade the immune response elicited by the viral proteins while maintaining the 
important latency enhancement functions through its miRNAs, which cannot be detected 
by the host immune system, and thus the virus can remain under the radar of the immune 
surveillance. 
  
We can surmise that the MHV-68 proteins and miRNAs may have some redundant 
functions related to promoting latency, but during late latency when the protein 
expression is highly restricted, the miRNAs are expressed and act as safety valves that 
prevent undesired disruption of latency. This speculation can explain the absence of a 
striking phenotype of the MHV-68.ΔmiRNAs virus during the early latency, whereas it 
displayed an accentuated reactivation phenotype during late latency. 
 
Another possibility is that the miRNAs may target some viral lytic genes for 
translational repression, particularly RTA. For instance, the 3’ UTR of RTA carries a 
predicted target site for mghv-miR-M1-1-3p. The similar lytic gene transcription levels 
in spleen cells from mice infected with the miRNA mutant MHV-68 and those infected 
with the WT MHV-68 virus during the establishment of latency does not guarantee 
similar protein expression levels. The absence of a pronounced phenotype during the 
establishment of latency is possibly because the inhibition of protein expression by the 
miRNAs was too subtle to cause a noticeable phenotype, but the phenotype is more 





pronounced over time when the viral protein levels decrease and the viral miRNAs 
levels increase. The finding that the MHV-68.ΔmiRNAs was able to establish latent 
infection similar to that of the WT virus does not exclude possible subtle roles of the 
miRNAs during the establishment of latency. Indeed, a previous study reported that an 
MHV-68 mutant virus lacking 14 miRNAs displayed modest decrease in frequency of 
the MHV-68-positive memory B cells as compared to that of the WT virus during 
latency establishment (Feldman, Kara et al. 2014), suggesting a role played by these 
miRNAs in increasing the numbers of MHV-68-infected memory B cells during latency 
establishment. 
 
6.8 Possible future work 
 
The role of the miRNAs in controlling reactivation can be scrutinized in cell lines 
supporting latent infection such as NS0 cell line. In addition, investigating the sensitivity 
of the MHV-68.ΔmiRNAs to reactivation inducers could be carried out in order to 
measure the ability of this virus to reactivate in vitro as compared to the WT virus. 
 
Given the significant increase in the genomic load of the MHV-68.ΔmiRNAs virus in 
the lung during late latency (49 dpi) as compared to the WT virus, it will be interesting 
to evaluate the level of virus reactivation in the lung epithelial cells as well as the level 
lytic gene expression at this time-point and probably at earlier time-points. 
 
Analysing the levels of lytic viral protein expression in the spleen, particularly during 
late latency can confirm whether the increase of the MHV-68.ΔmiRNAs lytic transcripts 





is accompanied by increase in the level of protein expression. Measuring the NF-κB 
activation level at 49 dpi will give insight into whether the MHV-68 miRNAs may 
modulate the NF-κB pathway in a manner similar to that of the KSHV miRNAs and 
whether the NF-κB signalling pathway is involved in the hyper-reactivation phenotype 
of the MHV-68.ΔmiRNAs virus at this stage of infection.  
 
Developing a marker miRNA mutant MHV-68 virus that is not attenuated in vivo could 
be a very powerful tool in investigating the previously mentioned potential roles of the 
miRNAs through isolating the latently infected cells and thus enriching for these rare 
cells, particularly during late latency. In addition, a marker virus could allow for 
investigation the potential miRNAs functions in B cell subpopulations and other cell 
types such as macrophages and dendritic cells during the course of latent infection in 
vivo. A marker miRNA mutant MHV-68 virus that carries a reporter gene fused to a 
lytic viral gene could be designed in order to monitor virus reactivation in vivo. For 
example, previous studies showed the use of a recombinant MHV-68 virus expressing 
firefly luciferase, which is driven by the M3 promoter, for real-time monitoring of the 
virus replication and reactivation in the same live animal non-invasively using a 
bioluminescence imaging technique (Hwang, Wu et al. 2008, Reese, Wakeman et al. 
2014). Such a technique could be useful in studying the role of the MHV-68 miRNAs in 
controlling reactivation in vivo provided that the latency establishment and maintenance 
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Figure 8.1 qRT-PCR melting curves for MHV-68 miRNAs and cellular mmu-miR-
191-5p expression in BHK-21 cells. qRT-PCR was carried out using RNA extracted 
from cells infected with MHV-68 at MOI of 5 for 24 hours (green) or from uninfected 
cells (red). No template control (black) is a sample in which water was added instead 
































Figure 8.2 mmu-miR-191-5p expression in 
BHK-21 cells. qRT-PCR was carried out using 
RNA extracted from BHK-21 cells infected with 
MHV-68 at MOI of 5 for 24 hours or from 
uninfected cells. Error bars represent mean ± 






















Figure 8.3 qRT-PCR melting curves of MHV-68 miRNAs expression in NIH 3T3 
cells infected with either WT MHV-68 virus or MHV-68.ΔmiRNAs virus. qRT-PCR 
was performed using RNA from NIH 3T3 cells infected with either WT MHV-68 virus 
(green) or MHV-68.ΔmiRNAs virus (blue) at MOI of 0.001 for 6 days. Uninfected 
control (red) and no template control (black) were used to monitor contamination and 
primer-dimer formation that could produce false positive results. 
 
